Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trial s.gov 
Identifier: 
Indication: 
Protocol ID: 
Clinical Program 
Manager: 
Gilead Medical Monitor: 
Protocol Version/Date: GILEAU 
CLINICAL STUDY PROTO COL 
A Phase 1 Study to Evaluate the Safety , Tolera bility, 
Phaimacokinetics, and Phaimacodynamics of GS-5829 as a 
Monotherapy in Subjects with Advance d Solid Tumors and 
Lymp homas and in Combin ation with Exemestane or Fulvestra nt 
in Subj ects with Es trogen Recepto r Positive Breast Cance r 
Gilead Sciences, Inc. 
333 Lakes ide Drive 
Foster City, CA 94404 
124032 
2016 -001912- 39 
[STUDY_ID_REMOVED] 
Solid tumors and lymphom as 
GS-US-35 0-1599 
Name: 
Telephone: 
Emai l: 
Name: 
Telephone: 
Fax: 
Mobi le: 
Emai l: 
Origina l: 
Ame ndm ent 1: 
Ame ndm ent 2: 
Ame ndm ent 3: 
Ame ndm ent 4: 
Ame ndm ent 5: 
Ame ndm ent 6: IPIPD 
IPIPD 
IPIPD 
IPIPD 
IPIPD 
IPIPD 
IPIPD 
IPIPD 
10 Dece mber 2014 
26 Januaiy 2015 
06 April 2015 
04 Nove mber 2015 
21 Mai·c h 2016 
24May2016 
20 June 2016 
CONFIDE NTIALITY STATEME NT 
The info1m ation contained in this document, paiiic ulai·ly unpublished data, is the prope 1iy or 
under control of G ilead Sciences, Inc., and is prov ided to you in confidence as an investigato r, 
potential investigato r, or consultant, for review by you, your staff , and an applicable 
Institutional Review Boai·d or Independent Ethics Commi ttee. The infonnatio n is on ly to be used 
by you in connec tion w ith author ized clinical studies of the investigatio nal diug described in the 
protocol. You will not disclose any of the info1mation to others w ithout written a uthorization 
from Gi lead Sciences, Inc., except to th e extent necessaiy to obtain info1med consent from those 
perso ns to whom the di11g may be adinini stered. 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 2 20 June 2016TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................................................
........................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 20
1. INTRODUCTION .............................................................................................................................................. 23
1.1. Background ............................................................................................................................................ 23
1.2. GS-5829 ................................................................................................................................................. 24
1.2.1. General Information ............................................................................................................. 24
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 25
1.2.3. Clinical Trials of GS -5829 ................................................................................................... 26
1.2.4. Information on Exemestane .................................................................................................. 26
1.2.5. Information on Fulvestrant ................................................................................................... 27
1.3. Rationale for Development of GS -5829 in Advanced Solid Tumors and Lymphomas 
(Group 1)................................................................................................................................................ 27
1.3.1. Rationale for Development of GS -5829 in Combination with Exemestane 
or Fulvestrant for the Treatment of Estrogen Receptor Positive Breast 
Cancer (Group 2) .................................................................................................................. 28
1.3.2. Rationale to Evaluate GS -5829 in Specific Aggressive Non -Hodgkin’s 
Lymphoma: DLBCL and PTCL (Group 3) .......................................................................... 30
1.3.3. Rationale for the Dose Selection .......................................................................................... 30
1.4. Com pliance ............................................................................................................................................ 31
1.5. Risk/Benefit Assessment for the Study .................................................................................................. 31
2. OBJECTIVES ................................................................................................
..................................................... 33
3. STUDY DESIGN ................................................................................................................................................ 34
3.1. Endpoints ............................................................................................................................................... 34
3.2. Study Design .......................................................................................................................................... 34
3.3. Study Treatments ................................................................................................................................... 38
3.4. Criteria for Discontinuation of Study Drug ............................................................................................ 38
3.5. Criteria for Removal from Study ............................................................................................................ 39
4. SUBJECT POPULATION .................................................................................................................................. 40
4.1. Number of Subjects and Subject Selection ............................................................................................ 40
4.2. Inclusion Criteria .................................................................................................................................... 40
4.3. Exclusion Criteria ................................................................................................................................... 41
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 44
5.1. Enrollment .............................................................................................................................................. 44
5.2. Description and Handling of GS -5829, Exemestane and Fulvestrant .................................................... 44
5.2.1. Form ulation .......................................................................................................................... 44
5.2.2. Packaging and Labeling ....................................................................................................... 44
5.2.3. Storage and Handling ........................................................................................................... 45
5.3. Dosage and Administration of GS -5829, Exemestane and Fulvestrant .................................................. 45
5.4. Prior and Concomitant Medications ....................................................................................................... 46
5.5. Accountability for GS -5829 ................................................................................................................... 46
5.5.1. GS-5829 Return or Disposal ................................................................................................ 47
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. Final 
Amendment6 
6. STUDY PROCEDURES .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 48 
6.1. Study Procedw · e Des cription s ............... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 48 
6 .1.1. Info1med Consent ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 48 
6.1.2. Medica l & Medica tion Histoiy ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 48 
6.1.3. Physical Examination .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 49 
6.1.4. Vital Signs .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 49 
6.1.5. Elect rocardiogra1n Assess1nent ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 49 
6.1.6. Echocardiograrn .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 49 
6.1.7. ECOG Perfonnance Status .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 49 
6.1.8. Prior and Concomi tant Medica tions ............. ........ ......... ........ ........ ......... ........ ........ ......... ..... 50 
6.1.9. Adverse Ev ents ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 50 
6.1.10. CT or MRI .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 50 
6.1.11. Bone Scan s (Group 2) Only ................ ................ .......... ........ ........ ........................ .......... ..... 51 
6.1.12. PET/CT Scan ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 51 
6.1.13. Blood and Urine Sa1nple s ............ ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 51 
6.1.14. Pregnancy Test for Female s of Childbearing Potential ................ .......... ........ ................ ...... 52 
6.2. Vitamin D Assessment for Patient s in Group 2 .............. ................ ................ .......... ........ ................ ...... 52 
6.2.1. Pha1macokinetic Sain les ............ ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 53 
6.3.4. U nschedu led Procedw ·es ............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
6.4. Post-treatmen t Assessment s .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
6.4.1. Post-Study Phone Call ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
6.5. Criteria for Discontinuation of Study Treatmen t. ........... ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
6.6. Replace1nent of Subject s ............... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
6.7. Dose Intenuption and Reduction .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 57 
6.7.1. GS-5829 ............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 57 
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ............... ......... ........ ........ ......... ........ ........ ......... ..... 60 
7 .1. Defini tions of Adverse Events, Adverse Reaction s, and Serious Adverse Ev ents .................. .......... ..... 60 
7 .1.1. Adverse Ev ents ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 60 
7.1.2. Seriou s Adverse Ev ents ............... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 60 
7.1.3. Clinical Labo rato1 y Abnonnalities and Other Abno 1mal Assessment s as 
Adverse Events or Serious Adverse Ev ents ........ .......... ........ ................ ................ .......... ..... 61 
7 .2. Assessmen t of Adverse Ev ents and Seriou s Adverse Ev ents .......... ........ ................ ................ .......... ..... 62 
7.2.1. Assessmen t of Causality for Study Drngs and Procedw-es .................... ................ .......... ..... 62 
7.2.2. Assess1nent of Severity ............... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 62 
7.3. Investigator Requirements and Instiuctions for Repo 1 ting Adverse Ev ents and Seriou s 
Adverse Ev ents to Gilead .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 63 
7 .3 .1. Requirement s for Collection Prior to Study Drng Initiation: ................ ................ .......... ..... 63 
7.3.2. Adverse Ev ents ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 63 
7.3.3. Seriou s Adverse Ev ents ............... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 63 
7 .3 .4. Electi ·onic Seriou s Adverse Ev ent ( eSAE ) Repo1ting Proce ss ............... ........ ........ ......... ..... 64 
7 .4. Gilead Repo 1 ting Requiremen ts ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 65 
7.4.1. Reporting of Adverse Events Relating to the Prima1y Endpoint and Othe r 
Anticipated Medica l Events in the Study Population ............ ................ ................ .......... ..... 65 
7.5. Toxicity Management .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 65 
7 .6. Special Situa tions Repo1t s ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 66 
7.6.1. Defini tions of Specia l Situations .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 66 
7 .6.2. Instiuctions for Reporting Specia l Situation s ................ ........ ........ ......... ........ ......... ........ ..... 66 
8. STATISTICALCONS IDERATIONS ............... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 68 
CONFIDENTIAL Page3 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 4 20 June 20168.1. Analysis Objectives and Endpoints ........................................................................................................ 68
8.1.1. Analysis Objectives .............................................................................................................. 68
8.1.2. Primary Endpoint ................................................................................................................. 68
8.1.3. Secondary Endpoint ............................................................................................................. 68
8.2. Analysis Conventions ............................................................................................................................. 69
8.2.1. Analysis Sets ........................................................................................................................ 69
8.3. Data Handling Conventions ................................................................................................................... 69
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 70
8.5. Efficacy Analysis ................................................................................................................................... 70
8.6. Safety Analysis ....................................................................................................................................... 70
8.6.1. Extent of Exposure ............................................................................................................... 70
8.6.2. Adverse Events ..................................................................................................................... 70
8.6.3. Laboratory Evaluations ........................................................................................................ 71
8.7. Pharm acokinetic Analysis ...................................................................................................................... 72
8.9. Sample Size ............................................................................................................................................ 72
9. RESPONSIBILITIES ................................................................
.......................................................................... 73
9.1. Investigator Responsibilities .................................................................................................................. 73
9.1.1. Good Clinical Practice .......................................................................................................... 73
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 73
9.1.3. Informed Consent ................................................................................................................. 73
9.1.4. Confidentiality ...................................................................................................................... 74
9.1.5. Study Files and Retention of Records .................................................................................. 74
9.1.6. Case Report Forms ............................................................................................................... 75
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 76
9.1.8. Inspections ............................................................................................................................ 76
9.1.9. Protocol Compliance ............................................................................................................ 76
9.2. Sponsor Responsibilities ........................................................................................................................ 76
9.2.1. Protocol Modifications ......................................................................................................... 76
9.2.2. Study Report and Publications ............................................................................................. 77
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 77
9.3.1. Payment Reporting ............................................................................................................... 77
9.3.2. Access to Information for Monitoring .................................................................................. 77
9.3.3. Access to Information for Auditing or Inspections .............................................................. 78
9.3.4. Study Discontin uation .......................................................................................................... 78
10. REFERENCES ................................................................................................................................................... 79
11. APPENDICES .................................................................................................................................................... 83
Appendix 1. Investigator Signature Page .................................................................................................... 84
Appendix 2. Study Procedures Table .......................................................................................................... 85
Appendix 3. RECIST 1.1 ............................................................................................................................ 89
Appendix 4. Criteria for Progression in Castration -Resistant Prostate Cancer ........................................... 90
Appendix 5. Lymphoma Efficacy Assessments .......................................................................................... 91
Appendix 6. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 .................................... 98
Appendix 7. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 99
Appendix 8. Performance Status Scoring System (ECOG) ...................................................................... 102
Appendix 9. Exemestane (Aromasin®) Prescribing Information .............................................................. 103
Appendix 10. Fulvestrant (Faslodex®) Prescribing Information ................................................................. 104
CCI
CCI-
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 5 20 June 2016LIST OF IN -TEXT TABLES
Table 3-1. Group 1: Single Agent GS -5829 ............................................................................................ 34
Table 3-2. Group 2: Com bination of GS -5829 in Breast Cancer ............................................................. 36
Table 3-3. Group 3: Single agent expansion in aggressive lymphomas .................................................. 37
Table 5-1. Examples of Concomitant Medications Prohibited in this Study ........................................... 46
Table 6-1. Blood and Urine Samples Collected During the Course of the Study .................................... 52
Table 6-2. Dose Reduction of GS -5829 ...............................................................
.................................... 58
Table 7-1. Grading of Adverse Event Severity ........................................................................................ 63
LIST OF IN -TEXT FIGURES
Figure 1-1. Mechanism of Action of GS -5829 to Reduce Transcription of MYC and AR Target 
Genes in Cancer Cells ............................................................................................................ 24
Figure 1-2. Mechanism of Action of GS -5829 to Reduce Transcription of ER Target Genes in 
Cancer Cells ........................................................................................................................... 29
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 6 20 June 2016PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: A Phase 1 Study  to Evaluate the Safet y, Tolerability , 
Pharmacokinet ics, and Pharmacod ynamics of GS -5829 as a 
Monotherap y in Subjects with Advanced Solid Tumors and 
Lym phomas and in Combination with Exemestane or Fulvestrant in 
Subjects with Estrogen Receptor Positive Breast Cancer
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:124032
2016-001912-39
[STUDY_ID_REMOVED]
Study Centers Planned: Approximately  5centers in the United States and approximately  
10centers in France
Objectives: The primary  objectives of this study  are as follows:
Characterize the safet y and tolerability  of GS -5829 as a 
monotherap y in subjects with advanced solid tumors and 
lymphomas
Determine the maximum tolerated dose (MTD) or 
recommended dose for phase 2 (RDP2) of GS -5829 as a 
monotherap y in subjects with advance d solid tumors and 
lymphomas
Characterize the safet y and tolerability  of G S-5829 in 
combination with exemestane or fulvestrant in subjects with 
advanced estrogen receptor positive breast cancer 
Determine the MTD or RDP2 of GS -5829 in combination with 
exem estane or fulvestrant in subjects with advanced estrogen 
receptor positive breast cancer 
The secondary  objective of this study  is: 
Evaluate 
the pharmacokinetics (PK) of GS -5829 alone in 
subjects with advanced solid tumors and ly mphomas and in 
combination with exemestane or fulvestrant in subjects with 
advanced estrogen receptor positive breast cancer 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences, Inc. 
Study Design: 
CONFIDENTIAL Final 
Amendment6 
This is an open-label , multice nter, sequential dose -escalation study 
to evaluate the safety, tolerability, PK, and PD of GS-5829 as a 
single agent in subjects with advanced solid tumors and lymphomas 
and in combinatio n with exemestane or fulvestrnnt in subjects with 
advanced estrnge n receptor positive breast cance r. 
Group 1: Single agent GS-5829 in solid tumor s and lymphomas 
Coh01t s of subjects with adva nced solid tumors and lymp homas 
who h ave failed or are intolerant to standa rd therapy or for whom no 
standard therapy exists will be sequentially enrolled at prog ressively 
higher dose levels to receive oral GS-5829 as monotherapy 
once daily (QD) . The starting dose will be 0.6 mg. Each dose level 
will enroll 1 subject until a ~ Grade 2 treatment-related toxicity is 
obse rved within the initial dosing period (Study Day 1 through 
C1D28 for all coho1ts). At Dose Level 5 or if a~ Grade 2 
treatment-related toxicity is obse1ved (whichever occurs first), the 
Page7 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 8 20 June 2016dose level will be expanded to 3 subjects. (Note: subjects enrolled 
with Grade 2 hemoglobin [Hb] must have Hb worsen b y at least 
1grade from baseline to be considered f or expansion of the cohort 
to 3subjects).
Once a dosing level has been expanded to 3 subjects, a standard 
3+3 study  design will begin and, dose escalation [3+3] will be 
performed at every  subsequent dose lev el with cohort sizes of 
3to6subjects. Subjects in the first 3 coh orts will receive a 
single dose and then approximately
7days later, initiate dosing once daily. Subjects will return to the 
clinic for frequent evaluation and monitoring as per Appendix 2.
The doses for each Dose Level are shown in the table below. 
Group 1: Single Agent GS -
5829
Dose Level GS-5829*
1 0.6 mg
2 1.4 mg
3 2 mg
4 3 mg
5 4 mg
6 6 mg
7 9 mg
8 12 mg
* Dose Levels maybe modified based on emerging safety and PK results.
If a dose limiting toxicity (DLT) occurs within the 28 day DLT 
period at an y dose level, this level willbe expanded to enroll 
3 additional subjects. 
The safet yandtolera bility ofeach dose level willbeassessed by a 
safety  review team (SRT) after all subjects inthecohort have been 
followed for at least 28 day s after the first dose of GS -5829. If no 
DLTs occur in up to 3 subjects or < 2 DLTs occur in up to 
6subjects on any Dose Level after 28 days on treatment, the next 
Dose Level will open. Each sub sequent Dose Level will open if the 
Dose Level preceding has no DL Ts in 3 subjects or < 2 DLTs in up 
to 6subjects.
Prior to initiating enrollment for Dose Level 4 in Group 1, an 
analysis of all available safet y, PK, and PD data from previous 
cohorts will be reviewed.
If a subject is enrolled in a dose level but does not complete the PK 
or PD anal ysis, they  may continue on study  but an additional 
subject may  be enrolled at that dose level.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 9 20 June 2016TheMTD isthehighest dose level with asubject incidence of 
≤ 1DLTsduring thefirst28days ofstudy drug dosing of6subjects. 
A minimum of 6 subjects need to be treated at a dose level before 
this dose level can be deemed as the MTD.
Group 2: Combination therapy of GS -5829 with exemestane or 
fulvestrant in pati ents with advanced stage estrogen receptor 
positive breast cancer
Cohorts of subjects with advanced stage estrogen receptor positive
breast cancer for whom no standard curative therapy  exists and who 
are candidates for exemestane or fulvestrant will be sequentiall y 
enrolled at progressivel y higher dose levels of oral GS- 5829 in 
combination with full standard doses of exemestane or fulv estrant. 
The starting dose of GS -5829 will be 2.0 mg QD, which is a dose 
level that has been demonstrated to be safe and tolerable (no 
Grade 2 or higher drug related toxicity ) as a single agent in patients 
with solid tumors. Dose escalation will continue w ith cohort sizes 
of 3-6 subjects in parallel arms: Group 2A will initiate with 2.0 mg 
of GS -5829 orall y once daily  on C ycle 1 Day 1 combined with 
25mg of exemestane administered once daily beginning on Cycle 1 
Day 1.The subject may  initiate exemestane an y time prior to, or on, 
Cycle1 Day  1.Group 2B will initiate with 2.0 mg of GS -5829 
orally  once daily on C ycle 1 Day  1 with 500 mg fulvestrant 
administered intramuscularly  (Cycle 1 Day  1 and then every  
28days (+/-3days). If Cy cle 1 Day  1 is the subject’ s first dose of 
fulvestrant, a one -time additional dose of fulvestrant should be
administered on Cy cle1 Day 15.
The candidate doses of GS -5829 for each Dose Level for Group 2 
are shown in the table below. 
Group 2: Combination of GS- 5829 in Breast Cancer
Dose Level GS-5829* Group 2A Exemestane Group 2B Fulvestrant
1 2 mg
25mg orally once daily500mg intramuscularly 
day1, 29 and then 
every 28 days**2 3 mg
3 4 mg
4 6 mg
5 9 mg
6 12 mg
* Dose Levels maybe modified based on emerging safety and PK results.
** Subjects initiating fulvestrant on this study should receive a single additional dose of 
fulvestrant on Cycle 1 Day 15.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 10 20 June 2016Group 2A and Group 2B will dose escalate independent of each 
other. In both Groups 2A and Group 2B, each cohort will consist of 
3newly  enrolled subjects who will be treated at the specified dose 
level. After all subjects ineach cohort have been followed for at 
least 28 days after the first dose of GS- 5829, a dose -DLT model 
(Bayesian logistic regression model) utilizing all available GS-5829 
safet y data will be built, and will provide estimates of DLT rates at 
all dose levels.
The dose -DLT model recommended dose for the next cohort will 
be the one having the highest probab ility that the DL T rate will fall 
in the target interval (16%, 33%), and a probability  of < 25% that 
the DLT rate exceeds 33%.
Group 3 L ymphoma expansion:
In addition to the minimum 6 subjects in Group 1 with solid tumors
or lymphomas who will be enrolled to confirm the MTD , an 
additional minimum of 6 subjects with aggressive NHL (DLBCL, 
or PTCL ) may be enrolled at a dose no higher than the MTD and 
complete a 28 day  safet y period. If ≤ 1 of these 6 subjects reports a 
DLT within this 28 day  safet y peri od, th en up to an additional 
34subjects may  be enrolled to evaluate the efficacy  and tolerability  
of GS -5829 in ly mphoma (a maximum total of 40 subjects with 
lymphoma enrolled). A minimum of 20 DL BCL and 5 PTCL  
subjects will be enrolled into this group. If ≥ 2of 6 subjects report a 
DLT, then an additional 6 subjects will be enrolled at a lower dose 
level, or at an alternative dosing schedule, which d ecreases the total 
amount of GS -5829 administered over a 28 -day period to at least 
25% less than the previous co hort (eg 14 day s on and 7 day s off).
The final dose escalation decisions will be made by  the SRT, 
following a review of the model recommendation and all relevant 
data available including safet y information, PK, biomarkers, 
clinical data from evaluable pat ients.
Group 3: Single agent expansion in aggressive lymphomas
Dose 
Level GS-5829*# of subjects 
enrolled initially Total number of subjects
1≤ MTD determined 
by Group 16 subjectsIf no DLT in first 6subjects 
expand to maximum total of 
40 (approx 34additional 
subjects)
-1is ≥25% less total 
GS-5829 
administered over a 
28 day  period6 subjectsIf no DLT in 6 subjects at 
this dose level, then expand 
to maximum total of all 
Group 3subjects of 40 
(approx 28 additional 
subjects)
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 11 20 June 2016Sites in France will be limited to Group 3 enrollment only .
Dose escalation in Group 1 will continue until identification of the 
MTD, or a suitable lower recommended dose, for Phase II studies. 
At least 6 subjects should be treated and evaluated at the GS-5829 
dose level recommended for Phase II studies.
ADLT in Group 1 or 2 isatoxicity defined below considered
possibly r ela tedto GS-5829 occurring during theDLTassess ment
window (Study  Day 1 through C1D28) ineach cohort:
Grade ≥ 4 neutropenia (absolute neutrophil count [ANC] 
< 500/ mm3)
Grade ≥ 3 neutropenia (ANC < 1000/mm3) with fever (a single 
temperature of > 38.3°C or a sustained temperature of ≥38°C 
for more than one hour)
Grade ≥ 3 thrombocy topenia 
Grade ≥ 2 bleeding (e.g. gastrointestinal, respiratory , epis taxis, 
purpura)
Grade ≥ 3 or higher non- hematologic toxicity , except:
Grade 3 nausea or emesis with maximum duration of 
48hours on adequate medical therap y
Grade 3 diarrhea which persists for < 72 hours in the absence of 
maximal medical therapy.
Grade ≥ 2 non-hematologic treatment- emergent adverse event 
(TEAE) that in the opinion of the investigator is of potential 
clinical significance such that further dose escalation would 
expose subjects to unacceptable risk
Treat ment interruption of ≥ 7 daysduetounresolved toxicity
For certain toxicities, such as laboratory  assessments without a 
clear clinical correlate, a discussion between the investigator and 
medical monitor, may  take place to determine if this adverse event 
(AE) should be assessed as a DLT necessitating dose reduction. 
However, an y Grade 3 or Grade 4 elevation in AST or ALT 
associated with a Grade 2 elevation in bilirubin that is at least 
possibly  related to study  drug will be considered a DL T.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 12 20 June 2016Group 3: For the first 6 subjects enrolled in the aggressive 
lymphom agroup (Group 3), a modification of the DL T assessment 
for hematologic toxicity  will be:
Grade ≥ 4 neutropenia (absolute neutrophil count [ANC] 
< 500/ mm3) which persist for > 3 day s upon interruption of 
GS-5829 (administration of growth factors not allowe d 
concurrently , but allowed during GS -5829 interruption)
Grade ≥ 4 thrombocy topenia (< 25,000/m m3)
Grade ≥ 3 thrombocy topenia (< 50,000/mm3to 25,000/mm3
which persists for > 7 day s upon interruption of GS -
5829
Number of Subjects 
Planned:Up to 160 subjects will be enrolled
Target Population: Adult subjects with ahistologicall y o rcytologic ally confir m ed
advanced malignant solid tumoror lymphoma thatisrefractory toor 
intolerant ofstandard therapy orforwhich nostandard therap yis 
available (Group 1) and post-menopausal women with advanced 
stage estrogen receptor positive breast cancer who are candidates 
for exemestane or fulvestrant (Group 2 A and Group 2B) . The 
Group 3 lymphoma expansion is limited to DLBCL or PTCL.
Duration of Treatment: Treatment will continue in the absence of dis ease progre ssion,
unacceptable tox
icity,withdrawal of consent, orother reasons
specified inSection 3.5.
Diagnosis and Main 
Eligibility  Criteria:Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be 
eligible for participation in this study :
1)Male or female ≥18 years of age . Subjects in Group 2 must be 
female.
2)Group 1: Histologicall y or cy tologically  confirmed advanced 
malignant solid tumor or ly mphoma (any subt ype) that is 
refractory  to or intolerant of standard therapy  or for which no 
standard therap y is available . 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 13 20 June 20163)Group 2: Histologicall y or cy tologically  confirmed breast 
cancer with evidence of metastatic or locall y advanced disease 
not amenable to resection or radiation therapy  with curative 
intent and who have progressed during treatment with at least 
oneprior hormonal therapy .Prior chemotherap y for 
advanced/metastatic disease is allowed.
a.Documentation of ER positive ( ≥ 1% positive stained cells 
by local standards) bas ed on the most recent tumor biopsy , 
unless bone only  disease.
b.Documented HER2- negative tumor based on local testing 
on most recent tumor biopsy  (immunohistochemistry  score 
0/1+ or negative b y in situ hy bridization HER2/CP17 ratio 
< 2or for single probe as sessment HER2 cop y number < 4)
c.Post, pre or peri -menopausal subjects considered to be in the 
post-menopausal state as defined b y one of the following:
i.Age ≥ 60 y ears
ii.Age < 60 years and cessation of regular menses for at 
least 12 consecutive months i n the absence of 
chemotherap y, tamoxifen, toremifene, or ovarian 
suppression and serum estradiol and FSH level within 
the post menopausal range
iii.Prior bilateral oophorectomy
iv.Pre/perimenopausal women can be enrolled if amenable 
to be treated with t he LHRH agonist goserelin. Patients 
must have commenced treatment with goserelin or an 
alternative LHRH agonist at least 4 weeks prior to 
firstdose of study  drug. If patients have received an 
alternative LHRH agonist prior to study  entry  they must 
switch to goserelin for the duration of the stud y.
4)Group 3 ly mphoma expansion: Subjects with ly mphoma are 
limited to diffuse large B -cell ly mphoma orperipheral T -cell 
lymphoma that are refractory  to or intolerant of standard 
therap y or for which no standard therap y is available .
5) All acute toxic eff ectsofanyprior antitum ortherapyresolved to
Grade ≤ 1before thestart ofstudy drug dosing (with the 
exception ofalope c
ia [Grade 1 or 2 perm itted] and neuroto xicity
[Grade 1 or 2 permitted])
6)Eastern Cooperative Oncology  Group (ECOG) Perfor mance
Status of≤ 1
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 14 20 June 20167)Life expectancy of ≥ 3 months, intheopinion ofthe Investigator
8)Adequate organ function defined asfollows:
a.Hematologic: Platelets ≥ 100 x 109/L; Hemoglobin 
≥ 9.0 g/dL; ANC ≥ 1.5 x 109/L (without platelet transfusion 
or an y growth factors within previous 7 day s of the 
hematologic laboratory  values obtained at screening visit). 
Patients in the Group 3 lymphoma ex pansion may  be 
enrolled with an ANC of ≥ 1.0 x 109/L; Platelets ≥75 x 
109/L. 
b.Hepatic: Aspartate transaminase (AST) / Alanine 
transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) 
(ifliver metastases are present, ≤ 5 x UL N); Total or 
conjugated bilirubin ≤ 1.5 x ULN
c.Renal: Serum Creatinine ≤ 1.5 x UL N or creatinine 
clearance (CrCl) ≥ 60 mL/min as calculated b y the 
Cockroft -Gault method
9) Coagulation: International Normalized Ratio (INR) ≤ 1.2
10)Negative serum pregnancy  test for female subjects 
(Appen dix7)
11)
Male subjects and female subjects of childbearing potential who 
engage in heterosexual intercourse must agree to use 
protocol -specified method(s) of contraception as described in 
Appendix 7.
12)
Females who are nursing must agree to discontinue nursing
before the first dose of GS -5829 
13)Able and willing to provide written informed consent to 
participate in the stud y
Exclusion Criteria:
Subjects who meet an y of the following exclusion criteria are not to 
be enrolled in this study :
1)History  or evidence of clinically  significant disorder, condition, 
or disease that, in the opinion of the Investigator or Medical 
Monitor would pose a risk to subject safet y or interfere with the 
study  evaluations, procedures, or completion
2)Pregnant 
3)Known brain metastasis or leptomeningeal disease
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 15 20 June 20164)Uncontrolled intercurrent illness including, but not limited to, 
active uncontrolled infection, active or chronic bleeding event 
within 28 day s prior to first dose of study  drug, uncontrolled 
cardiac arrh ythmia, or psy chiatric illn ess/social situation that 
would limit compliance with study  requirements as judged by  
treating ph ysician
5)Myocardial infarction, symptoma ticcongestive heart failure 
(New York Heart Association Clas
sification >Class II), 
unstable angina, orserious uncontrolled cardiac arrhy thmia 
within thelast6 months ofstudy Day 1
6)Major surgery , defined as any  surgical procedure that involves 
general anesthesia and a significant incision (ie, larger than 
what is required for placement of central venous access, 
percutaneous feeding tube, or biopsy ) within 28 day s of the 
firstdose of study  drug
7)Impairment of gastrointestinal (GI) function or GI disease that 
may significantly  alter the absorption of GS -5829, including 
any unresolved nausea, vomiting, or diarrhea t hat is Common 
Terminology  Criteria for Adverse Events (CTCAE) Grade > 1
8)Minor surgical procedure(s) within 7 day s of enrollment or 
randomization, or not y et recovered from prior surgery  
(placement of central venous access device, fine needle 
aspiration, or endoscopic biliary  stent ≥ 1 day  before enrollment 
or randomization is acceptable)
9) Anti- tumor therap y (chemotherap y, antibod y therapy, molecular 
targeted therapy) within 21 days or 5 half -lives, whichever is 
longer, of stud y drug dosing (6 weeks for nitro soureas, 
mitomy cin C, or molecular agents with t 1/2 > 10 days); 
concurrent use of hormone therap y for prostate cancer is 
permitted , and concurrent use of exemestane or fulvestrant (and 
goserelin for pre/perimenopausal breast cancer as per inclusion 
criter ia 2.c.iv) for subjects enrolled in Group 2 (advanced breast 
cancer) is permitted.
10)History  of long QT s yndrome or whose corrected QT interval 
(QTc) measured (Fridericia method) at screening is prolonged 
(>450 ms for males and > 470 ms for females). Subjec ts who 
screen fail due to this criterion are not eligible to be re- screened
11)Prior exposure to bromodomain (BET) inhibitors
12)Clinically  significant bleeding within 28 day s of study  Day 1
13)Known human immunodeficiency  virus (HIV) infection
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 16 20 June 201614)HBsAg positive
15)HCV antibody  positive
16) Use of moderate/strong cytochrome P450 (CYP)3A4 inhibitors 
or moderate/strong CYP3A4 inducers within 2 weeks prior to 
the first dose of stud y drug
17)Evidence of bleeding diathesis
18)History  of hemopty sis of ≥ 2.5 mL/1teaspoon within 6 months
of study  Day  1
19)History  of high grade esophageal or gastric varices
20)No anticoagulation therapy  within 7 day s of study Day 1, 
including acet ylsalicy lic acid, low molecular weight heparin, or 
warfarin.
Study  Procedures/
Frequency :Screening:
Screening will comm ence with obtaining the subje ct’ss igned
inform edconsent andwilloccur up to28 day s prior tothefirst
dosing ofstudy drug onStudy  Day 1/C1D1. Screening procedur es
willi
nclude thefollowi ng:m edical history review, phy sical exam,
vital signs, 12-lead electrocardiogram (ECG), ECOG Perfor mance
Status, prior/conco mitant medication review, blood collection for
pregnancy test(
females of child bearing potential), chemistry and 
hematology andcoagulation (chemistry , hematology  and 
coagulation to be collected within 7 day s of Study  Day  1/C1D1) ,
AEassess ment,andcomputed tom ograph y(CT) ormagnetic
resonance i
maging (MRI) (scans that meet protocol requirements 
that are obtained aspartofstandard medical practice up to28days
prior to Study  Day 1/C1D1 areacceptab le).Subjects who are 
enrolled in Group 2 will also undergo a baseline radionuclide bone 
scan. Subjects who are enrolled in Group 3 will undergo a baseline 
PET/CT in the place of a CT scan if available. Baseline tumor
lesions will be measured andcharacterized prior toStudy  
Day1/C1D
1toassess the subject disease status p riortobeginning
treatment.
Treatment:
Subjects who meet eligibility criteria willreceive GS-5829 orally  
once daily.Subjects in the first 3 cohorts of Group 1 will receive a 
single dose of GS -5829 and then approximately  7 day s later start 
their first 28 day
 cycle of GS -5829 once dail y. Each cy cle will 
consist of 28 days.Safety and efficacy assessmentswilloccur on an
outpatient basis i
ncluding assess mentof tumor response, physical
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 17 20 June 2016exam,vitals, ECG, collection ofblood samples (forroutine safet y
labs, GS-5829 PK, PD m arkers, andbiomarkers at applicable visits),
urine pregnancy test (every 4weeks while receiving GS -
5829 in
female of childbearing potential), andassess mentof AEs. In
addition, subjects willundergo CT/MRI or applicable scans every  
8weeks for the first year and then every  12 weeks. Subjects in 
Group 3 will undergo a PET/CT if available instead of a CT scan 
alone at week 16.  A subjectwho does notshow evidence ofdisease
progression by clinical assess mentorbyCT/MRI or applicable scan 
may continue receiving GS -5829 once daily until disease 
progres s
ion(clinical or radiographic), unacce ptable tox i city,
withdrawal ofconsent, or other reaso ns specified inSection 3.5.
Plasma samples for GS-5829 PK will be collected (± 10minutes) in 
cohorts 1
-3 of Group 1 on Study  Day  1 at pre -dose (0hr), 0.5, 1, 2, 
3, 4, 6, 8, 12, and 24 hours post-dose and in cohorts 4- 8 of Group 1 
and all cohor ts of Group 2 on Cy cle 1 Day  1 at pre -dose (0 hr), 0.5, 
1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose. Additional samples will 
be collected at 48 and 72 hours post- dose in cohorts 1 – 3 of 
Group 1 relative to first dose of GS -5829. Plasma samples for 
GS-5829 PK will be collected in all cohorts (Group 1 an d Group 2) 
at pre -dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post -dose 
relative to GS -5829 administration on Cy cle1 Day 8. Sparse PK 
samples will be collected in all cohorts (Group 1 and Group 2) at 
trough (20 -
26hours post -dose) on C ycle 1 Day 4, 2 -4 hours 
post-dose on Cy cle 1 Day 15, and any time post -dose on Day 1 of 
Cycles 2 through 6. In one or more cohorts, PK samples will be 
collected on Day  1 of C ycle 2 at pre -dose and 0.5, 1, 2, 3, 4, 6, 8, 
and 24 hours post -dose. GS -
5829 dose will be administered in fed 
state on Day 1 of C ycle 2.
Urine will be collected for GS -5829 PK in Group 1 cohorts 1-3 on 
Study  Day 1 and in Group 1 cohorts 4- 8 on Cy cle 1 Day 1 at 
pre-dose, 0 -6 hours, 6- 12 hours, and 12- 24 hours post -dose relative 
to first dose of GS -5829.
Subjects in the Group 3 lymphoma expansion will have PK drawn 
at pre -dose, 1, 2, 4, 6, and 24 hours post -dose on Cy cle 1, Day 8. 
PK samples will also be drawn at pre -dose on Day  1 of 
Cycles2,
4,and6.
After discontinuation of treatment, subjects will be followed for 
safet y for 30 days .
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 18 20 June 2016Test Product, Dose, and 
Mode of Administration:GS-5829 tablets will be self-administered orall y once daily, 
beginning on Cy cle 1 Day  1 of the study  and thereafter at 
approximately  the same time each day  until end of treatment.
Subjects in the first 3 Dose Levels will be administered GS -5829 in 
the clinic as a single dose and then 7 day s later will self -administer 
GS-5829 orally  once daily .GS-5829 is supplied as 0.2, 1, 5, and 
10mgtablets.
For subjects in Group 2A, exemestane tablets will be 
self-
administered orall y once dail y, beginning on Cy cle 1 Day 1 of 
the study  and thereafter at approximately  the same time each day  
until the end of treatment.
For subjects in Group 2B, fulvestrant will be administered 
intramuscularl y by the clinic staff on Cycle 1 Day 1, Cy cle 1 
Day 15 and C ycle 2 Day 1 of the study and thereafter at 
approximately  every  28days (+/-3 day s) until the end of treatment.
Reference Therapy, 
Dose, and Mode of 
Administration:Not Applicable
Criteria for Evaluation:
Safety : Safety  will be evaluated by  assessment of clinical laboratory  tests, 
physical examination, 12 -lead ECG, vital signs measurements, and 
the documentation of AEs
Efficacy Efficacy  will be evaluated by  overall response rate (O RR) 
(complete response [CR] + partial response [PR], assessed as per 
RECI ST v1.1 or appropriate evaluation such as Cheson Criteria for 
lymphoma or based on the Prostate Cancer Working Group 
[PCWG] for p
rostate cancer ) and progression-free survival (PFS), 
defined as the interval from first dose date of study  drug to the 
earlier of the first documentation of definitive disease progression 
or death from an y cause.
Pharmacokinetics: The following PK parameters for GS -5829 will be calculated as 
applicable: Cmax, AUC last, AUC tau, Ctau, Tmax, and t 1/2
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 19 20 June 2016Statistical Methods: Analysis Methods
The Full Anal ysis Set (FAS) will be used in the analy ses of subject 
characteristics and efficacy  endpoints. The FAS consists of all 
subjects who receive ≥ 1 dose of study  drug. A Safety  Anal ysis Set 
for this study  will be the same as FAS since this study  is a 
non-randomized study . Other anal ysis sets (DLT -Evaluable and 
PK/PD analy sis sets) will be use d for additional analy ses as well.
Subject characteristics and study  results will be described and 
summarized by  group (Group 1, Group 2A and Group 2B, Group 3 
lymphoma expansion), dose level, and assessment for the relevant 
analysis sets. Descriptive summ aries will be prepared to show 
sample size, mean, standard deviation (StD), 90% confidence 
intervals (CIs) on the mean, median, minimum and maximum for 
continuous variables, and counts, percentages and 90% CI s on the 
percentage for categorical variables.
Efficacy  endpoints, ORR and PFS, will be listed only .
Based on the Safet
y Analysis Set, information regarding stud y drug 
administration, study  drug compliance and safet y variables will be 
described and summarized.
Using data from the PK and PD Analy sis Sets, GS -5829 plasma 
concentrations and PK parameters and whole blood PD markers 
will also be described and summarized. Plasma concentrations of 
GS-5829 metabolite(s) may  also be determined and PK explored.
Sample Size
The sample size of the study  will be dete rmined based on the 
number of dose levels evaluated and the emerging GS-5829-related 
toxicities. The study  will consist of up to 160 subjects.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) ,
including archiving of essential documents.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 20 20 June 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
AAG Alpha- 1 Acid Glycoprotein
ABC activated B -cell
AE adverse event
AI aromatase inhibitor
ALT alanine transaminase
AML acute myeloid leukemia
ANC absolute neutrophil count
APTT Activated partial thromboplastin time
AR androgen receptor
AR-V7 AR splice variant 7
AST aspartate transaminase
AUC area under the concentration versus time curve
BCL B-cell lymphoma
BCRP breast cancer resistance protein
BET brom odom ain and extra -terminal
BRD brom odom ain
CA 15 -3 cancer antigen 15 -3
CA 19 -9 carbohydrate antigen 19 -9
CA 27.29 cancer antigen 27.29
CA-125 cancer antigen -125
CDK 4/6 cyclin-dependent kinase 4/6
CEA carcinoembryonic antigen
CP17 centromeric probe for chromosome 17
CFR code of federal regulations
CI confidence interval
CR complete response
CrCl creatinine clearance
CRF case report form
CRO contract research organization
CRPC castrate -resistant prostate cancer
CT computed tomography
CTC circulating tumor cell s
CTCAE Common Terminology Criteria for Adverse Events
CYP cytochrome P450
DDI drug-drug interaction
DLBCL diffuse large B -cell lymphoma
DLT dose limiting toxicity
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 21 20 June 2016E2 estradiol
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic CRF
ER estrogen receptor
eSAE electronic SAE
FAS full analysis set
FDA Food and Drug Administration
FSH Follicle stimulating hormone
GCP good clinical practice
GI gastrointestinal
Hb hemoglobin
HBsAg Hepatitis B surface Antigen
hCG human chorionic gonadotropin
HCV hepatitis c virus
HED human equivalent dose
HER2 human epidermal growth factor receptor 2
HIV Human Immunodeficiency Virus
HNSTD highest non -severely toxic dose
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
INR International Normalized Ratio
IP investigational product
IRB Institutional Review Board
IUD intrauterine device
IxRS Interactive voice/web Response System
LD longest diameter
LHRH lutenizing hormone -releasing hormone
LPD longest perpendicular diameter
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
MTD maximum tolerated dose
NCI National Cancer Institute
ORR overall response rate
PCWG Prostate Cancer Working Group
PD pharmacodynamics
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetics
PR partial response
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 22 20 June 2016PSA prostate- specific antigen
PT prothrombin time
PTCL peripheral T cell lymphoma
QD every day
QTc corrected QT interval
R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
RDP2 Recommended dose for phasae 2
RECIST Response Evaluation Criteria in Solid Tumors
RNA ribon ucleic acid
RNAPII RNA polymerase II
SADR serious adverse drug reaction
SAE serious adverse event
SOC system organ class
SOP standard operating procedure
SPD sum of the product
SRT safety revie w team
STD severely toxic dose
StD standard deviation
SUSAR suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event
ULN upper limit of normal
US United States
WBC white blood cell
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 23 20 June 20161. INTRODUCTION
1.1. Background
GS-5829 is a small- molecule inhibitor of the highly conserved bromodomain pockets of the 
bromodomain and extraterminal (BET) proteins. Bromodomain and extraterminal proteins 
regulate specific gene expression by  enhancing ribonucleic acid (RNA) poly merase II 
(RNAPII) -mediated transcription. Signal transduction pathway s recruit BET proteins to target 
genes through posttranslational modification of histone proteins in the form of ly sine acet ylation 
{Belkina et al 2012 , Hargreaves et al 2009 }. The tandem bromodomain motifs of BET proteins 
specificall y recognize acetylated histones and, in turn, recruit protei n factors that regulate 
RNAPII {Shi et al 2014a }. The BET family  includes bromodomain -containing proteins 2, 3, 4, 
and T (BRD2, 3, 4, and T). BRD2, 3and 4 are widely  expressed and regulate gene transcription 
in diverse cell t ypes, including malignant cells, whereas BRDT expression is restricted to the 
testes.
BRD2, 3, 4 are essential regulators of the expression or activity  of several key oncogenic 
transcription factors, including v -myc avian my elocy tomatosis viral oncogene homolog (MYC) 
and the androgen receptor (AR) {Shi et al 2014a }. Transcription of the MYC gene is dependent 
on BET proteins in many cells {Mertz et al 2011 }
(Figure 1-1). Androgen receptor- dependent 
transcription of target genes requires BET proteins in prostate cancer cell s {Asangani et al 2014 }.
Cancer cells addicted to MYC and AR are highly  sensitive to BET protein inhibition 
{Asangani et 
al 2014 , Delmore et al 2011 , Mertz et al 2011 }, which provides the basic therapeutic rationale for 
BET inhibition with GS -5829 for the treatment of cancer.
MYC promotes cell proliferation, cell survival, and metabolic adaptation and is frequently  
overexpressed in human cancers {Dang 2012 }. Data generated at Gilead demonstrated MYC 
overexpression to be prevalent in 76% of prostate cancer (n = 60), 67% of diffuse large B -cell 
lymphoma (DLBCL) (n = 98), 65% of multiple myeloma (MM, n=30), 73% of colorectal cancer 
(n=60), and 80% of ovarian cancer (n = 60) cases examined ( PC-
350-2083 ). These data are 
consistent with literature that reports a high incidence of MYC expression in these and other 
cancers {Affer et al 2014 , Barrans et al 2010 , Chesi et al 2008 , Chng et al 2011 , Glitza et al 2014 , 
Hawksworth et al 2010 , Nesbit et al 1999 , Nupponen et al 1998 , Perry  et al 2014 }. The AR is a 
nuclear hormone receptor that is nearly  ubiquitously e xpressed in prostate cancer (PC -350- 2083) 
and activates growth and survival signals both by  binding to androgen, its natural ligand, and 
through androgen -independent mechanisms {Yuan et al 2014 }.
A number of orally  administered, BET -directed compounds (TEN -010, CPI -0610, OTX015, 
ZEN -3365, and GSK525762) are currently  in early -stage clinical development for the treatment 
of solid tumors or hematologic cancers. Initial evidence of clinical activity  at tolerated doses has 
been reported for the BET inhibitor OTX 015 in patients with refractory  hematological cancers 
{Herait et al 2014}. GS-5829 is an orally  available small - molecule inhibitor of BET proteins that 
is being developed b y Gilead Sciences, Inc. for the treatment of s olid tumors, including 
castrate -resistant prostate cancer (CRPC), estrogen receptor positive advanced stage breast 
cancer and hematologic malignanc ies. In nonclinical studies, GS -5829 inhibited cell growth and 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 24 20 June 2016induced apoptosis of solid tumor and hematological cancer cells by inhibiting B ET 
protein -dependent transcription of MYC and other oncogenic pathways, including transcription 
mediated b y the AR in prostate cancer cells and the ER in breast cancer cells. 
Figure 1-1. Mechanism of Action of GS -5829 to Reduce Transcription of MYC 
and AR Target Genes in Cancer Cells
Bromodomain and extraterminal proteins, including BRD4, are recruited to the MYC promoter and enhancer elements through an 
interaction between the tandem bromodomains and acetylated histone proteins in chromatin (top panel). BRD4 recruits the 
positive tran scription elongation factor b (pTEFb) complex to the MYC gene, which phosphorylates RNAPII to increase 
transcription of the MYC gene. GS -5829 binds to the bromodomains of BET proteins, thereby blocking the interaction with 
acetylated histone proteins and l eading to a reduction of MYC transcription. GS -5829 similarly functions to inhibit the 
transcription of AR target genes in prostate cancer cells, including the kallikrein -related peptidase 3 (KLK3) gene that encodes 
prostate specific antigen (bottom panel) . 
1.2. GS-5829
1.2.1. General Information
For further information on GS-5829, refer to the current investigator’s brochure for GS-5829 .
.GS-5829 
MYC .. 
.GS-5829 .. 
AR targets 
• KLK2 
• KLK3 (PSA) 
• TMPRSS2 
• SLC45A3 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 25 20 June 20161.2.2. Preclinical Pharmacology and Toxicology
1.2.2.1. Absorption, Distribution, Metabolism, and Elimination 
GS-5829 shows moderate plasma protein binding and volumes of distribution in nonclinical 
species that are similar to or slightly  higher than total body  water. Systemic clear in nonclinical 
species is generall y well predicted from the rates of metab olism by  hepatocy tes.Since GS -5829 
has high metabolic stability  with human hepatic material in vitro, it is likely to show low 
clearance in humans. The major route of metabolism of GS -5829 involves hy droxy lation of the 
5-methy l moiet y on the 3,4 -dimethly  isoxazole ring catal yzed primaril y by CYP3A4 and 
CYP3A5 enzy mes in humans.
Consistent with the moderate to high bioavailability seen in nonclinical species, shows high 
forward permeability across Caco- 2 monolay ers, and low efflux, but GS -5829 is a substrate of 
human P -g and BCRP.
GS-5829 has relativel y high unbound fraction in cell culture medium containing fetal bovine 
serum. Competitive dialysis between cell culture median and human, dog and mouse plasma 
yielded a ratio of unbound fractions of 5.7, 15.2 and 13.2 respectivel y.
GS-5829 is unl ikely  to cause clinical interaction through inhibition of CYP1A2, CYP2C9, 
CYP2C19, or CYP2D6, CYP2B6, CYP2C8, CYP3A or UGT1A1, so the potential for causing 
drug interactions through inhibition of those enzy mes is low. GS-5829 is also a weak inhibitor of 
the human efflux transporters, P -gp and BCRP, and the uptake transporters, OATP1B1 and 
OATP1B3. 
1.2.2.2. Nonclinical Toxicology
Nonclinical safety  pharmacology  and toxicology  studies have characterized the safet y of 
GS-5829 through repeat dose toxicology  studies. All pivotal toxicology  studies were conducted 
in full compliance with G ood 
Laboratory  Practice regulations (21 CFR 58). The scope of the 
nonclinical safet y evaluation is consistent with the guidance issued b y the International 
Conference on Harmonisation (ICH). 
In nonclinical pharmacology  studies, GS
-5829 showed no significant adverse effects on central 
nervous, respiratory  or cardiovascular s ystem functioning at the projected exposure and human 
target dose of 25 mg once daily
.
The following target organ s/systems were identified in the nonclinical toxicology  studies: 
hematopoietic and male reproductive s ystem (mice and dogs), the adrenal and skin (mice), and 
the gastrointestinal tract, respiratory  and cardiac (dogs). With the exception of the adrenals in the 
mouse and the respiratory  and cardiac hemorrhages observed in dogs, target organs are as 
expected based on the known pharmacology .The dog was the more sensitive species, with t he 
no-observed - adverse- effect levels in the mouse and dog 10 and 0.03 mg/kg /day respectively .The 
severel y toxic dose in 10% of mice and the highes t HNSTD in dogs were 25 and 0.1 mg/kg/day , 
respectivel y.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 26 20 June 2016Hematopoietic effects include decreases in white blood cells, ly mphocy tes, platelets and 
reticulocy te counts as well as mild r educed cellularity  in the marrow in mice at doses of 
≥ 10 mg/kg/day .Minimal to marked decrease in bone marrow cellularit y, decrease in 
lymphocy tes in the l ymphoid tissues (spleen, thymus, ly mph nodes and gastrointestinal 
associated l ymphoid tissue), decre ase in neutrophils and platelets were observed at 
0.3mg/kg/day  in dogs. Elevated fibrinogen was also noted at the 0.3 mg/kg /day in dogs. 
Mild to moderate alveolar (lung) hemorrhage was obser ved at ≥ 0.1 mg/kg/day  in dogs. Mild 
hemorrhage in the left atrioventricular valve of the heart was seen at the 0.3 mg/kg/day  in 1of 
6dogs. The mechanism for the hemorrhage is not known. Protime and partial thromboplastin 
time measurements were normal. The anatomic pattern of the hemorrhage in the lung field and 
microscopy appears were considered potentiall y consistent with pneumonia, however bacteria 
were not identified.
In the male reproductive sy stem, decreased testes weight with oligospermia/aspermia were 
observed in both mouse and dog studies at 25 mg and 0.3 mg /kg/day  respectively .Minimal to 
moderate vacuolation of the seminiferous tubules occurred at ≥ 0.1 mg/kg/day  in the dog. These 
changes are consistent with the known effects of a bromodomain inhibitor on the testes.
The gastrointestinal findings in the dog included minimal to mild mucosal atrophy , mucosal 
hemorrhage and cry pt hyperplasia in the stomach or intestines at ≥ 0.1 mg/kg/day .Adrenal gland 
weight decreases were noted at 25 mg/kg/day  and cy toplasmic vacuolation a t ≥ 10 mg/kg/day  in 
the mouse studie s, of unknown cause. QT prolongation is not expected based on hERG, rodent 
and dog studies.
1.2.3. Clinical Trials of GS-5829
Study  GS-US-350- 1604, a Phase 1b/2 study  to evaluate the safety , tolerability , PK and 
pharmacod ynamics of GS -5829 as a single agent and in combination with enzalutamide in 
subjects with CRPC, initiated in November 2015 and is actively  enrolling.
1.2.4. Information on Exemestane
Exemestane is an irreversible, steroidal aromatase inactivator, structurally  related to the natural 
substrate androstene dione. It acts as a false substrate for the aromatase enzy me and is processed 
to an intermediate that binds irreversibl y to the active site of the enzyme, causing its inactivation, 
an effect also known as “suicide inhibition.” Exemestane significantl y lowe
rs circulating 
estrogen concentrations in postmenoapusal women. In the US, exemestane is approved for the 
treatment of advanced breast cancer in postmenopausal women whose dis ease has progressed 
following tamoxifen therapy .For current information about ex emestane (Aromasin ®)refer to 
the prescribing information ( Appendix 9)or the summary  of product characteristics in the 
pharmacy  binder .
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 27 20 June 20161.2.5. Information on Fulvestrant 
Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive 
manner with affinity  comparable to that of estradiol and downregulates the ER protein in human 
breast cancer cells. In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the 
growth of tamoxifen resistant as well as estr ogen sensitive human breast cance rcell lines. In vivo 
tumor studies fulvestrant delay ed the establishmen t oftumors from xenografts of human breast 
cancer MCF -7 cells in nude mice. Fulvestrant inhibited the growth of established MCF7 
xenograft sand of tamoxi fen resistant breast tumor xenogra fts.In the US, fulvestrant is approved 
for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal 
women with disease progression fo llowing antiestrogen therap y. For current informat ion about
fulvestrant (Faslodex®), refer to the prescribing information ( Appendix 10) or the summary  of 
product characteristics in the pharmacy  binder
1.3. Rationale for 
Development of GS-5829 in Advanced Solid Tumors and 
Lymphomas (Group 1)
In 2014, it is estimated that over 500,000 people will die from cancer in the United States ( US)
alone, with the vast majority  due to progression of advanced stage solid tumors {National Cancer 
Institute 2014 }. Strong evidence exists that the MYC oncogene famil y pla ys a critical role in the 
pathogenesis of man y of these cancers. Overexpression or amplification of MYC has been 
observed in prostate, breast, colorectal, gastric, melanoma, non -small cell lung, small cell lung, 
medullary  thyroid cancer, rhabdom yosarcoma, multiple myeloma ,
and aggressive non -Hodgkin’s 
lymphomas such as Burkett’s and DLBCL {He et al 2014, Koh et al 2010, Lin et al 2010 , 
Moly neux et al 2012, Nair et al 2014 , Nesbit et al 1999 , Odia et al 2013 , Petrich et al 2014, van 
Dam et al 1994 , Yoo et al 2004 }. GS-5829 is expected to have broad activity in tumor s that 
overexpress MYC by  decreasing t he transcription of MYC RNA. GS -5829 also has potential for 
activity  in tumor ty pes that are highl y dependent on the activity of other oncogenic transcription 
factors regulated by  BET proteins. These include the AR in prostate cancer {Asangani et al 2014 } , 
the estrogen receptor and Twist in breast cancer {Feng et al 2014 , Shi et al 2014b }, FOS -like 
antigen 1 in nonsmall cell lung cancer and pancreatic cancer {Lockwood et al 2012 , Sahai et al 
2014}, and Smoothened in basal cell carcinoma and medulloblastoma {Tang et al 2014 }. 
In 2014, it is estimated that there will be 233,000 new case
s of prostate cancer and 29,480 deaths 
due to prostate cancer in the US {National Cancer I nstitute 2014 }. The majority  of men 
(approximately  90%) are diagnosed with loco -regional disease that is treated surgically  and/or 
with radiation therap y; 5-year survival approaches 100% for these patients. However, despite the 
availability  of a variet
y of therapies, including pharmacological inhibitors of AR activity, 
immunotherapy ,radiation, and chemotherap y,metastatic prostate cancer has a 5 -year survival of 
only 30%, with most patients dy ing from prostate cancer. 
In patients with advanced prostate cancer who have progressed while receiving therap y with 
chemical or surgical castration, the androgen/AR axis remains the target of current standard of 
care agents abiraterone and e nzalutamide. Primary and acquired resistance to such agents occurs 
when the AR is activated in an androgen -independent manner, most notabl y through the 
expression of the constitutively  active AR splice variant 7 (AR- V7) {Antonar akis et al 2014 , 
Guo et al 2009
}. In nonclinical studies, GS -5829 inhibited growth and induced apoptosis in 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 28 20 June 2016prostate cancer cell lines by  inhibiting MYC expression and AR -target gen e expression in both 
AR-and AR -V7-expressing prostate cancer cell lines.
Diffuse large B -cell ly mphoma is the mo st common subty pe of non -Hodgkin’s ly mphoma, 
accounting for approximately 30% of all l ymphoma diagnoses {Morton et al 2006}. Currently , 
the combination of rituximab, cy clophosphamide, doxorubicin, vincristine, and prednisone 
(R-CHOP) is considered to be the standard of care for DLBCL. While approximatel y half of 
patients with DLBCL achieve durable remissions, patients who relapse or who are refractory to 
primary  therap y have a poorer outcome. For patients who are not transplant eligible, salvage 
therapies, which generally include chemotherap y with or wit hout rituximab, offer little chance of 
prolonged disease control. Response rates range from 30% to 60%, with overall survival 
less than 12 months {Vacirca et al 2014 }.
GS-5829 is being developed for the treatment of DLBCL based on the known rol e of BET 
proteins to regulate the transcription of key  oncog enic pathway s related to MYC, B -cell 
lymphoma 6 (BCL6), and nuclear factor kappa- light-chain -enhancer of activated B cell (NF -B) 
{Ceribelli et al 2014 , Chapuy  et al 2013 }. In nonclinical studies, GS -5829 reduces the 
transcription of MYC in DLBCL cell lines vit ro and in vivo, resulting in potent cell growth 
inhibition and/or apoptosis. GS -5829 exhibits equivalent potent activity  in DLBCL cell lines 
irrespective of known poor prognosis factors for patients, including activated B -cell (ABC) 
subclass or MYC/ B-cell ly mphoma 2(BCL2) coexpression.
1.3.1. Rationale for Development of GS- 5829 in Combination with Exemestane or 
Fulvestrant for the Treatment of Estrogen Receptor Positive Breast Cancer
(Group 2)
Approximately  75% of breast cancers express the estrogen receptor (ER ), a nuclear hormone 
receptor and transcription factor that promotes the expression of genes involved in cell growth 
and survival {Clark et al 1984}. Anti- estrogen endocrine therapies, such as aroma tase inhibitors 
(AIs) and tamoxifen are the primary  treatments for earl y stage ER -positive breast cancers, but 
many  women relapse during or after completing these adjuvant hormonal therapies. In the 
metastatic setting, single -agent treatment with AI s, tamo xifen, or the selective ER degrader, 
fulvestrant, has limited benefit. When combined with other targeted therapies such as the 
Cyclin
-Dependent Kinase ( CDK) 4/6 inhibitor, palbociclib, the benefit of first- line anti -estrogen 
therap y significantl y improves progression- free survival (PFS). Standard of care includes 
sequential administration of endocrine therapies until hormone resistance occurs, at which time 
patients are usuall y transitioned to chemotherap y and eventuall y die. Therefore, the development 
of effective therapies that improve response to endocrine therap y and prevent or reverse 
resistance continues to be of clinical importance. 
Resistance to endocrine therap y is mediated b y several mechanisms that enable reactivation of 
ER-driven transcription under conditions of low estrogen (i.e. estrogen -independent transcription 
by the ER). These mechanisms include ER overexpression, activating ER mutations, increased 
expression of ER co
-activators, or increased ex pression of ER -target genes such as MYC and 
cyclin D1 {Osborne et al 2011}. Importantly , BET proteins are required for both 
estrogen -
dependent and estrogen- independent transcription by  the ER receptor. BRD4 and 
BRD3 are recruited to ER target genes, including MYC, where they  promote transcription by  
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 29 20 June 2016RNA polymerase II. In preclinical studies, the BET inhibitor ,JQ1,decreased ER -mediated gene 
transcription and inhibited the growth of ER- positive tumors {Nagarajan et al 2014 , Sengupta et 
al 2015
}. In addition, combination of JQ1 with fulvestrant significantly increased time to disease 
progression in an endocrine -resistant ER-positive xenograft mouse breast tumor {Feng et al 
2014}.
We hy pothesize that the combination of GS -5829 and an anti -
estrogen such as fulvestrant or an 
AIsuch as exem estane ,may increase the efficacy of endocrine therapy  in patients with advanced 
ER-positive breast cancer by targeting orthogonal mechanisms (Figure 1-2). The combination is 
expected to lead to overall greater inhibition of ER- dependent transcription by  blocking distinct 
aspects of ER signaling (reduced ligand -dependent ER activation with AI , reduced ER protein 
stability  with fulvestrant, and reduced BET -dependent transcrip tion of ER target genes with 
GS-5829). By directl y inhibiting the transcription of E R target genes such as MYC, GS -5829 is 
hypothesized to block established mechanisms of resistance to endocrine therapy .BET proteins 
also promote transcription of several ER -independent cell cy cle genes, including CDK 6, which 
may additionally  contribute t o the combination activity  in ER+ breast cancer cells. Preliminary  
Gilead data has demonstrated a s ynergistic effect of fulvestrant and GS -5829 to inhibit growth of 
ER-
positive cell breast cancer lines in vitro and to inhib it growth of patient -derived ER -positive 
breast cancer xenografts in mice. 
Figure 1
-2. Mechanism of Action of GS -5829 to R educe Transcription of E R 
Target Genes in Cancer Cells
Overall ,the pre -clinical studies demonstrate that GS -5829 is a potent and selective inhibitor of 
BET proteins andsupport the use of GS -5829 to treat solid tumor sand hematological cancers. 
••• 
Aromatase lnhitlilor __J ! 
(First lin.e) -----i •• 
Tamoxifen ---I l {First Ii rte} 
Fulvestrant 1 •• 1 {Seca n.rl I ine} . l ER 
-L • ER deg:radation 
Nucreus Cytoplasm 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 30 20 June 20161.3.2. Rationale to Evaluate GS -5829 in Specific Aggressive Non- Hodgkin’s 
Lymph oma: DLBCL and PTCL (Group 3)
Specific subty pes of aggressive ly mphoma may  have a greater potential for sensitivity  to BETi.
DLBCL andPTCL are included in this category  and are also notable for poor OS for patients in 
the relapsed and/or refractory  settin g who are not bone marrow transplant candidates; 9 -12 
months for relapsed DLBCL {Nagle et al 2013 }and5.5 months for PTCL {Mak et al 2013 }.
These dismal OS rates highlight an urgent need for improved therapeutic options.
In mature T -cell l ymphomas, such as PTCL , BET inhibition may be a favorable target. Cell cycle 
arrest and reduction of MYC mRNA levels in fiv e out of seven anaplastic large -cell T -cell 
lymphoma cell lines has been reported with the BETi, OTX -015 { Bonetti et al 2012 }.
Data supporting the single agent evaluatio n of BETi in treating DLBCL have been discussed in 
Section 1.3.1 .
1.3.3. Rationale for the Dose Selection
The starting dose of 0.6 mg GS -5829 was selected based on preclinical repeat- dose toxicology  
data, where this dose represented 1/6 the highest non- severely  toxic dose (HNSTD) in dog, the 
most sensitive nonclinical species tested. This dose is commensurate with the recommendation 
outlined in the ICH Guidance for Industry , “S9 Nonclinical Evaluation for Anticancer 
Pharmaceuticals” (March 2010). The starting dose of 0.6 mg GS -5829 once daily  provide d
margins of approximately 203 -fold of the severely  toxic dose (STD10) in the mouse 
(25mg/kg/day ) and 5.5- fold of the HNSTD in the dog (0.1 mg/kg/day ) on a human equivalent 
dose (HED) bas is as determined in the repeat dose toxicity  studies. 
PK data from the first 3 dose levels suggests that exposure in humans i shigher than initially  
predicted and the refore additional intermediate dose levels have been added.
Based on preliminary  pharmacokinetic data in the earl y dose levels of this study , the potentiall y 
clinically  efficacious exposure (AUC 2.5 h.µg/mL) in humans is anticipated to be achieved with 
once dail y dosing of 3 to 4 mg of GS-5829 , which is anticipated to achieve adequate target 
inhibition for a portion of the dosing interval as supported by  in vivo preclinical data.  
Dose Levels of 0.6, 1.4, 2.0 and 3.0 enrolled a single subject with the pla n to expand to at lea st 
3subjects if a ≥ Grade 2 treatment- related toxicity was observed within the initial dosing period 
(Study  Day  1 through C1D28). No drug related toxicities w ere observed at Dose Levels 
0.6through 2.0 mg. Should a ≥ Grade 2 treatment- related toxicity  be observed in the subject 
receiving 3.0 mg, then a standard 3+3 stud y design will initiate at the 3.0 mg dose. Should no 
≥Grade 2 treatment -related toxicity be observed in the subject receiving 3.0 mg dose, the next 
dose to be enrolled, Dose L evel 4.0 mg will expand enroll ment to at least 3subjec tsand the 
study  will proceed with a standard 3 + 3 study  design. The stud y will proceed until MTD is 
identified.
Due to the narrow therapeutic index observed in dogs, the percentage dose increment 
sequentially  decreases at each dose level.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 31 20 June 2016The breast cancer arm of the study  (Group 2A and 2B) will initiate at 2.0 mg which has been 
demonstrated to be safe and tolerable in patients with advanced stage solid tumors and 
lymphoma in Group 1 of t his study . No drug interaction sor overlapping toxicit iesareexpected 
between GS -5829 and exemestane or fulvestrant . Group 2 will not dose escalate bey ond the 
single agent MTD of GS -5829.
TheGroup 3lymphoma expansion arm will initiate at a dose ≤ to the MTD as determined in 
Group 1; e.g. a dose that has been demonstrated to be safe and tolerable in patients with 
advanced stage solid tumors and ly mphoma in Group 1 of this study .  
1.4. Compliance
This study  will be conducted in compliance with this protocol, G
ood Clinical Practice (GCP), 
and all applicable regulatory  requirements.
1.5. Risk/Benefit Assessment for the Study
Based on the s ystemic concentrations of GS -5829 measured in the repeat dose toxicity  studies in 
mice and dogs, the margins of exposure at the severel y toxic dose in 10% of rodents (STD10) in 
mice and HNSTD in dog are approximately  6.3- and 1-fold , respecti vely, at the anticipated 
clinically  efficacious exposure.  Another bromodomain inhibitor in development has identified 
thrombocy topenia as the earliest sign of toxicity  in human studies, a toxicity  which may  be easily  
monitored. 
Target organs identified i n the repeat -dose toxicity studies included hematopoietic and male 
reproductive s ystems (mice and dogs), the adrenal glands (mice), and the GI tract and respiratory  
system (dogs). With the exception of the adrenal glands in the mouse and the respiratory  system 
in dogs, all other target organs are expected based on the known pharmacology  of GS -5829 to 
inhibit BET proteins. The effects on the hematopoietic sy stem, male reproductive tract, adrenal 
glands, and GI tract were considered reversible and can be moni tored in the clinic.
As of a data cutoff of 12 October 2015 , in this First-In-Human stud y GS -US- 350-1599 no deaths 
resulting from adverse events ( AEs)have occurred.  Two subjects experienced 3 serious adverse 
events ( SAEs )
which were considered by the investigator to be Grade 3 and not related to study  
drug (cholangitis and sepsis in 1 subject at 0.6 mg and throm bocy topenia in 1 subject at 1.4 mg). 
The following AEs were considered related to study  drug: fatigue (1 subject, 0.6 -mggroup and 
1subject, 1.4 -mggroup), nausea (1 subject, 0.6 -mggroup and 1 subject, 1.4 -mggroup), 
splenomegaly (1subject, 1.4 -mggroup), and dizziness (1subject, 1.4 -mggroup). No AEs lead to 
discontinuation of study  drug.
  After the data cut, a DLT of adrenal hemorrhage was re ported in 
a subject receiving 4 mg of GS- 5829.   The subject had normal coagulation parameters and a 
platelet count higher than normal at baseline which did not change at the time of the event.  An 
additional DL T of Grade 3 thrombocy topenia was reported in a subject receiving 3 mg of 
GS-5829.
Assessments for AEs and monitoring for laboratory abnormalities are specified in the protocol 
and include s ymptom and AE assessment on Da ys 1, 8, 15, 22 of the first 28 day cycle and then 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 32 20 June 2016every  28 day s, until en d of tr eatment followed b y a 30-day Safet y Follow -Up V isit. Phy sical 
examinations will occur on Day  1of each 28- day cycle until end of treatment ,followed by  a 
30-day Safet y Follow - Up visit.
The safet y monitoring frequency is considered sufficient to identify potential AEs as they  
emerge. In addition, mitigation strategies are incorporated into the stud y design. The inclusion 
and exclusion criteria are designed to ensure subjects have acceptable organ function to be 
eligible for this study  such that confounding significant co -morbidities are excluded. 
Study medications will continue until disease progression, unacceptable toxicity , consent 
withdrawal, or subject’s refusal of treatment.
Potential Benefits
The primary  potential benefit of BET inhibition is that th erapy ma y delay  progression or improve 
overall survival in patients with ly mphoma or solid tumor who do not have alternative therapies 
which have been demonstrated to provide significant clinical benefit. For patients with breast 
cancer ,the potential ben efit of BET inhibition administered in combination with sta ndard 
anti-estrogen therap y is to delay progression or improve overall survival.  
Participants are informed that their involvement in the study  may  offer benefits to other current 
or future cancer patients by  enhancing knowledge relating to treatment.
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
2. OBJE CTIVES 
The pr ima1 y objectives of this study are: Final 
Amendment6 
• Ch aracte rize the safety and tolerabi lity of GS-5829 as a mon otherapy in subjects with 
adva nced solid tumors and l ymphomas 
• Dete nnine the MTD or r ecommended dose for phase 2 study (RDP2) of GS-5829 as a 
monotherapy in subjects with adva nced solid tumors and lymph omas 
• Ch aracte rize the safety and tolerabi lity of GS-5829 in combinatio n with exemestane or 
fulvestrant in subjects with adva nced estroge n recepto r positive breast cancer 
• Dete nnine the MTD or RDP 2 of GS-5829 in combination w ith exemestane or fulvestra nt in 
subjects with adva nced estrogen recepto r positive breast cancer 
The secondaiy objective of this study is: 
• Evaluate the PK of GS-5829 alo ne in subjects with advanced solid tumors and lymphomas 
and in comb ination with exemesta ne or fulvestrant in subjects with advanced estroge n 
recepto r positive breast cancer 
I 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 33 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 34 20 June 20163. STUDY  DESIGN
3.1. Endpoints
The endpoints for this study  are described in Section 8.
3.2. Study Design
This isanopen -label,multicenter, sequenti al dose- esc ala tionstudy toevaluate thesafet y,
tolerability ,PK,and PD of GS-5829 as a single agent in subjects with advanced solid tumors and 
lymphomas and in 
combination with exemestane or fulvestrant in subjects with advanced 
estrogen receptor positive breast cancer.   
Group 1 : Single agent GS -5829 in solid tumors and lymphomas
Cohorts ofsubjects with advanced solid tumors and ly mphomas who have failed or areintolerant
tostan
dardtherap yorforwhom no standard therapy existswillbe sequenti allyenrolled at
progressi vely higher dose levels toreceive oral GS- 5829 asmonothe rapy once daily  (QD ).The 
starting dose will be 0.6 mg. Each dose level will enroll 1 subject until a ≥ Grade 2 
treatment -related toxicity is observed wit hin the initial dosing period (Study Day 1 through 
C1D28 for all cohorts). At Dose Level 5 or if a ≥ Grade 2 treatment -related toxicity  is observed
(whichever occurs first) , the dose level will be expanded to 3 subjects .(Note: subjects enrolled 
with a Grade 2 hemoglobin [Hb]must have Hb worsen b y at least 1 grade from baseline to be 
considered for expan sion of the cohort to 3subjects) .Once a dosi ng level has been expanded to 
3subjects, a standard 3+3 study  design will begin and, dose escalation [3+3] willbeperformed
with coho rtsizes of 3to6subje cts.Subjects in the first 3cohorts will receive a single dose and 
then approximately  7 days later, initiate dosing once dail y.  Subjects will return to the clinic for 
frequent evaluation and monitoring as per Appendix 2.
The doses for each candidate dose level in Group 1 are shown i n Table 3-1.
Table 3-1. Group 1: Single Agent GS - 5829
Dose Level GS-5829*
1 0.6 mg
2 1.4mg
3 2mg
4 3 mg
5 4 mg
6 6mg
7 9mg
8 12mg
* Dose levels may be modified based on emerging safety and PK results.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 35 20 June 2016If a DLT occurs within the 28 day  DLT period at any  dose level, this level will be expanded to 
enroll 3 additional subjects.
The safet yandtolera bility ofeach dose level willbeassessed by a safety  review team (SRT) after
all subjects inthecohort have been followed for at least 28 da ys after the first dose of GS -5829. 
If no DLTs occur in up to 3 subjects or < 2 DLTs occur in up to 6 subjects on any Dose Level 
after 28 days on treatment, the next Dose L evel will open .  Each subsequent Dose Le vel will 
open if the Dose Level preceding has no DLTs in 3 subjects or <2 DLTs in up to 6 subjects.
The SRT will consist of at least one investigator and the following: 
Gilead Sciences, Inc.(Gilead) study  team members: the medical monitor, representative s from 
Drug Safet y and Public Health (DSPH), Clinical Operations, and Biostatistics. Others may be 
invited to participate as members of the SRT if additional expertise is desired. The medical 
monitor serves as the chair of the SRT .
Prior to initiating enro llment for Dose Level 4 in Group 1, an anal ysis of all available safet y, PK, 
and PD data from previous cohorts will be reviewed.
If a subject is enrolled in a dose level but does not complete the PK or PD analy sis, they  may  
continue on study  but an additio nal subject may  be enrolled at that dose level.
TheMTD isthehighest dose level with asubject incidence of ≤ 1 DLT during thefirst28days of
study drug dosing of 6 subjects. A minimum of 6 subjects need to be treated at a dose level 
before this dose level can be deemed as the MTD. 
Group 2 :Combination therapy of GS -5829 with exemestane or fulvestrant in patient swith 
advanced stage estrogen receptor positive breast cancer
Cohorts of subjects with advanced estrogen receptor positive breast cancer for whom no standard 
curative therap
y exists and who are candidates for exemestane or fulvestrant will be sequentially  
enrolled at progressivel y higher dose levels oforal GS -5829 in combination with full standard 
doses of exemestane or fulvestrant. The starting dose of GS -5829 will be 2.0 mg QD, which is a
dose level that has been demonstrated to be safe and toler able (no Grade 2 or higher drug related 
toxicity ) in patients with solid tumors and prostate cancer.  Dose escalation will continue with 
cohort sizes of 3 -6 subjects in parallel arms:  Group 2A will initiate with 2.0 mg of GS -5829 
orally  once dail y on C ycle 1 Day  1 combi ned with 25mg of exemestane once daily beginning on 
Cycle 1 Day 1.  The subject may  initiate exemestane any time prior to, or on, Cy cle1 Day  1. 
Group 2B will initiate with 2.0 mg of GS
-5829 orally  once dail y on Cycle 1 Day 1 with 500 mg 
fulvestrant admini stered intramuscular ly(Cycle 1 Day 1 and then every  28days (+/-3 day s).  If 
Cycle 1 Day  1 is the subject’s f irst dose of fulvestrant, a one -time additional dose of fulvestrant 
should be administered on Cy cle 1 Day  15)
.  
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 36 20 June 2016The doses for each candidate dos e level in group 2 are shown in Table 3-2.  
Table 3-2. Group 2: Combination of GS- 5829 in Breast Cancer
Dose Level GS-5829* Group 2A Exemestane
Group 2B Fulvestrant
1 2 mg
25mg orally once daily500mg intramuscularly day 1,
29 and then every 28 days**2 3 mg
3 4 mg
4 6 mg
5 9 mg
6 12 mg
* Dose Levels may be modified based on emerging safety and PK results.
** Subjects initiating fulvestrant on this study should receive a single additional dos e of fulvestrant on Cycle 1 Day 15.
Group 2A and Group 2B will dose escalate independent of each other. In both Group 2A and 
Group 2B, each cohort will consist of 3 newly  enrolled subjects who will be treated at the 
specified dose level. After all subjects ineach cohort have been followed for at least 28 days after 
the first dose of GS -5829, a dose -DLT model ( Bayesian logistic regression model) utilizing all 
available GS -5829 safe tydata will be built and will provide estimates of DLT rates at all dose 
levels. The 
dose-DLT model recommended dose for the next cohort will be the one hav ingthe 
highest chance that the D LTrate will fall in the target interval [16%, 33%) and a probability of 
<25% that the DLT rate exceed s 33%.
Group 3 L ymphom a expansion:
In addition to the minimum 6 subjects in Group 1 with solid tumors or lymphomas who will be 
enrolled to confirm the MTD , an additional minimum of 6 s ubjects with aggressive NHL 
(DLBCL or PTCL) may be enrolled at a dose no higher than the MTD and complete a 28 day  
safety period.  If ≤ 1 of these 6 subjects reports a DL T within this 28 day safet y period, then up 
to an additional 34 subjects may  be enrolled to evaluate the efficacy  and tolerability of GS -5829 
in lymphoma (a maximum total of 40 subjects with ly mphoma enrolled) .A minimum of 20 
DLBCL and 5 PTCL subjects will be enrolled into this group.  If ≥ 2 of 6 subjects report a DLT, 
then an  additional 6 subjects will be enrolled at a lower dose level, or at an alternative dosing 
schedule, which decreases the total amount of GS -5829 administered over a 28 -day period to at 
least 25% less than the previous cohort (eg 14 days on and 7 day s off).  
The final dose escalation decisions will be made by  the SRT, following a review of the model 
recommendation and all relevant data available including safet y information, PK,  
clinical data from evaluable patients.
CCI -
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 37 20 June 2016Table 3-3. Group 3: Single agent exp ansion in aggressive lymphomas  
Dose 
Level GS-5829*# of subjects 
enrolled initially Total number of subjects
1 ≤ MTD determined by Group 1 6 subjectsIf no DLT in first 6subjects expand to
maximum total of 40 
(approx. 34additional subjects)
-1is ≥25% less total GS -5829 
administered over a 28 day period6 subjectsIf no DLT in 6 subjects at this dose 
level, then expand to maximum total of 
all Group 3subjects of 40 
(approx. 28additional subjects)
Sitesin France will be limited to Group 3 enroll ment only .
Dose escalation in Group 1 will continue until identification of the MTD, or a suitable lower 
recommended dose, for Phase II studies. At least 6 subjects should be treated and evaluated at 
the GS -5829 dose level recommended for Phase II studies.
ADLT in Group 1 or 2 isatoxicity de
fined below c onsidered possibly r ela tedto GS-5829
occurring during theDLT assess mentwindow ( Study  Day 1 through C1D28) ineach cohort.
Grade ≥ 4 neutropenia (absolute neutrophil count [ANC] < 500/ mm
3) 
Grade ≥ 3 neutropenia (ANC < 1000/mm3) with f ever (a single temperature of > 38.3°C or a 
sustained temperature of ≥ 38°C for more than one hour)
Grade ≥ 3throm bocy topenia 
Grade ≥2 bleeding (e.g. gastrointestinal, respiratory , epistaxis, purpura)
Grade ≥ 3 or higher non-hema tologic toxicity , except:
Grade 3 nausea or emesis with maximum duration of 48 hours on adequate medical 
therap y
Grade 3 diarrhea which persists for < 72 hours in the absence of maximal medical 
therap y
Grade ≥ 2 non
-hematologic treatment -emergent adverse event ( TEAE) that in the opinion of 
the investigator is of potential clinical significance such that further dose escalation would 
expose subjects to unacceptable risk
Treat ment interruption of ≥ 7 daysduetounresolved toxicity
For certain toxicities such as laboratory  assessments without a clear clinical correlate, 
adiscussion between the Investigator andMedical Monitor may  take place to determine if 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 38 20 June 2016this AE should be assessed as a DLT necessitating dose reduction . However , any Grade 3 or 
Grade 4 elevation in AST or ALT associated with a Grade 2 elevation in bilirubin that is at 
least possibly  related to study  drug will be considered a DLT.
Group 3: For the first 6 subjects enrolled in the aggressive l ymphoma group (Gr oup
3), a 
modification of the DLT assessment for hematologic toxicity  will be:
Grade ≥ 4 neutropenia (absolute neutrophil count [ANC ] <500/mm3) which persist for 
> 3days upon interruption of GS -5829 (administration of growth factors not allowed 
concurrently , but allowed during GS -5829 interruption)
Grade ≥ 4 thrombocy topenia (< 25,000/m m3)
Grade ≥ 3 thrombocy topenia  (< 50,000/mm3to 25,000/mm3which persists for > 7days 
upon interruption of GS -5829
3.3. Study Treatments
Subjects who meet eligibility criteria will receive GS -5829 orally  once daily .  Subjects in the 
first 3 cohorts will receive a single dose of GS -5829 and then approximately 7days later start 
their first 28 day  cycle of GS -5829 once dail y.  Each cy cle will consist of 28 days.  Safet y and 
efficacy  assessments will occur on an outpatient basis including assessment of tumor response, 
physical exam, vitals, electrocardiogram ( ECG ), collection of blood samples (for routine safet y 
labs, GS -5829 PK,  at applicable visits), urine pregnancy  (every  
4 weeks while receiving GS-5829 in females of childbearing potential), and assessment of AEs. 
In addition, subjects will undergo computed tomography  (CT)/magnetic resonance imaging 
(MRI )or applica ble scans every  8 weeks for the first year and then every  12weeks .Subjects in 
Group 3 will undergo a PET/CT if available instead of a CT scan alone at week 16.
A subject who does not show evidence of disease progression by clinical assessment or by  
CT/MRI or applicable scan may  continue receiving GS - 5829 once dail y day until disease 
progression (clinical or radiographic), unacceptable toxicity , withdrawal of consent, or other 
reasons specified in Section 3.4.
For subjects in Group 2 ,a radionuclide bone scan (whole bod y) is also required at screening and 
then as clinicall y indicated or to confirm a complete response. 
Study  drug dosing will continue in the absence of disease progression or toxicity  warranting 
discontinuation of therap y.
3.4. Criteria for Discontinuation of Study Drug
Study  medication may  be discontinued in the following instances:
Documented progression of malignant disease
Pregnancy
CCI
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 39 20 June 2016Investigator discretion 
Non-compliance with study  drug
Subject never dosed with study  drug
Protocol violation
Subject decision
Lost to follow -
up
Study  termination by  the sponsor
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or 
toxicity  that, in the judgment of the investigator, compromise s the ability  to continue 
study -specific procedures or is considered to not be in the subject’s best interest
3.5. Criteria for Removal from Study
Subjects may  be removed from the study  for the following reasons:
Documented progression of malignant disease
Death
Pregnancy
Investigator discretion 
Non-compliance with study  drug
Protocol violation
Withdrawal of consent 
Lost to follow -up
Study  termina tion by  the sponsor
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 40 20 June 20164. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Up to 160 subjects who meet the eligibility  criteria will be enrolled.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for particip ation in this 
study .
1)Male or female ≥ 18 y ears of age . Subjects in Group 2 must be female.
2)Group 1: Histologicall y or cy tologically  confirmed advanced malignant solid tumor or 
lymphoma (an y subt ype) that is refractory  to or intolerant of standard therapy  or for which no 
standard therap y is available . 
3)Group 2: Histologicall y or cy tologically  confirmed breast cancer with evidence of metastatic 
or locally  advanced disease not amenable to resection or radiation therapy  with curative 
intent and who have progre ssed during treatment with at least one prior hormonal therapy .  
Prior chemotherap y for advanced/metastatic disease is allowed.
a.Documentation of ER positive ( ≥ 1% positive stained cells b y local standards) based on 
the most recent tumor biopsy , unless bone onl y disease.
b. HER2- negative tumor based on local testing on most recent tumor biops y 
(immunohistochemistry  score 0/1+ or negative b y in situ hy bridization HER2/CP17 ratio 
< 2 or for single probe assessment HER2 cop y number < 4)
c.Post, pre or peri -menopausa l subjects to be in the post -menopausal state as defined b y 
one of the following:
i.Age ≥60 years
ii.Age < 60 years and cessation of regular menses for at least 12 consecutive months 
in 
the absence of chemotherapy , tamoxifen, toremifene, or ovarian su ppression and 
serum estradiol and FSH level within the post-menopausal range
iii.Prior bilateral oophorectomy
iv.Pre/perimenopausal women can be enrolled if amenable to be treated with the LHRH 
agonist goserelin. Patients must have commenced treatment with goserelin or an 
alternative LHRH agonist at least 4 weeks prior to first dose of study drug. If patients 
have received an alternative L HRH agonist prior to study  entry  they  must switch to 
goserelin for the duration of the study .
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 41 20 June 20164)Group 3 ly mphoma expan sion: Subjects with ly mphoma are limited to diffuse large B -cell 
lymphoma orperipheral T -cell l ymphoma that are refractory  to or intolerant of standard 
therap y or for which no standard therap y is available
5)All acute toxic effects of any  prior antitumor therapy  resolved to Grade ≤ 1 before the start of 
study  drug dosing (with the exception of alopecia [Grade 1 or 2 permitted] and neurotoxicity  
[Grade 1 or 2 permitted])
6) ECOG Performance Status of ≤ 1
7)Life expectancy of > 3 months, intheopinion ofthe Investigator
8)Adequate organ function defined asfollows:
a.Hematologic: Platelets ≥ 100 x 109/L;Hemoglobin ≥ 9.0 g/ dL; ANC ≥ 1.5 x 109/L 
(without platelet transfusion or an y growth factors within previous 7 day s of the 
hematologic laboratory  values obtained at screening visit).  Patients in the Group 3 
lymphoma expansion may be enrolled with an ANC of ≥ 1.0 x 109/L; 
Platelets ≥ 75 x 109/L.
b.Hepati c:Aspartate transaminase ( AST ) /Alanine transaminase ( ALT) ≤ 2.5 x upper limit of 
normal ( ULN)(ifliver metastases are present, ≤ 5 x ULN); Total orconjugated bilirubin 
≤ 1.5 x ULN
c.Renal: Serum Creatinine ≤ 1.5 x UL N or creatinine clearance (CrCl) ≥ 60 ml/min as 
calculated b y the Cockroft -Gault method
9)Coagulation: Intern ationalNormalized Ratio ( INR) ≤ 1.2 
10)Negative serum pregnancy  test for female subjects ( Appendix 7)
11)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendi x
7.
12)
Females who are nursing must agree to discontinue nursing before the first dose of GS-5829
13)Able and willing to provide written informed consent to participate in the study
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)History or evidence of clinically significant disorder, condition, ordisease that, intheopinion
oftheInvestigator or Medical Monitor would pose a
risktosubject safety or interfere with the
study evaluations, procedures, or co mpletion
2)Pregnant 
3)Known brain metastasis or leptomeningeal disease
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 42 20 June 20164) Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, 
active or chronic bleeding event within 28 day s prior to first dose of study  drug, uncontrolled 
cardiac arrh ythmia, or psy chiatric illness/social situation that would limit compliance with 
study  requirements as judged b y treating ph ysician
5)Myocardial infarction, symptoma ticcongestive heartfailure (New York Heart Association
Clas
sification >Class II), unstable angina, orserious uncontrolled cardiac arrhy thmia within
thelast6 months ofstudy Day 1
6)Major surgery , defined as any  surgical procedure that involves general anesthesia and a 
significant incision (ie , larger than what is required for placement of central venous access, 
percutaneous feeding tube, or biopsy ) within 28 day s of first dose of study  drug
7)Impairment of gastrointestinal (GI) function or GI disease that may  significantl y alter the 
absorption of GS -5829, including an y unresolved nausea, vomiting, or diarrhea that is 
Common Terminology  Criteria for Adverse Events ( CTCAE ) Grade >1
8)Minor surgical procedure(s) within 7 day s of enrollment or randomization, or not y et 
recovered from prior minor surgery  (placement of central venous access device, fine needle 
aspiration, or endoscopic biliary  stent ≥ 1 day  before enrollment or randomization is 
acceptable)
9) Anti- tumortherap y(chemotherapy ,antibody therapy , molecular targeted therapy)within
21daysor5half -lives, whichever islonger, ofstudy drug dosing (6weeks for nitrosourea s,
mitomycin C,or molecular agentswith t½> 10 days); concurrent useofhormone therap yfor 
prost atecancer isperm itted, and concurrent use of exemestane or fulvestrant (and goserelin 
for pre/perimenopausal breast cancer as per inclusion criteria 2.c.iv) for subjects enrolled in 
Group 2 (advanced breast cancer) is permitted
10)History  of long QT s yndrome or whose 
corrected QT interval ( QTc)measured 
(Fridericia method) at screening is prolonge d (> 450 ms for males and > 470ms for females). 
Subject s who screen- fail due to this criterion are not eligible to be re -screened
11)Prior exposure to BET inhibitors
12)Clinically  significant bleeding within 28 day s of study  Day  1
13) K nown human immunodeficiency  virus (HIV) infection
14)HBsA gpositive
15)HCV antibody  positive
16)Use of strong /moderate CYP3A4 inhibitors or strong /moderate CYP3A4 inducers within 
2week sprior to the first dose of study  drug
17)Evidence of bleeding diatheses
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 43 20 June 201618)History  of hemopty sis of ≥ 2.5 mL /1 teaspo on within 6 months of study  Day 1
19)History  of high grade esophageal or gastric varices
20)No active anticoagulation within 7 day s of study  Day  1; including acet ylsalicy lic acid, 
lowmolecular weight heparin , or warfarin.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 44 20 June 20165. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Enrollment
It is the responsibility  of the I nvestigator to ensure that subjects are eligible for the study  prior to 
enrollment. Subjects will be assigned a unique screening number at the time of consent.
Once eligibility  is confirmed subjects will be assigned a unique subject number. This is an 
open -label stud y.
All baseline tests and procedures must be completed prior to the administration of the first dose 
of study  drug on Day 1. On ce a subject number is assigned to a subject, it will not be reassigned 
to another subject .
Sites in France will be limited to Group 3 enrollment only .
5.2. Description and Handling of GS-5829, Exemestane and Fulvestrant
5.2.1. Formulation
GS-
5829 will be supplied as gray, plain- faced, film -coated, round tablets c ontaining either 
0.2,
1,or 10 mg GS -5829 (0.24, 1.22 or 12.20 mg GS -5829- 02, phosphate salt form of GS - 5829, 
respectivel y). Also, GS -5829 will be supplied as orange, plain- faced, film -coated, round tablets 
containing 5 mg GS -5829 (6.10 mg GS -5829- 02, phosphate salt form of GS -5829). In addition to 
the active ingredient, 0.2 mg, 1 mg, and 10 mg tablets contain the following commonly  used 
excipients: microcry stalline cellulose, lactose monohy drate, crospovidone, magnesium stearate, 
polyvinyl alcohol, ti tanium dioxide, poly ethylene gl ycol, talc, and iron oxide black. In addition 
to the active ingredient, 5 mg tablets contain the following common ly used excipients: 
microcry stalline cellulose, lactose monohy drate, c rospovidone, magnesium stearate, pol yvinyl 
alcohol, titanium dioxide, poly ethylene gly col, talc, FD&C y ellow#6, and iron oxide y ellow. 
Exemestane and fulvestrant are commerciall y sourced. Information regarding the formulation 
can be found in the current prescribing information
. 
5.2.2. Packaging and Labeling
GS-5829 tablets (0.2, 1, 5, and 1 0mg) are packaged in white, high density  poly ethylene bottles 
with desiccant and pol yester packing ma terial. Each bottle contains 30 tablets and is enclosed 
with a white, co ntinuous thread, child -resistant screw cap wit h an induction -sealed, 
aluminum -faced liner.
GS-
5829 bottles to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food a nd Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice –Annex 13 (Investigational Medicinal 
Products), and/or other local regulations .
Sufficient quantities of GS -5829 tablets will be shipped to the investigator or qualified designee 
from Gilead Sciences Clinical Supplies Management (or its designee).
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 45 20 June 2016Exemestane and fulvestrant will be labeled to meet applicable requirements of the United States 
Food and Drug Administration (FDA), EU Guideline to Good Manufacturing Practice –
Annex 13 (I nvestigational Medicinal Products), and/or other local regulations. 
5.2.3. Storage and Handling
GS-5829 tablets should be stored at controlled room temperature until required for 
administration.  Controlled room temperature is defined as 25°C (77°F); excurs ions are permitted 
between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. 
Until dispensed to the subjects, all bottles of study  drug should be stored in a securel y locked 
area, accessible only to authorized site personnel. T he study  center will be required to maintain a 
log of dail y temperature readings in the storage area for the duration of the study . To ensure the 
stability  and proper identification, the drug product should not be stored in a container other than 
the conta iner in which they  were supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact with the body . 
Appropriate precautions should be followed to avoid direct ey e contact or exposure through 
inhalation when handling GS-5829 tablets.
Exemestane and fulvestrant are commerciall y sourced. Information regarding the storage 
condition can be found in the current prescribing information.
5.3. Dosage and Administration of GS-5829, Exemestane and Fulvestrant
GS-5829 tablets will be provided b y Gilead Sciences, Inc. and will be taken orally. Initiation of 
treatment with the study  drug will take place after enrollment and cohort assignment. Thefirst
3cohorts of subject s will take a single dose of GS
-5829 and the n approximately  7days later take 
their dose of stud y drug at approximately 24- hour intervals. Subjects in dose levels 4-8will take 
their dose of stud y drug at approximately  24
-hour intervals.  To reduce inter -subject variability  
on efficacy  and safet y, subject s will be instructed to take GS -5829 approximately 1hour before 
or 2 hours after a meal.  Grapefruit juice is prohibited while on study  drug .
At one or more dose levels , GS-5829 dose will be administered in fed state with a standardized 
meal (~500 to 600 calories and ~30% of calories from fat) on Day  1 of C ycle2.
If the subject misses a dose, he/she should be instructed to take the stud y drug as soon as he/she 
remembers, unless more than 8 hours has elapsed since the scheduled time of the missed d ose. In 
this case, the subject should be instructed to wait and take the next dose at the regularl y 
scheduled time. Subjects should not take more than 1 dose of study  drug at a time .
If a subject vomits within 5 minutes of dosing and the tablet is visible, the subject should be 
instructed to re -dose.  If a subject vomits more than 5 minutes after dosing or if the tablet is not 
visible, the subject should be instructed to wait and take the next dose at the regularly  scheduled 
time.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 46 20 June 2016Aromasin® (exemestane) will be supplied as 25 mg tablets for oral administration.  Subjects 
assigned to receive exemestane in combination with GS- 5829 in the study  will self -administer 
exemestane orall y once daily , beginning on or before Cycle 1 Day  1of the study  and thereafter at 
approximately  the same time each day  until the end of treatment .  Refer to Appendix 9for 
further details.
Faslodex®(fulvestrant) is supplied as 50 mg/mL for intramuscular administration.  Subjects 
assigned to receive fulve strant in combination with GS
-5829 in this study  will receive fulvestrant 
on Cy cle 1 Day  1 and every  28 day s (+/-3 day s) until the end of treatment . For subjects initiating 
fulvestrant on this study , a single additional do se of fulvestrant 500 mg should b e administered 
on Cy cle 1 Day  15 (+/- 3 day s).  Fulvestrant should be administered intramuscularl y into the 
buttocks slowly  (1 –2 minutes per injection) as two 5mL  injections, one in each buttock.  Refer 
to Appendix 10for further details.
5.4.
Prior and Conco mitant Medications
In vitro data indicate GS -5829 is a substrate of CYP3A4. Co -administration of CYP3A4 
inhibitors may  increase GS -5829 exposure. As such, co -administration of moderate and strong 
CYP3A4 inhibitors with study  drug is prohibited in this stud y. Co-administration of CYP3A4 
inducers may  decrease GS -5829 exposure. As such, moderate and potent CYP3A4 inducers are 
prohibited while subject is on study  drug and within 2 weeks prior to stud y drug administration. 
Examples of moderate and strong CYP3A4 inhibitors and inducers are provided in the table 
below.
Table 5-1. Examples of C oncomitant Medications Prohibited in this Study
Moderate Strong
CYP3A4 Inhibitoraprepitant, ciprofloxacin, crizotinib, 
diltiazem, erythromycin, fluconazole, 
imatinib, verapamilclarithromycin, conivaptan, grapefruit 
juice, itraconazole, ketoconazole, 
nefazodone, posaconazole, 
telithromycin, voriconazole
CYP3A4 Inducer bosentan, modafinil, nafcillincarbamazepine, phenytoin, ri fampin, 
St.John’s w ort
Toxicology  data from dogs demonstrate dminimal to moderate gastrointestinal, pulmonary , 
muscular and intracardiac bleeding.  The mechanism for the bleeding is not understood.  
Anticoagulant medications are prohibited on study ; this includes vitamin K antagonists 
(eg,warfarin), low molecular weight heparin, Factor Xa inhibitors, thrombin inhibitors and 
acetylsalicy lic acid . If anticoagulation therap y needs to be initiated while on study treatment, the 
Investigator should consult with the Medical Monitor to determine if study  treatment should be 
discontinued.
5.5. Accountability for GS-5829
The investigator is responsible for ensu ring adequate accountability  of all used and unused study  
drug. This includes acknowledgement of receipt of each shipment of study  drug (quantity  and 
condition). All used and unused study  drug dispensed to subjects must be returned to the site.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 47 20 June 2016GS-5829 a ccountability  records will be provided to each stud y site to:
Record the date received and quantity  of study  drug kits
Record the date, subject number, subject initials, and the quantity  of study  drug dispensed
Record the date, quantity of used and unused study drug returned, along with the initials of 
the person recording the information.
5.5.1. GS-5829 Return or Disposal
Study  drug should be retrieved from each subject at the end o f each dispensing interval. 
Thequantity  of study  drug and the date returned by  thesubject should be recorded in the study  
drug accountability  records. All study  drug returned by  the subject should be retained for review 
by the study  site monitor prior to destruction.
Please see Section 9.1.7 for more information.
GS-5829 
Protoco l GS-US -350-1599 
Gilead Sciences , Inc. 
6. STUDY PROCEDURES Final 
Amendment6 
The study proced ures to be conducted for each subject enrolled in the study are presented in 
tabul ar fonn in Appendix 2 and described in the text below. 
The investigator must doclllllent any deviation from protoco l proce dures and notify the spon sor 
or contract research org anization (CRO). 
Safety and tolerability assess ments will include regular mo nitoring of AEs, changes from 
baseline in laborato1 y v ariables, physical examinations, vital signs, and special safety assess ment 
like ECGs . 
From the time of obtaining info1med consent through the first admini stration of investigational 
medicinal product, r ecord all serious ad verse events (SAEs), as well as any non-serious AEs 
related to protoco l-mand ated proced ures on the AEs electronic case repo1 i fonn (eCRF). 
All other untowa rd me dical occunences observed durin g the Screening period, including 
exace rbation or ch anges in medical histo1 y are to be captured on the me dical histo1 y eCRF. 
See Section 7 for additional details. 
6.1. Study Procedure Description s 
During the tr eatment pe riod, all visits may be performed wit hin the specified window for that 
study visit (see Appendix 2). A subj ect is considered enrolled into the study once enrollment in 
the IxRS system is completed. 
6.1.1. Informed Consent 
Subjects who screen fail must re-sign the info1med consent, if any screening proced ures will be 
perfo1med ou tside of the 28-day screening window from the time of the first info1med consent. 
6.1.2. Medical & Medication History 
A complete medical histo1 y w ill be ob tained by the Investigator or designee. Medica l histo1 y w ill 
include infonnation on the s ubject's significant past medical events (eg, prior hospitalizations or 
surgeries), a review of the disease under study, prior anti- cancer therapies, and any concunent 
illnesses . 
CONFIDENTIAL Page48 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 49 20 June 20166.1.3. Physical Examination
The Investigator or qualified designee will perform a phy sical examination at Screening and 
timepoints outlined in the Study  Procedures Tables ( Appendix 2). Pre -dose abnormal findings 
will be reported on the m edical history  page of the eCRF. Any changes from the pre -dose 
baseline ph ysical examination which represent a clinically  significant deterioration will be 
documented on the AE page of the eCRF.
Weight (without shoes) should be measured with each ph ysical examination.
Height (without shoes) should be measured at Screening only .
6.1.4. Vital Signs
Vital signs, including blood pressure, respiratory  rate, pulse, and temperature will be measured at 
the time points listed in the Study  Procedures Tables in Appendix 2. All measurements will be 
recorded on the appropriate eCRF page with appropriate source documentation. Any  abnormal 
measurements may  be repeated and reported as AEs if appropriate.  All measures of blood 
pressure will be performed using standard sph ygmomano metry .  Measurements of blood 
pressure should be taken per institutional guidelines . 
6.1.5. Electrocardiogram Assessment
Triplicate 12-lead ECGs reporting ventricular rate, PR, QRS, QT, and QTc intervals will be 
obtained at the timepoints outlined in the Study  Procedures Tables ( Appendix 2)and transferred 
to a central vendor for storage .  ECG s should alwa ys be collected prior to PK (or any other blood 
draw) if they  are to be collected at the same nominal timepoint. Subjects should be resting 
quietly  and free of distraction (e.g. tv, conversation) for 10 minutes prior to ECG collection and 
ECGs should be collected over a 5 minute window at each timepoint.
The Investigator or qualified designee will review all ECGs. The ECG tracings will be 
maintained in the source documentation of each subject and the appropriate data reported on the 
eCRF .
6.1.6. Echocardiogram
Echocardiograms will be performed at the timepoints listed in the Study  Procedures Tables 
(Appendix 2).  
Abnormal echocardiogram findings that are considered clin ically  significant by  the Investigator 
should be reported as AEs and recorded in the AE eCRF if the finding meets the definition of an 
AE. 
6.1.7. ECOG Performance Status
The Eastern Cooperative Oncology  Group (ECOG) Performance Status will be performed at the 
timepoints listed in the Study  Procedures Tables ( Appendix 2).  ECOG will be scored using the 
scale index in 
Appendix 8.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 50 20 June 20166.1.8. Prior and Concomitant Medications
At Screening, all medication taken up to 30 day s prior to the screening visit will be recorded on 
the eCRF.  At each study visit, the site will capture an y and all medications taken b y the subject 
since the last visit or during the visit (as applicable). Conco mitant medications include 
prescription and non -prescription medications, pre -infusion medications (eg, anti-emetics), and 
vitamins and minerals.
In addition, supportive therapies given during the course of the stud y (eg, blood transfusion, 
growth factor) should be collected and recorded on the eCRF. 
6.1.9. Adverse Events
Subjects will be assessed for 
adverse events ( AEs)per guidelines in the National Cancer Institute 
(NCI)CTCAE (version 4.03) at the timepoints outlined in the Study  Procedures Tables 
(Appendix 2). Any  AEs reported after informed consent is obtained and throughout the study  
will be recorded on the eCRF with appropriate source documentation.  The site will contact the 
study  subject b y phone approximately  30days after the last dose of stud y drug t o assess AEs.   
Please refer to Appendix 6for CTCAE grading criteria.
Please refer to Section 7for additional information on AE reporting.
6.1.10. CT or MRI
CT scans will be obtained to document metastatic disease, identify  target lesions as described in 
RECI ST (version 1.1), and to assess response and disease progression. Patients with ly mphoma 
will be assessed b y Cheson Criteria (Appendix 5). Patients with Prostate Cancer will be assessed 
by radionuclide bone scan and CT scan (or MRI) of the chest, abdomen and p elvis.  Response 
and disease progression for patients with prostate cancer will be assessed based on PCWG
criteria ( Appendix 4).In subjects who cannot tolerate iodinated contrast, a CT of the lung 
without contrast and MRI of the abdomen should be performed.  Imaging by CT scan 
(with contrast) or MRI 
or applicable scan will be performed at Screening (within 8weeks before 
Day 1 if t he scan was performed as part of standard medical practice) and at the timepoints 
outlined in the Study  Procedures Tables ( Appendix 2).  Please refer to Appendix 3-Appendix 5
for additional information on RECI ST (version 
1.1), Cheson Criteria and PCWG2 Cri teria.
The same radiographic procedure and specification (eg, the same contrast agent, slice thickness, 
etc.) used to define measurable lesions must be used throughout the study for each subject. An y 
subject with sy mptoms suggestive of disease progression should be evaluated for tumor response 
at the time the sy mptoms occur. Tumor burden will be characterized at Baseline and subsequent 
response assessments will be carried out according to the RECI ST (version 1.1) criteria (solid 
tumors) , Cheson Criteria ( lymphoma )and PCWG Criteria (prostate) .
For subjects in wh
oma radiologic CR is determined, a bone marrow biopsy  may  be required for 
complete assessment. In a subject who has a baseline bone marrow involvement with ly mphoma 
or does not have a baseline bone marrow ex amination, declaration of an on- study  CR requires 
bone marrow biops y documentation of the absence of bone marrow l ymphoma. I n a subject who 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 51 20 June 2016has a baseline bone marrow biopsy  showing no evidence of l ymphoma, declaration of an 
on-study  CR does not require bone marrow examination as long as other criteria fo r CR are met. 
The bone marrow biops y will be performed at the local lab .
6.1.11. Bone Scans (Group 2 )Only
Subjects in Group 2 (breast cancer) 
will undergo radionuclide bone scan at Screening, as 
clinically  indicated orto confirm complete response during the treatment period and at the end of 
treatment for sites of disease identified at Screening (unless disease progression has been 
confirmed elsewhere). 
Group 2 Tumor Assessment Requirements:
Method Screening Treatm ent Period End of Treatment Visit
CT or MRI of chest, 
abdomen, and pelvisRequired Required Required if not done within 4 weeks
CT or MRI of any other 
site of disease, as 
clinically indicatedRequiredRequired for sites of 
disease identified at 
screeningRequir ed if not done within 4 weeks. 
Required f or sites of disease identified 
at screening, unless disease progression 
has been confirmed elsewhere
Radionuclide bone scan 
(whole body) and 
confirmatory imaging in 
case of any hots spots 
(CT, MRI, or X- ray)RequiredAs clinically indicated or 
to co nfirm complete 
responseRequi red if not done within 4 weeks.
Required for sites of disease identified 
at screening, unless disease progression 
has been confirmed elsewhere
Photographs of all 
superficial lesions as 
applicableRequiredRequired for sites of 
disea se identified at 
screeningRequi red if not done within 4 weeks.
Required for sites of disease identified 
at screening, unless disease progression 
has been confirmed elsewhere
6.1.12. PET/CT S can
Subjects who are enrolled in Group 3 (DLBCL or PTCL) will undergo apositron emission 
tomograph y (PET) and CT scan at Screening and at Week 16 to evaluate response, unless the 
subject has demonstrated disease progression prior to this date.   
6.1.13. Blood and Urine Samples
Blood and urine for laboratory safet y tests will be collected according to the Study  Procedures 
Tables ( Appendix 2). The date and time of blood and urine collection will be recorded in the 
subject’s source documentation. The date and time of previous GS -
5829 dose will be recorded in 
the subject’s source documen tation on day s where PK is collected. The tests will be analy zed 
using standard procedures. White blood cell (WBC) differentials will be reported as absolute 
counts. Al l laboratory  tests must be reviewed for clinical significance by  the Investigator or 
qualified designee.   Eligibility  will be based on central laboratory  assessments and will be 
collected within 7 day s of Study  Day  1 / C1D1
.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 52 20 June 2016Day 1 pre -dose samples may  be drawn up to 2 day s prior to the Day  1 visit.
The anal ytes listed in Table 6-1will be tested.
Table 6-1. Blood and Urine Samples Collected During the Course of the Study
Serum Che mistry Hem atology Other
Sodium
Potassium
Chloride
Glucose
BUN
Creatinine
ALT
AST
Alkaline phosphatase
Total bilirubina
Total protein
Album in
Calcium
Magnesium
Phosphate
Lactate dehydrogenase
AAGWhite Blood Cell (WBC) Count
Hem oglobin
Hem atocrit
Platelet Count
Neutrophils (ANC)
Lymphocytes
Monocytes
Basophils
EosinophilsGS-5829 concentration
Serum and Plasma 
Hepatitis B surface 
antigen (HBsAg)
Hepatitis C (HCV) 
antibody
25-hydroxyvitamin D
Coagulation
PT/INR
aPTT
Platelet Activationb
Pregnancy Testing Urine
Serum Qualitative -human chorionic 
gonadotropin (h CG)(fem ales)
Urine Pregnancy (fem ales)Urinalysis
a Includes direct bilirubin
b platelet activation testing to be performed at specified sites
6.1.14. Pregnancy Test for Females of Childbearing Potential
All female subjects of childbearing potential (as defined in Appendix 7) will have a serum 
pregnancy  test at Screening and a urine pregnancy test prior to Day 1 dosing, every  28days 
thereafter, and at the EOT visit. The results must be confirmed as negative prior to continued 
administration of study  drug .
6.2. Vitamin D Assessment for Patients in Group 2
Routine assessment of 25 -hydroxy  vitamin D levels prior to the start of exemestane and 
fulvestrant treatment should be performed, due to the high prevalence of vitamin
Ddeficiency  in 
women with breast cancer . Women with vitamin D deficiency  should receive supplementation 
with vitamin D
CCI-
GS-5829 
Protoco l GS-US-350-1599 
Gilead Sciences , Inc. 
6.2.1. Pharmacokin etic Samples Final 
Amendment6 
Plasma samp les for GS-5829 PK will be collected(± 10 minutes) in coho1is 1-3 of Group 1 on 
Study Day 1 at pre-dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose and in coho1is 4-8 
of Group 1 and all coho1is of Group 2 on Cycle 1 Day 1 at pre-dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 
12, and 24 hours post-dose. Additio nal samples wi ll be collected at 48 and 72 hours post-dose in 
dose levels 1 - 3 of Group 1 relative to first dose of GS-5829. Plasma samp les for GS-5829 PK 
will be collected in all coho1is (Group 1 and Group 2) at pre-dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, 
and 24 hours post-dose relative to GS-5829 administration on Cycle 1 Day 8. Sparse PK samp les 
will be collected in all coho1is (Group 1 and Group 2) at trough (20-26 hours post-dose) on 
Cycle 1 Day 4, 2 - 4 h ours post-dose on Cycle 1 Day 15, and anytime post-dose on D ay 1 of 
Cycles 2 through 6. 
At one or more dose levels, PK samples wi ll be collected on D ay 1 of Cycle 2 at pre-dose (0 hr) 
and 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. GS-5829 dose will be administe red in fed state 
on Day 1 of Cycle 2. 
Urine will be collected for GS-5829 PK in Group 1 cohorts 1-3 on Study Day 1 and in Group 1 
coho1is 4-8 on Cycle 1 Day 1 at pre-dose, 0-6 h ours, 6-12 hours, and 12-24 hours post-dose 
relative to first dose of GS-5829. 
Subjects in the Group 3 lymphoma expansio n will have PK drawn at pre-dose , 1, 2, 4, 6, and 
24 hours post-dose on Cycle 1, Day 8. PK samples wi ll also be drawn at pre-dose on Day 1 of 
Cycles 2, 4, and 6. 
Plasma and urine conce ntrations of GS-5829 will be detennined and PK evaluated. Plasma and 
urine conce ntrations of GS-5829 metabolite(s) maybe detenn ined and PK explored. Unbound 
concentrat ions of GS-5829 and/or metabolites may be detenn ined. Plasma concentratio ns of 
fulvestrant , exemestane , or metabolites may be detenn ined and PK explored. 
-
CONFIDENTIAL Page 53 20 June 2016 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
-
-
--
CONFIDENTIAL Page 54 Final 
Amendment6 
20 June 2016 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
-
CONFIDENTIAL Page 55 Final 
Amendment6 
20 June 2016 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences, Inc. 
6.3.4. Unscheduled Procedure s Final 
Amendment6 
Unscheduled proced ures, including, but not limited to, vital signs, 12-lead ECG, and CT or MRI, 
will be recorded on the a pplicable eCRFs. 
6.4. 
6.4.1. Post-treatment Assessment s 
Post-Study Phone Call 
Subjects will be contacted by phone 30 days(± 7 days) after the l ast dose of GS-5829 to assess 
for AEs. For subjects who come off study for reasons ot her than disease prog ressio n, the site 
shou ld also obtain infonnation post-study anti-cancer therapies , surgeries, and date of definiti ve 
disease prog ressio n (if know n). 
6.5. Criteria for Discontinuation of Study Treatment 
See Sec tions 3.4 and 3.5 for disco ntinu ation cr iteria. 
6.6. Replacement of Subject s 
If a subject is with draw n from the study for any reason other than a DL T prior to completion of 
the DLT assess ment window, a replace ment subject will be enrolled at the same dose level as the 
replaced subject. To be eva luable for the D LT observ ation, a su bject must receive at least 
21 doses of GS-5829 , complete all safety proced ures through D ay 28, or experience a DLT prior 
to Day 28. 
CONFIDENTIAL Page 56 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 57 20 June 20166.7. Dose Interruption and Reduction
The following are the guidelines for dose interruption and/or reduction.  If an AEis attributed to 
study  drug, the investigator’s discretion will be used to determine if the drug not att ributed to the 
AEwill be withheld based on the investigator’s assessment of risk- benefit of withholding the 
study  drug.
6.7.1. GS-
5829
For subjects without l ymphoma , if at an y time in the study a subject experiences a t oxicity  
consistent with a Grade 4 DL T(seeSection 3.2for the definition of a DLT), GS- 5829 treatment 
will be discontinued permanently , with the exception of Grade 4 ne utropenia or 
thrombocy topenia. If a subject experiences Grade 4 neutropenia or thromb ocytopenia or any  
other < Grade 4 toxicity  consistent with a DLT (per Section 3.2), dosing with GS - 5829 will be 
postponed until the toxicity  is resolved to Grade 0 or 1 (as defined by  the CTCAE, version 4.03) 
or returns to the subject’s baseline value. If the toxicity  resolves to Grade 0 or 1 or retu rns to the 
subject’s baseline value within 28 days from the start of the event, the subject may  resume 
dosing of GS -5829 at a dose that is at least one dose level 
lower after discussion with the Gilead 
Medical Monitor.   
For subjects with l ymphoma, if the toxicity  is neutropenia or thrombocy topenia consistent with 
the definition of a DLT , the dose may  be resumed at either one lower dose level, or the s ame 
dose with an alternative dosing schedule, which decreases the total amount of GS -5829 
administered over a 28 day  period to at least 25% less than the previous cohort (eg 14 day s on 
and 7 day s off). If the subject experiences a recurrence of a non -hematologic toxicity  meeting 
criteria for DLT after restarting stud y drug at a lower dose or if the toxicity does not resolve 
within 28 days, treatment wi thGS-5829 will be discontinued.  For subjects with ly mphoma, if 
the recurrent toxicity  is hematologic a second dose decrease is a llowed (lowest dose allowed 
1.0mg) in either total daily  dose or b y a change in schedule such that the total amount of
GS-5829 administered over a 28 day period is decreased by  at least 25% after discussion with the 
Gilead Medical Monitor .
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 58 20 June 2016Table 6-2. Dose Reduction of GS -5829
NCI CTCAE Gr adeRecommendation
Group 1 and 2: Non-lymphoma 
GS-5829Group 3: Lymphom a 
GS-5829 
HEMATOLOGICAL ADVERSE EVENTS
Neutropenia
Grade ≤ 3 Neutropenia Maintain current dose level and schedule.
Grade 4 neutropenia 
(oroccurrence of Grade ≥ 3 
neutropenia 
(ANC <1000/mm3) with 
fever (a single temperature 
of > 38.3°C or a sustained 
temperature of ≥38°C for 
more than one hour) or 
infectionHold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1. If the 
toxicity resolves to ≤1 within 28 days, 
the subject may resume dosing of 
GS-5829 at a dose that is at least one 
dose level lowerafter discussion with 
the Gilead Medical Monitor . 
Granulocyte -colony Stimulating Factor 
(GCSF) is allow edHold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1. If the toxicity 
resolves to ≤1within 4 days, the subject 
may resume dosing of GS -5829 at the 
same dose or a dose low er. If recovery to 
grade ≤1 takes > 4days, but within 
28days, then the subject may resume 
dosing of GS -5829 at a dose that is at 
least one dose level lower after discussion 
with the Gilead Medical Monitor. GCSF 
is allowed during dose interruption, but is 
not to be administered on the same day as 
GS-5829
Thrombocytopenia
Grade ≤ 2 
ThrombocytopeniaMaintain current dose level and schedule.
Grade 3 Thombocytopenia Hold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1. If the 
toxicity resolves to ≤1 within 28 days, 
the subject may resume dosing of 
GS-5829 at a dose that is at least one 
dose level lowerafter discussion with 
the Gilead Medical MonitorHold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1.  If the toxicity 
resolves within 7 days, the subject may 
either resume at the same dose or a dose 
with is one level low er or at an
intermittent dosing schedule.
If the toxicity takes > 7 days to resolve to 
≤ Grade 1 , then the drug must be resumed 
at a low er dose or an intermittent dosing 
schedule after discussion with the Gilead 
Medical Monitor
Grade 4 ThrombocytopeniaHold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1. If the 
toxicity resolves to ≤1 within 28 days, 
the subject may resume dosing of 
GS-5829 at a dose that is at least one 
dose level lowerafter discussion with 
the Gilead Medical Monitor .
If it takes > 28 days, then GS -5829 w ill 
be permanently discontinuedHold dosing with GS -5829 until the 
toxicity is resolved to ≤ 1 at which time
the subject may either resume at a dose 
with is one level low er, or at intermittent 
dosing schedule (atleast 25% less 
GS-5829 in a 28 day dosing period) after 
discussion with the Gilead Medical 
Monitor.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 59 20 June 2016NCI CTCAE Gr adeRecommendation
Group 1 and 2: Non-lymphoma 
GS-5829Group 3: Lymphom a 
GS-5829 
NON -HEMATOLOGICAL ADVERSE EVENTS
Hepatic Adverse Events (elevations in ALT, AST or bilirubin)
Grade 1
(ALT/AST ≤ 3xULN)
(Bilirubin ≤ 1.5xULN)Maintain current dose level and schedule.
Grade 2
(ALT/AST > 3 -5xULN)
(Bilirubin>1.5 -≤ 3xULN)Maintain current dose level and schedule. Monitor ALT, AST, ALP, and bilirubin at 
least 1x per w eek.
Grade 3 Hold dosing until ≤ grade 2.
Perm anently discontinue if any Grade 3 or Grade 4 elevation in AST or ALT 
associated with a Grade 2 elevation in bilirubin
Grade 4 Perm anently discontinue GS -5829
Non hepatic, non -hematologic adverse events
Grade ≤ 2 No change in dosing required. Dosing may be interrupted until Grad e≤ 1 or baseline
Grade 3Hold dosing until ≤ grade 1 and decrease dose by at least one dose level and or by a 
change in schedule which decreases total GS-5829 administered over a 28 day 
dosing period
Grade 4 Perm anently discontinue GS -5829
If the subject was not receiving GS -5829 at the time disease progression was documented 
(eg,due to reversible toxicity ), after discussion with the Gilead Sciences Medical Monitor, 
GS-5829 may  be re - started if the criteria for resuming treatment as described in Section 6.7.1 are 
met and the Investigator feels it is in the subject’s best interest to do so.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 60 20 June 20167. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and
/orunintended sign, symptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, l ack of efficacy , overdose, drug abuse/misuse reports, or 
occupational exposure . Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not i nclude the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion
.
The condition that led to the procedure may be an AEand must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities pr esent or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Sect ion7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be docume nted on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) or serious adverse drug reaction (SADR) is defined as an event 
that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in t he definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 61 20 June 2016Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such eve nts may  not be immediately  
life-threatening or result in death or hospitalization but may jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically  important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, inf ections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
Clarification of Serious Adverse Events
Death is an outcome of an AE, and not an AE in itself
An SAE may  occur even if the subject was not on study  drug at the time of occurrence of the 
event. Dosing may  have been given as treatment cycles or interrupted temporaril y before the 
onset of the SAE
“Life-threatening” means that the subject was at immediate risk of death from the event as it 
occurred. This does not include an event that might have led to death if it had occurred with 
greater severity
Complications that occur during hospitalizations are AEs. If a complication prolongs the 
hospitalization, it is a SAE
“In-patient hospitalization” means the subject is formally  admitted to a hospital for medical 
reasons, for an y length of time. This may or may not be overnight. It does not include 
presentation and care within an emergency  department
The investigator should attempt to establish a diagnosis of the event on the basis of signs, 
symptoms and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE and/or SAE and not the individual signs/sy mptoms
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, ECG , x-rays, vital signs) that are associated with 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 62 20 June 2016signs and/or s ymptoms must be recorded as an AE or SAE if they  meet the definition of an AE 
or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  abnormality  is part of a 
syndrome, record the s yndrome 
or diagnosis (eg, anemia), not the laboratory  result (ie, decreased 
hemoglobin).
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to study  
drug therapy  using clinical judgment and the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug . For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the study  drug .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
The relat ionship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures, (eg,venipun cture )
7.2.2. Assessment of Severity
The severit y of AEs will be graded using the CTCAE, Version 4.03 (Appendix 6). For each 
episode, the highest severity  grade attained should be reported.
If a CTCAE cri terion does not exist, the investigator should use the grade or adjectives: 
Grade 1
(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life- threatening), or 
Grade 5(fatal) to describe the maximum intensity  of the AE. For purposes of consistency  with 
the CTCAE, these intensity  grades are defined in Table 7-1.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 63 20 June 2016Table 7-1. Grading of Adverse Event Severity
Grade Adjective Description
Grade 1 MildSign or symptom is present, but it is easily tolerated, is not expected to have a 
clinically significant effect on the subject’s overall health and w ell-being, does not 
interfere with the subject’s usual function, and is not likely to require medical 
attention.
Grade 2 ModerateSign or symptom causes interference with usual activity or affect clinical status, 
and may require medical intervention.
Grade 3 SevereSign or symptom is incapacitating or significantly affects clinical status and likely 
requires medical intervention and/or close follow -up.
Grade 4 Life-threatening Sign or symptom results in a potential threat to life.
Grade 5 Fatal Sign or symptom results in death.
The distinction between the seriousness and the severity  of an AE should be noted. Severe is a 
measure of intensit y; thus, a severe reaction is not necessarily  a serious reaction. For example, a 
headache may  be severe in intensity , but would not be classified as serious unless it met 1 of the 
criteria for serious events listed in Section 7.1.2.
7.3.
Investigator Requirements and Instructio ns for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
7.3.1. Requirements for C ollection Prior to S tudy D rug Initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the e CRF: all SAEs and AEs related to protocol- mandated procedures.
7.3.2. Adverse Events
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until 30 day s after last administration of study  drug must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the AE is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
7.3.3. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up per iod, must be reported in the 
eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
GS-5829 
Protoco l GS-US -350-1599 
Gilead Sciences , Inc. Final 
Amendment6 
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30 days of the 
last dose of study diug, regardle ss of causality, should also be repo1ied. 
Investigators are not o bligated to actively seek SAEs after the 30-day period Howeve r, if the 
investigato r learns of any SAEs that occur after study paiiicipation has concluded and the event 
is deemed releva nt to the use of study diug , he/she sho uld promptl y documen t and repo1i the 
event to Gilead DSPH. 
All AEs and SAEs will be recorded in the eCRF database within the time lines outlined in the 
eCRF completion guideline. 
7.3.4. Electronic Serious Adverse Event ( eSAE) Reporting Process 
• Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
infonnation to Gilead DSPH within 24 hours of the investigator 's knowledge of the event. 
Detailed instructio ns can be found in the eCRF completion guidelines. 
• If for any reason it is not possib le to record the SAE infonnation electr · onically, ie, the eCRF 
database is not functioning, record the SAE on the paper SAE reporting fo1m and submi t 
within 24 hours of the investigator's knowle dge of the event to: 
Gilead DSPH: 
• As soon as it is possible to do so, any SAE reported via paper must be tr·anscribed into the 
eCRF Database accord ing to instructio ns in the eCRF comple tion guidelines. 
• If an SAE has been repo1ied via a paper fonn because the eCRF database has been locked, no 
fuither action is neces saiy. 
• A ll AEs and SAEs will be recorded in the eCRF database within the time lines outlined in the 
eCRF completion guideline. 
• For fatal or life-threatening events, copies of h ospital case repo1is, autopsy repo1is, and other 
documen ts ai· e also to be submitted by e-mail or fax when re quested and applicable . 
Tran smission of such docume nts sho uld occur witho ut personal subject identification, 
maintainin g the tr·aceability of a document to the subject identifier s. 
• Additio nal infonnation may be requested to ensure the timely completion of accurate safety 
repo1is. 
• Any medications necessaiy for tr·eatinent of the SAE must be recorded onto the co ncomitant 
medicat ion section of the subject 's eCRF and the event description section of the SAE fonn 
CONFIDENTIAL Page 64 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 65 20 June 20167.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, inclu ding the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory  agencies reports of SAEs, SADRs, or suspected unexpected serious 
adverse reactions (SUSARs). I n accordance with the EU Clinical Trials Directive (2001/20/EC), 
Gilead or a specified designee will notify  worldwide regulatory  agencies and the relevant IEC in 
concerned Member S tates of applicable SUSARs as outlined in current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investig ators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  drug . The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b
y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.4.1. Reporting of Adverse Events Relating to the Primary Endpoint and Other 
Anticipated Medical Events in the Study Population
Given the endpoints of the study, in order to maintain the integrity  of the study , the following 
events that are assessed as unrelated to study  drug will not be considered SAEs:
Progression of disease
Death related to progression of disease
Disease progression and death from disease progression should be reported as SAEs by the 
investiga tor onl
y if it is assessed that the study drug caused or contributed to the disease 
progression (ie, b y a means other than lack of effect). Unrelated disease progression should be 
captured on the eCRF.
7.5. Toxicity Management 
Treatment -emergent toxicities wil l be noted by  the Investigator and brought to the attention of 
the Gilead Sciences Medical Monitor or designee. Whether or not considered treatment -related, 
all subjects experiencing AEs must be monitored periodicall y until symptoms subside, any 
abnormal l aboratory  values have resolved or returned to baseline levels or they  are considered 
irreversible, or until there is a satisfactory explanation for the changes observed.
Grade 3 or 4 clinicall y significant laboratory abnormalities should be confirmed by re peat testing 
as soon as practical to do so, and preferabl y within 3 calendar day s after receipt of the original 
test results. Any questions regarding toxicity  management s hould be directed to the 
Gilead Sciences Medical Monitor or designee.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 66 20 June 20167.6. Special Situati ons Reports
7.6.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose , reports 
of AEs associated with product complaints, and pregnancy  reports regardless of an associated 
AE.  Reports of a dverse reactions in infants following exposure from breastfeeding, and reports 
of adverse reactions associated with product complaints and reports arising from occupational 
exposure are also considered special situation reports.
A pregnancy  report is used to report an y pregnancy in female subjects onl y, orfemale 
partners of male subjects on study
Medication error is an y unintentional error in the prescribing, dispensing, or administration 
of a medicinal product while in the control of the health care provider, subject, or consumer
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  
a subject
Misuse is defined as an y intentional or inappropriate use of a medicinal product that is not in 
accordance with the pro tocol instructions or the local prescribing information
An overdose is defined as an accidental or intentional administration of a quantity  of a 
medicinal product given per administration or cumulatively  which is above the maximum 
recommended dose as per p rotocol or in the product labelling (as it applies to the daily  dose 
of the subject in question). In cases of a discrepancy  in drug accountability , overdose will be 
established only  when it is clear that the subject has taken the excess dose(s). Overdose 
cannot be established when the subject cannot account for the discrepancy  except in cases in 
which the investigator has reason to suspect that the subject has taken the additional dose(s)
Product complaint is defined as complaints arising from potential dev iations in the 
manufacture, packaging, or distribution of the medicinal product
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study drug follow - up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .Refer to the eCRF completi on guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
GS-5829 
Protoco l GS-US -350-1599 
Gilead Sciences , Inc. Final 
Amendmen t 6 
Any premature termination of pregnancy ( eg, a sponta neous abo1iio n, an induced therapeut ic 
abo1 iion due to complicat ions or other medical reasons) must be repo1ied within 24 hours as an 
SAE . The underlying medical reason for this procedure shou ld be recorded as the AE te1m. 
A spontaneo us abo1 iion is always considered to be an SAE and will be repo1ied as such. 
Furthe1more , any SAE occu ning as an adverse pregna ncy outcome post study must be reported 
to Gilead DSPH. 
The su bject shou ld receive approp riate monitor ing and care until the co nclusion of the 
pregna ncy. The outcome shou ld be repo1ied to Gilead DSPH using the pregnancy outcome repo1i 
f01m . If the end of the pregna ncy occurs after the study has been comple ted, the outcome should 
be reported direc tly to Gilead DSPH. 
Pregnancies of fema le paiiners of male study subjects exposed to Gilead or other stu dy diugs 
must also be repo1 ied and r eleva nt info1matio n shou ld be submitted to or Gilead DSPH using the 
pregnancy and pregna ncy outcome fo1ms within 24 hours . Monitor ing of the su bject shou ld 
continue until the conclusion of the pr egnancy. If the e nd of the pregnancy occurs after the stu dy 
has been completed, the out come should be r eported directly to Gilead DSPH. 
Gilead DSPH: Fax:IPIPD 
Emai l: IPD 
Refe r to Appendix 7 for Pregna ncy Precautio ns, D efinition for Female of Childbeai ·ing Potential, 
and Contraceptive Requireme nts. 
7.6.2.2. Repo 1 iing Othe r Special Situatio ns 
All other specia l situ ation repo1 i s must be repo1 i ed on the special situat ions repo1 i fonn and 
fo1wai·ded to Gilead DSPH within 24 hours of the investigator becoming aware of the situa tion. 
These repo1is must consist of situations that involve study diug and/o r Gilead conc01nita nt 
medicat ions, but do not apply to non-Gilead concomitant medications. 
Specia l situ ations involving non -Gilead conc01nita nt medicat ions d oes not need to be repo1 ied on 
the special situat ions repo1i f01m; however , for specia l situ ations th at result in AEs due to a 
non-Gilead concomitant medicatio n, the AE shou ld be repo1 i ed on the AE fonn. 
Any inappropria te use of conc01nita nt medicat ions prohibited by this protocol shou ld not be 
repo1 ied as "inisuse," but may be more approp riately docume nted as a protocol devia tion. 
Refe r to the eCRF completio n guidelines for full instruc tions on the mechanism of special 
situat ions repo1 iing. 
All clinical seque lae in relation to these special situat ion repo1 i s wi ll be repo1ied as AEs or SAEs 
at the same time using the AE eCRF and/o r the SAE repo1 i fonn. Detai ls of the symptoms and 
signs, clinical management , and outcome will be reported , when available. 
CONFIDENTIAL Page 67 20 June 2016 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
8. 
8.1. 
8.1.1. STATISTICAL CONSIDERATIONS 
Analysis Objectives and Endpoints 
Analysis Objectives 
The prima1 y objectives of this study are: Final 
Amendment6 
• Cha racterize the s afety and tolerability of GS-5829 as a mono therapy in subjects with 
advanced solid tumors and lymphomas 
• D etennin e the M TD or RDP 2 of GS-5829 as a mono therapy in subjects with advanced stage 
solid tumors and lymphom as 
• Cha racterize the safety and tolerability of GS-5829 in combination with exemestane or 
fulvestrant in subjects with advanced estrogen recepto r positive breast cancer 
• D etennin e MID or RDP 2 of GS- 5829 in combination with exemestane or fulvestrant in 
subjects with advanced estrogen recepto r positive breast cancer 
8.1.2. Primar y Endpoint 
The prima1 y endpo int of this study is incidence of DLT as defined in Section 3.2. 
8.1.3. Secondary Endpoint 
Seco ndary endpo ints of this study are: 
• PK param eters (Cmax, Ctau, AUC1ast, AUCtau, Tmax, and t½) for GS- 5829 . -
I 
I 
I 
CONFIDENTIAL Page 68 20 June 2016 
GS-5829 
Protoco l GS-US -350-1599 
Gilead Sciences , Inc. 
8.2. 
8.2.1. 
8.2.1.1. Anal ysis Convention s 
Anal ysis Sets 
Full Analysis Set (FAS) Final 
Amendment6 
The FAS includes all subjects who r eceive::::: 1 dose of study drng (GS-5829 , exemestane or 
fulvestrant) . This analysis set will be used for subject characte ristics and efficacy endpoints. 
8.2.1.2. Safety Analysis Set 
The Safety Analysis Set for this study will be the same as FAS since this study is a 
non-randomized study. This analysis set will be used for safety endpoints , study tr eatme nt 
admin istration and post-st udy therapy. 
8.2.1.3. DLT- Eval uable Analysis Set 
The DLT-E valuable Analysis Set includes all subjects in the Safety Analysis Set who complete 
all treatment and safety procedures through Day 29, or expe rienced a DLT prior to Day 29. 
Dete nnination of the MID will be in DLT-Eval uable Analysis Set. 
8.2.1.4. Phaimacodynam ic and Ph a1macok inetic Analysis Sets 
The- PK Analysis Sets consist of all subjects in the FAS who h ave the necessaiy baseline 
and on-study meas urements to provi de interpretable results for the specific parameters of 
interest. 
8.3. Data Handling Convention s 
By-subject listings will be created for impo 1iant variables from each eCRF modu le. 
Summaiy tables for co ntinuous vai·iables will contain the following statist ics: N (n mnber in 
popu lation), n (n mnber with data) , mean, standai·d deviatio n (StD), 90% confidence intervals 
(Cls) on the mean, median, minimmn , and m aximum. Summa1 y tables for catego rical vai·iables 
will include: N, n, percentage, and 90% Cls on the percentage. Unless othe1 w i se indicated, 90% 
Cls for binaiy vai·iables will be calcu lated using the b inomial distribution ( exact method) and 
will be 2-sided. Data will be described and sUillllla rized by releva nt study group, dose level, 
analysis set, and ti me point. As approp riate, chan ges from baseline to each subseque nt time point 
will be described and sUilllllai· ized by study group and dose level. Similarly , as approp riate, the 
best change from baseline during the study will also be described and summar ized by study 
group and dose level. Grap hical techn iques (eg, wate rfall plots , Kaplan-Meie r curves, line plots) 
may be used when such methods ai· e appropr iate and info1mat ive. 
CONFIDENTIAL Page 69 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 70 20 June 2016The baseline value will be the last (most recent) pre- treatment value .Data from all sites will be 
pooled for all analy ses. Analy ses will be based upon the observed data unless methods for 
handling missing data are specified. If there is a significant degree of non -normality , analy ses 
may be performed on log- transformed data or nonparametric tests may  be applied, as 
appropria te.
8.4. Demographic Data and Baseline Characteristics
Subject demographic and baseline characteristics will be listed and summarized by  study  group 
and dose level for the Safety  Anal ysis Set.
8.5. Efficacy Analysis
ORR and PFS will be listed only .
8.6. Safety Analysis
All safet y data collected on or after the date that study  drug (GS-5829, exemestane or 
fulvestrant ) was first dispensed up to the date of last dose of study  drug plus 30 days
will be 
summarized by  study  group and dose level . Data for the pretreatment will be included in data 
listings.
8.6.1. Extent of Exposure
Descriptive information will be provided by  study group and dose level regarding the number of 
doses of study  drug prescribed (GS-5829, exemestane or fulvestrant )
, the total number of doses 
taken, the percen t of expected doses taken, the number of day s of study  drug, and the number 
and timing of prescribed dose modification and interruptions.
GS-5829 c ompliance will be described b y study  group and dose level in terms of the proportion 
of study  drug actuall y taken based on returned pill count relative to the amount that was 
dispensed (taking into account phy sician -prescribed modification and interruptions).
8.6.2. Adverse Events
All AEs will be listed. The focus of AE summarization will be on treatment- emergent AEs. 
Atreatment -emergent AE is defined as an AE that occurs or worse ns in the period from the 
firstdose of study  drug (GS-5829, exemestane or fulvestrant ) to 30 day s after the last dose of 
study  drug.
AEs will be coded using the Medical Dictionary  for Regulat ory Activities (MedDRA 
http://www.meddramsso.com) with descriptions by System Organ Class (SOC), High -Level 
Group Term, High- Level Term, Preferred Term, and L ower -Level Term. The severit y of AEs 
will be graded b y the investigator according to the CTCAE, Ve rsion 4.03, whenever possible. If 
a CTCAE criterion does not exist for a specific type of AE, the grade corresponding to the 
appropriate adjective will be used b y the investigator to describe the maximum intensity  of the 
AE: Grade 1 (mild), Grade 2 (modera te), Grade 3 (severe), Grade 4 (life threatening), 
orGrade 5(fatal). The relationship of the AE to the I P will be categorized as related or unrelated.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 71 20 June 2016TEAEs will be summarized by  dose level. Summary  tables will be presented to show the number 
of subjects reporting treatment -emergent AEs b y severit y grade and corresponding percentages. 
A subject who reports multiple treatment -emergent AEs wit hin the same Preferred Term 
(orSOC ) is counted onl y once for that Preferred Term (or SOC ) using the worst severit y grade. 
AE descriptions will be presented b y decreasing frequency for a given SOC and Preferred Term. 
Separate listings and summaries will be prepared for the following t ypes of treatment emergent 
AEs:
Study -drug-related (GS-5829, exemestane or fulvestrant )AEs
AEs that are Grade ≥ 3 in severit y
AEs leading to study  drug (GS -5829, exemestane or fulvestrant ) interruption and/or dose 
modification
AEs leading to study  drug (GS -5829, exemestane or fulvestrant ) discontinuation
SAEs
8.6.3. Laboratory Evaluations
All laboratory  data will be listed. Summaries of laboratory  data will be based on observed data. 
The focus of laboratory  data summarization will be on treatment -emergent laboratory  
abnormalities. A treatment -emergent laboratory  abnormality  is defined as an abnorma lity that, 
compared to baseline, worsens b y ≥ 1 grade in the period from the fi
rst dose of study  drug 
(GS-5829, exemestane or fulvestrant ) to 30 days after the last dose of stud y drug. If baseline data 
are missing, then an y graded abnormalit y (ie, an abnormality that is Grade ≥ 1in severity ) will 
be considered treatment emergent.
Hematological, serum biochemistry , and urine data will be programmatically  graded according 
to CTCAE severity  grade, when applicable. For parameters for which a CTCAE scale does not 
exist, reference ranges from the central laboratory will be used to determine programmatically  if 
a laboratory  parameter is below, within, or above the normal range for the subject’s age, sex, etc. 
Hematological and serum biochemistry  and their changes from baseline will be summarized by  
study  group, dose level, and visit. Summary  tables will be presented for each relevant assay  to 
show the numb er of subjects by  CTCAE severit y grade with corresponding percentages. For 
parameters for which a CTCAE scale does not exist, the frequency  of subjects with values 
below, within, and above the normal ranges will be summarized. Subjects will be characterize d 
only once for a given assay , based on their worst severit y grade observed during a period of 
interest (eg, during the study  or from baseline to a particular visit).
Shift tables for hematology  and serum biochemistry  will also be presented by  showing chan ge in 
CTCAE severity  grade from baseline to the worst grade post -baseline. For parameters for which 
a CTCAE scale does not exist, shift tables will be presented showing change in results from 
baseline to the worst grade post baseline. Separate listings and summaries will be prepared for 
laboratory  abnormalities that are Grade ≥ 3 in severity .
GS-5829 
Protoco l GS-US-350-1599 
Gilead Science s, Inc. 
8.7. Pharmacokinetic Analysis Final 
Amendment6 
The conce ntrntion data of GS-5829 will be summar ized by nominal sampling time using 
descriptive statistics. PK parameter s (Cmax, Ciau, AUC1as t, AUCtau, Tmax, and t½ ), will be listed and 
summa rized using descr iptive statistics ( eg, sample size, arithmet ic mean, geometi· ic mean, 
coefficient of variation(%) StD, median , minimum, and maximum) . Plasma concenh'ations over 
time will be plotted in semi-logarithmic and linear fonnats as mean± StD, and median (QI, Q3) 
if applicable. 
8.9. Sample Size 
The sample size of the study will be detennined based on the numb er of dose levels evaluated 
and the emerging GS-5829-related toxicities . The study will consist of up to160 subjects. 
CONFIDENTIAL Page 72 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 73 20 June 20169. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), ICH guidelines, or with the laws and regulations of the country  in which the 
research is conducted, whichever affords the greater protection to the study  subject. 
These standards are consistent wi th the European Union Clinical Trials Directive 2001/20/EC 
and Good Clinical Practice (GCP) Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of GCP , as outlined in 
21CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 1998, 
and 21 CFR, part 56, 1998 .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportab le interests during the study  and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheet s, or descriptions of the study  used to obtain 
informed consent) to an IRB. The investigator will not begin an y stud y subject activities until 
approval from the IRB has been documented and provided as a letter to the investigator.
Before implementation, th e investigator will submit to and receive documented approval from 
the IRB/IEConany modifications made to the protocol or an y accompan ying material to be 
provided to the subject after initial approval, with the exception of those necessary to reduce 
imme diate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB-approved consent form for documenting written 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 74 20 June 2016informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and date d by the subject or the subject’s legally  authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by  local 
requirements. The consent form will inform subjects about genomic testing and sample retention, 
and their right to receive clinically  relevant genomic analysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only s ubject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB,or laboratory . Laboratory  specimens 
must be labeled in such a wa y as to protect subject identity  while allowing the results to be 
recorded to the proper subject. Refer to specific laboratory instructions . NOTE :The investigator 
must keep a screening log showing codes, names, and addresses for all subjects screened and for 
all subjects enrolled in the trial. Subject data will be processed in accordance with all applicable 
regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator 
brochure, this protocol, CRF /eCRF , the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, and 
governmental approval wi th correspondence, informed consent, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information fo r each subject:
Subject identification (name, date of birth, gender)
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria)
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 75 20 June 2016Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number)
Study  discussed and date of informed consent
Dates of all visits
Documentation that protocol specific procedures were performed
Results 
of efficacy  parameters, as required b y the protocol
Start and end date (including dose regimen) of study  drug , including dates of dispensing and 
return
Record of all AEs and other safety  parameters (start and end date, and including causality  
and severit y)
Concomitant medication (including start and end date, dose if relevant; dose changes)
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws,
whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, US , Europe, or Japan) and until there are no pending or planned marketing 
applications in an I CH region; or, if no application is filed or if the application is not approved 
for such indication, until 2 years after the investigation is discontinued and regulatory  authorities 
have been notified. Investigators may  be required to retain documents longer if specified by  
regulatory
 requirements, by  local regulations, or by  an agreement with Gilead. The investigator 
must notify  Gilead before destroy ing an y clinical study records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safet y data.Subsequent to data entry , a study monitor will perform source data verification 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 76 20 June 2016within the EDC sy stem. Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem. Prior to database lock (or any  interim time points as described in the 
clinical data management plan), the investigator will use his/her log in credentials to confirm that 
the forms have been reviewed, and that the entries accuratel y reflect the information in the 
source documents. The eCRF capture the data required per the protocol schedule of events and 
procedures. System -generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  the monitor or internal Gilead staff, who routinely  review the 
data for completeness, correctness, and consistency. The site coordinator is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason f
or the update (eg ,data entry  
error). At the conclusion of the trial, Gilead will provide the site with a read -only archive copy  of 
the data entered b y that site. This archive must be stored in accordance with the records retention 
requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability 
and Return
Gilead recommends that used and unused stud y drug supplies be destro yed at sites if they have 
applicable standard operating procedure (SOP) to do so. The study  monitor will evaluat e each 
study  center’s stud y drug disposal procedures and provide appropriate instruction for destruction 
of unused study  drug supplies, as needed. If the site has an appropriate SOP for drug destruction 
as determined b y Gilead Clinical Operations or designee (per SOP-CR-23035), the site may  
destroy  used (empt y or partially empty) and unused study drug supplies in accordance with that 
site’s approved SOP. A copy  of the site’s approved SOP will be obtained for central files.  If the 
site does not have an acce ptable SOP to destroy , or cannot due to other regulatory  reasons, 
Gilead will provide instruction for the return if the study drug for disposal/destruction.
9.1.8. Inspections
The investigator will make available all source documents and other records for this tr ial to 
Gilead’s appointed stud y monitors , to IRBs, or to regulatory  authorit y or health authority 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations describe d in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the in 
accordance with local requirements and receive documented approval before modifications can 
be implemented.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 77 20 June 20169.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency . Gilead will ensure 
that the report meets the standards set out in the ICH Guideline for Structure and Content of 
Clinical Study  Reports (ICH E3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientifi c journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least 2 years
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publicatio n or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg ,attendance at I nvestigator's Meetings.  If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Fede ral and State agencies an y 
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance w ith regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular inte rvals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected 
through an y type of monitoring (central, on site) are resolved.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 78 20 June 20169.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of G ilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to e protection of the subjects’ interests.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 79 20 June 201610. REFERENCES
Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K, et al. Promiscuous 
rearrangements of the MYC locus  hijack enhancers but mostly  super -enhancers 
to dy sregulate MYC express ion in multiple my eloma. Leukemia 2014:1- 43.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR -V7 and resistance 
to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371 
(11):1028-38.
Asangani IA, Dommeti VL , Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting 
of BET bromodomain proteins in castration
-resistant prostate cancer. Nature 
2014;510 (7504):278-82.
Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is 
associate d with poor prognosis in patients with diffuse large B- cell ly mphoma 
treated in the era of rituximab. J Clin Oncol 2010;28 (20):3360
-5.
Belkina AC, Denis GV. BET domain co -regulators in obesity , inflammation and cancer. Nature 
reviews. Cancer 2012;12 (7):4 65-77.
Bonetti P, Boi M, Ponzoni M, Tibiletti MG, Stahis A, I nghirami G, et al. The Brd
-Inhibitor 
OTX015 Is Active in Pre -Clinical Models of Mature B -Cell Ly mphoid Tumors 
[Abstract 1657]. American Society  of Hematology  (ASH); 2012 08- 11 December; 
Atlanta, GA. 
Ceribelli M, Kelly  PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic 
IkappaB kinase activity  in diffuse large B -cell l ymphoma by  bromodomain and 
extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014.
Chapuy  B, Mc Keown MR, L in CY, Monti S, Roemer MG, Qi J, et al. Discovery  and 
characterization of super -enhancer -associated dependencies in diffuse large B cell 
lymphoma. Cancer cell 2013;24 (6):777 -90.
Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, et a l. AID -dependent 
activation of a MYC transgene induces multiple myeloma in a conditional mouse 
model of post -germinal center malignancies. Cancer cell 2008;13 (2):167 -80.
Cheson BD, Pfistner B, Juweid ME, Gasco yne RD, Specht L, Horning SJ, et al. Revised 
response criteria for malignant l ymphoma. J Clin Oncol 2007;25 (5):579- 86.
Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez
-Paz N, Troska-Price T, et al. Clinical and 
biological implications of MYC activation: a common difference between MGUS 
and newl y diagnose d multiple my eloma. Leukemia 2011;25 (6):1026 -35.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 80 20 June 2016Clark GM, Osborne CK, McGuire WL . Correlations between estrogen receptor, progesterone 
receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2 
(10):1102-9.
Dang CV. MYC on the path to cancer. Cell 2012;149 (1):22 -35.
Delmore JE, I ssa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain 
inhibition as a therapeutic strategy  to target c -Myc. Cell 2011;146 (6):904 -17.
Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, et al. An epigenomic 
approach to therap y for tamoxifen- resistant breast cancer. Cell research 2014;24 
(7):809-19.
Glitza I C, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, et al. Chromosome 8q24.1/c -MYC 
abnormality : a marker for high- risk my eloma. Leuk Ly mphoma 2014:1-6.
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice 
variant is up -regulated during prostate cancer progression and promotes androgen 
depletion -resistant growth. Cancer Res 2009;69 (6):2305-13.
Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by  signal -
dependent transcriptional elongation. Cell 2009;138 (1):129 -
45.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. 
Overexpression of C -MYC oncogene in prostate cancer predicts biochemical 
recurrence. Prostate cancer and prostatic diseases 2010;13 (4):311 -5.
He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, et al. Expression and prognostic value of c -
Myc and Fas (CD95/APO1) in patients with pancreatic cancer. International 
journal of clinical and experimental pathology  2014;7 (2):742 -50.
Herait PE, Berthon C, Thieblemont C, Raffoux E, Magarotto V, Stathis A, et al. BET-
bromodomain inhibitor OTX015 shows clinically  meaningful activity  at nontoxi c 
doses: interim results of an ongoing phase I trial in hematologic malignancies 
[Abstract CT231]. American Association for Cancer Research Annual Meeting 
(AACR); 2014 April 5 -9; San Diego, CA. 
Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and 
Prostate Cancer. Genes & cancer 2010;1 (6):617 -28.
Lin CP, L iu CR, Lee CN, Chan TS, L iu HE. Targeting c -Myc as a novel approach for 
hepatocellular carcinoma. World journal of hepatology  2010;2 (1):16 -20.
Lockwood WW, Zejnullahu K, Bra dner JE, Varmus H. Sensitivity  of human lung 
adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling 
proteins. Proc Natl Acad Sci U S A 2012;109 (47):19408-13.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 81 20 June 2016Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L H, et al. Survival of patients with 
peripheral T -cell ly mphoma after first relapse or progression: spectrum of disease 
and rare long -term survivors. J Clin Oncol 2013;31 (16):1970 -6.
Mertz JA, Conery  AR, Bry ant BM, Sandy  P, Balasubramanian S, Mele DA, et al. Targeting 
MYC de pendence in cancer b y inhibiting BET bromodomains. Proc Natl Acad 
Sci U S A 2011;108 (40):16669-74.
Moly neux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's 
lymphoma. Lancet 2012;379 (9822):1234 -
44.
Morton L M, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Ly mphoma 
incidence patterns b y WHO subtype in the United States, 1992 -2001. Blood 
2006;107 (1):265 -76.
Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, et al. Bromodomain 
protein BRD4 is required for e strogen receptor -dependent enhancer activation and 
gene transcription. Cell reports 2014;8 (2):460 -9.
Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, et al. Outcomes of patients 
with relapsed/refractory  diffuse large B -cell l ymphoma with progression of 
lymphoma after autologous stem cell transplantation in the rituximab era. Am J 
Hematol 2013;88 (10):890-4.
Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, et al. c -Myc and Her2 cooperate to 
drive a stem -like phenot ype with poor prognosi s in breast cancer. Oncogene 
2014;33 (30):3992 -4002.
National Cancer Institute. SEER Stat Fact Sheets: Prostate Cancer. Available at: 
http://seer.cancer.gov/statfacts/html/prost.html. Accessed: 11 November 2014.
Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. 
Oncogene 1999;18 (19):3004-16.
Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone -refractory  
recurrent prostate carcinomas. Am J Pathol 1998;153 (1):141-8.
Odia Y, Orr BA, Bell WR, Eberha rt CG, Rodriguez FJ. cMYC expression in infiltrating gliomas: 
associations with IDH1 mutations, clinicopathologic features and outcome. J 
Neurooncol 2013;115 (2):249-59.
Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Me d 
2011;62:233 -47.
Owen RG, Kyle RA, Stone MJ, Rawstron AC, L eblond V, Merlini G, et al. Response assessment 
in Waldenstrom macroglobulinaemia: update from the VI th International 
Workshop. Br J Haematol 2013;160 (2):171 -6.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 82 20 June 2016Perry  AM, Alvarado- Bernal Y, Lauri ni JA, Smith LM, Slack GW, Tan KL, et al. MYC and 
BCL2 protein expression predicts survival in patients with diffuse large B -cell 
lymphoma treated with rituximab. Br J Haematol 2014;165 (3):382 -91.
Petrich AM, Nabhan C, Smith SM. MYC- associated and double -hit ly mphomas: A review of 
pathobiology , prognosis, and therapeutic approaches. Cancer 2014.
Sahai V, Kumar K, Knab L M, Chow CR, Raza SS, Bentrem DJ, et al. BET bromodomain 
inhibitors block growth of pancreatic cancer cells in three- dimensional collagen. 
Mol Cancer Ther 2014;13 (7):1907 -17.
Sengupta S, Biarnes MC, Clarke R, Jordan VC. I nhibition of BET proteins impairs estrogen -
mediated growth and transcription in breast cancers by  pausing RNA polymerase 
advancement. Breast Cancer Res Treat 2015;150 (2):265-78.
Shi J, Vakoc CR. The mechanisms behind the therapeutic activity  of BET bromodomain 
inhibition. Mol Cell 2014a;54 (5):728 -36.
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, et al. Disrupting the interaction of BRD4 with 
diacet ylated Twist suppresses tumorigenesis in basal- like breast cancer. Cancer 
cell 2014b;25 (2):210 -25.
Tang Y, Gholamin S, Schubert S, Willardson MI , Lee A, Bandopadhay ay P, et al. Epigenetic 
targeting of Hedgehog pathway  transcriptional output through BET bromodomain 
inhibition. Nat Med 2014;20 (7):732-40.
Vacirca J L, Acs PI, Tabbara IA, Rosen PJ, Lee P, Ly nam E. Bendamustine combined with 
rituximab for patients with relapsed or refractory  diffuse large B cell ly mphoma. 
Ann Hematol 2014;93 (3):403-9.
van Dam PA, Vergote IB, L owe DG, W atson JV, van Damme P, van der Auwera JC, et al. 
Expression of c -erbB -2, c-myc, and c -ras oncoproteins, insulin- like growth factor 
receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin 
Pathol 1994;47 (10):914-9.
Yoo J, Kim CH, Song SH, Shim BY, Jeong YJ, Ahn MI , et al. Expression of caspase -3 and c -
myc in non -small cell lung cancer. Cancer research and treatment : official journal 
of Korean Cancer Association 2004;36 (5):303-7.
Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration- resistant 
prostate cancer and mechanisms of resistance to new agents targeting the 
androgen axis. Oncogene 2014;33 (22):2815-25.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 83 20 June 201611. APPENDICES
Appendix 1. Investi gator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. RECIST 1.1
Appendix 4. Criteria for Progression in Castration -Resistant Prostate Cancer
Appendix 5. Lymphoma Efficacy Assessments
Appendix 6. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Appendix 7. Pregnancy Precautions, Definiti on for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 8. Performance Status Scoring System (ECOG)
Appendix 9. Exemestane (Aromasin®) Prescribing Information
Appendix 10. Fulvestrant (Faslodex®) Prescribing Information
GS-5829 
Protoco l GS-U S-350-159 9 
Gilead Sciences, Inc. 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT Final 
Amen dment6 
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and 
Pharmacodynamics of GS-5829 as a Monotherapy in Subjects with Advanced Solid Tumors 
and Lymphomas and in Combination with Exemestane or Fulvestrant in Subjects with 
Estrogen Receptor Positive Breast Cancer 
GS-US-350-1599, Amendment 6, 20 June 2016 
This protocol has been approved by Gilead Sciences , Inc. The following signature documents 
this approval. 
PD PD 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contain s all necessary 
details for me and my staff to conduct this study as described . I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study _personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principa] Investi gator Name (Printed ) Signature 
Date Site Number 
co:NFIDENTIAL Page 84 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 85 20 June 2016Appendix 2. Study Procedures Table
Study Phase Cycle DayScreening 
Day 28Study 
Day 1aFirst 28 Days
Cycl e2 
Day 1 and 
Every 
2weeks*Cycle 2 
Day 1 
and 
Every 
4weeksEvery 
8weeks EOT30day 
Safety 
Follow -
upkCycle 1 
Day 1bDay 2Day 4Day 8Day 11 Day 15 Day 22
Window (day) -28 ±0 ±3 ±0 ±0 ±1 ±1 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Informed Consent X
Medical and Medication 
Historyc X
Physical ExaminationdX X X X X X X X X X X
Vital SignseX X X X X X X X X X X
Oxygen saturationfX X X X X X X X X X X
EchocardiogramrX X X
Triplicate 12-lead ECGgX X X X X X
Adverse events/
Concomitant medicationsh X X X X X X X X X X X X
IP Dispensing  XiX X
Exemestane or Fulvestrantw
(Group 2 only)X X X
Dosing Diary Accountability X X X X X X X X
IXRS Registration X X XjX X
CBC with differential XsX X X X X X X X X
ChemistryyXsX X X X X X X X X
CoagulationqXsX X X X
25-hydroxy vitamin D
(Group 2 only)X
Urinalysis and Urine 
ChemistryX X X X X X
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 86 20 June 2016Study Phase Cycle DayScreening 
Day 28Study 
Day 1aFirst 28 Days
Cycl e2 
Day 1 and 
Every 
2weeks*Cycle 2 
Day 1 
and 
Every 
4weeksEvery 
8weeks EOT30day 
Safety 
Follow -upkCycle 1 
Day 1bDay 2Day 4Day 8Day 11 Day 15 Day 22
Window (day) -28 ±0 ±3 ±0 ±0 ±1 ±1 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Pregnancy TestlX X XjX X
GS-5829 Intensive PKmX X X Xv
GS-5829 Sparse PKmX X Xv
Biopsies for Group 3
lymphoma expansionx X XxX
CT Scan w/Contrast or MRIPX X XP
PET Scan (Group 3 only)zX
Bone Scan(Group 2 only) X X
ECOG Performance Status X X X X X X X
Treatment Response 
Assessmentt X X
* Day 1 of subsequent cycles.
a Study Day 1 is applicable to Cohorts 1 -3 only of Group 1 .
b Cycle 1 Day 1 occurs on Study Day 7 for subjects in Cohorts 1-3 of Group 1 and must occur at least 5days, but no more than 9 days after Study Day 1 . For Group 1 Cohorts 4 
and higher and all cohorts of Group 2 the first day of study is Cycle 1 Day 1 .
c Med
ical history includes significant past medical events (eg, prior hospitalizations or surgeries), a review of the disease under study, prior anti-cancer therapies, and any 
concurrent medical illnesses.
d Screening and End of Treatment Physical Examinations (PE) will be a complete PE. Beginning at Study Day 1 (Group 1 Cohorts 1 -3) and C1D1 (all groups) , a modified 
physical examination will be performed to monitor for any changes (e.g. lymph nodes, lung, cardiac, abdomen, skin, neurologic, and any systems, as clinically indicated).  
Weight ( without shoes) should be measured at each PE.  Height ( without shoes) should be measured at screening only.
e Study Day 1 (Cohorts 1 -3of Group 1 ) and C1D1 (all groups) vital signs will be taken within 15 min pre-GS -5829 dos e.  C1D1 vitals will also be collected at 2 and 4 hours 
post dose (+/ -15 min); vital signs will be taken pre -dose only at all subsequent visits.
CCI
CCI
CCI
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
f Oxygen saturation will be tested with a pulse oximeter. Final 
Amendment6 
g ECG : At Screening , at predo se on Day 1 of each Cycle sta1ting with Cycle 2, and at EOT, a triplicate 12-lead ECG will be collected at a single timepoint. On Study 
Day l(Coho1ts 1-3 only) and ClDl (Coho 1ts 4-8 only and all coho1ts of Group 2), C1D8 (all coho1ts ) (at predose , 1 hour, 2 hom·s , 3 hotu-s , 4 hom·s , 6 hotu-s, 8 hom·s , and 
12 hotu'S post fu-st dose+/-20 min) and Day 1 of cycles 2-6 ( at pre-dose). Subjec ts in the Group 3 lymphoma expansion will have ECGs collected at pre-dose, 1, 2, 4, 6, and 
24 hotu'S post-dose on Cycle 1, Day 8. ECGs will also be collected at pre-dose on Day 1 of Cycles 2, 4, and 6. ECGs should always be collected prior to PK (or any other 
blood draw) if they are to be collected at the same nominal timep oint. Subjec ts should be resting quietly and free of distraction (eg, TV, conver sation) for 10 minutes prior to 
ECG collection and ECGs sh ould be collected over a 5 minute window at each timep oint. 
h Adverse events will be assessed at pre- and post-GS-5829 dosing dtuing applicable clinic visits. Subjects will also rettun to clinic at 30-day post last IP dose , to assess AEs 
andSAE s. 
Coho1ts 1-3 of Group 1 will receive one dose of GS-5829 on Study Day 1, which will be administere d in the clinic. 
J Not applicable to subjects in Coho1t 1-3 of Group 1. 
k Subjec ts who miss the 30 day Safety Follow-up visit will be contacted by phone 30 days(± 2 days) after the last dose of GS-5829 to assess AEs. 
I If applica ble (females of child bearing potential ). Serum pregnancy will be conducted at Screening. U1ine pregnancy will be conducted pre-dose on Study Day 1/ClDl of 
each cycle and at EOT. 
m Plasma sample s for GS-5829 PK will be collected(± 10 minutes ) in coho1ts 1-3 of Group lon Study Day 1 at pre-dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hom·s post-dose, 
and in coho1ts 4-8 of Group 1 and all coho1ts of Group 2 on Cycle 1 Day 1 at pre-dose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hour s post-dose. Additional samples will be 
collected at 48 and 72 hotu 'S post-dose in coho1ts 1 -3 of Group 1 relative to first dose of GS-5829. Plasma sample s for GS-5829 PK will be collected in all cohorts (Group 1 
and Group 2) at pre-dose (0 Ju'), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hotu 'S post-dose relative to GS-5829 administration on Cycle 1 Day 8. Spa1-se PK sample s will be collected in 
all coho1ts (Group 1 and Group 2) at trough (20-26 hom·s post-dose) on Cycle 1 Day 4, 2 - 4 hotu -s post-dose on Cycle 1 Day 15, and anytime post-dose on Day 1 of Cycles 2 
through 6. Urine will be collected for GS-5829 PK in Group 1 cohorts 1-3 on Study Day 1 and in Group lcoho1ts 4-8 on Cycle 1 Day 1 at pre-dose (0 hr), 0-6 hotu·s , 
6-12 hotu -s, and 12-24 hotu 'S post-dose relative tofu -st dose ofGS -5829 . Subjec ts in the Group 3 lymphoma expansion will have PK drawn at pre-dose , 1, 2, 4, 6, and 24 hotu·s 
I ' ost-dose on cle 1, Da 8. PK sam !es will also be drawn at re-dose on Da 1 ofC des 2, 4, and 6 
I ' 
p 
q 
r Echocardiogram will be pe1formed at screening , C2D l , and EOT . MUGA is acceptable. The same modality must be used throughou t study pa1ticipation . 
s Screening chemi stty, hematology and coagulation to be collected within 7 days of Study Day 1/ClDl. 
Bone man'Ow biopsy is only to be pe1fon11ed to assess suspec ted CR, and only if the subject had lymphoma involvement of the man·ow at baseline ( or did not have a b aseline 
matTow biopsy). After CR is detem1ined , there is no need for any fiuther bone matTow biopsy assessmen ts. 
CONFIDENTIAL Page 87 20 June 2016 
GS-5829 
Protocol GS-US -350-1599 
Gilead Sciences , Inc. 
r Final 
Amendment6 
v At one or more ose evels , GS-5829 will be adminis tered in fed state on Day 1 of Cycle 2 and PK sample s will be collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, and 24 hour s 
post-dose. In subjects where intensive PK is collected on Cycle 2, Day 1, sparse PK sample s do not need to be collected at that visit. 
w Subjec ts assigned to receive exemestane in combination with GS-5829 in the study will self-administer exeme stane orally once daily starting on or before on Cycle 1 Day 1 
and thereafter at approximately the same time each day until the end of treatment. Subjects assigne d to receive fulve strant in combination with GS-5829 in this study will 
receive fulvestrant 500 mg IM on Cycle 1 Day 1 and every 28 days(+ /- 3 days) until the end of treatment. For subjects initiating fulve strant on this study a single dose of 
fulvestrant 500 mg should be admini stered on Cycle 1 Day 15 (+/- 3 days) . 
x Biopsies are reque sted from subjec ts with accessible disease and should be core needle or excision biopsies. The pre-treatment biopsy can be obtained any time after the last 
line of therap y and prior to the first dose , the Cycle 2 Day 15 biopsy can be obtained anytime between Cycle 2 Day 1 and Cycle 2Day 21. The EOT biop sy should be collected 
at progre ssion only for subjec ts with progre ssive disease . 
y AAG will be collected at Screening, pre-dose on ClDl and C1D8 only . Fen-itin and CRP will be collected pre-dose on ClDl and Day 1 of every subsequent cycle. 
z Subjects who are enrolled in Group 3 will undergo a baseline PET/CT scan and at Week 16 in the place of a CT scan if available. 
CONFIDENTIAL Page 88 20 June 2016 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 89 20 June 2016Appendix 3. RECIST 1.1
EUROPEAN JOURNAL Of CANCER 45 (2009) 228 247 
available at www.sciencedirect.co m 
-,,1 
•;;,. ScienceDirect 
ELSEVIER journ s l homepage: www. ejconline.com 
New response evaluation criteria in solid tumours: 
Revised RECIST guideline (version 1.1) 
E.A. Eisenhauer a,•, P. Therass e0, } . Bogaert sc, L.H. Schwartzd, D. Sargente , R. Fordf, 
J. Dancey9, s. Arbuck h, s. Gwytheri, M . Mooney9, L. Rubinstein9, L. Shankar9, L. Dodd9, 
R. Kaplan i, D. Lacombec , }. Verw ei? 
•National Cancer Institute of Canada Clinical Trials Group, 10 Stu.art Street, Queen's University, Kin9swn, ON, Canada 
bG!axoSmithKline Biologicals, Rixensart, Belgium 
cEuropean Organisation for Research and Jreatment of Cancer, Data Centre, Brussels, Belgium 
dMemorial Sloan Kettering Cancer Center, New York, NY, USA 
"Mayo Clinic, Rochester, MN, USA 
fRadPhann, Princeton, NJ, USA 
8Division of Cancer 1reatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA 
bSchering Plough, Kenilworth, NJ, USA 
;East Surrey Hospital , Redhill, Surrey , UK 
iNational Cancer Research Network, Leeds , UK 
kErasmus University Medical Center, Rotterdam, The Netherlands 
ARTICLE INFO 
Article history: 
Received 17 October 2008 
Accepted 29 October 2008 
Keywords : 
Response criteria 
Solid tumours 
Guidelines ABSTRACT 
Background : Assessment of the change in tumour burden is an important feature of the 
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) 
and disease progression are useful endpoints in clinical trials. Since RECISTwas published 
in 2000, many investigators , cooperative groups, industry and government authorities have 
adopted these criteria in the assessmen t of treatment outcomes . However, a number of 
questions and issues have arisen which have led to the development of a revised RECIST 
guideline (version 1.1). Evidence for changes, summarised in separa te papers in this special 
issue, has come from assessment of a large data warehouse (>6500 patients), simulation 
studies and literature reviews. 
Highlights of revised R.ECIST 1.1: Major changes i nc;!ude: Number of 12,;ions to be assesse d: base d 
on evidence from numerous trial databases merged into a data warehouse for analysis pur 
poses, the number of lesions required to assess tumour burden for response determination 
has been reduced from a maximum of lOto a maximum of five total (and from five to two 
per organ , maximum). Assessment of pathological lymph nodes is now incorporated: nodes 
with a short axis of ;a, 15 mm are considered measurable and assessable as target lesions . 
The short axis measurement should be included in the sum of lesions in calculation of 
tumour response. Nodes that shrink to <10 mm short axis are considered normal. Conjirma 
tion of response is required for trials with response primary endpoint but is no longer 
required in randomised studies since the control arm serves as appropriate means of inter 
pretation of data. Disease progrnssion is clarified in several aspects: in addition to the previ 
ous definition of progression in target disease of 20% increase in sum , a 5 mm absolute 
increase is now required as well to guard against over calling PD when the total sum is very 
• Corresponding author : Tel: PPD fax: ._iP_ P_ D ____ ,. 
E mail address: PD (£.A. Eisenhauer). 
0959 8049/$ see front matter © 2008 Elsevier Ltd. All rights reserved. 
doi:10.1016/j.ejca.2008.10.026 
small. Furthermore, there is guidance offered on what constitutes ‘unequivocal progres
sion’ of non measurable/non target disease, a source of confusion in the original RECISTguideline. Finally, a section on detection of new lesions, including the interpretation ofFDG PET scan assessment is included. Imaging guidance : the revised RECIST includes a
new imaging appendix with updated recommendations on the optimal anatomical assess
ment of lesions.
Future work: A key question considered by the RECIST Working Group in developing RECIST
1.1 was whether it was appropriate to move from anatomic unidimensional assessment of
tumour burden to either volumetric anatomical assessment or to functional assessmentwith PET or MRI. It was concluded that, at present, there is not sufﬁcient standardisationor evidence to abandon anatomical assessment of tumour burden. The only exception tothis is in the use of FDG PET imaging as an adjunct to determination of progression. Asis detailed in the ﬁnal paper in this special issue, the use of these promising newerapproaches requires appropriate clinical validation studies.
/C2112008 Elsevier Ltd. All rights reserved.
1. Background
1.1. History of RECIST criteria
Assessment of the change in tumour burden is an important
feature of the clinical evaluation of cancer therapeutics. Both
tumour shrinkage (objective response) and time to the development of disease progression are important endpoints in
cancer clinical trials. The use of tumour regression as the
endpoint for phase II trials screening new agents for evidence of anti tumour effect is supported by years of evidence suggesting that, for many solid tumours, agentswhich produce tumour shrinkage in a proportion of patientshave a reasonable (albeit imperfect) chance of subsequentlydemonstrating an improvement in overall survival or othertime to event measures in randomised phase III studies (reviewed in [1 4] ). At the current time objective response car
ries with it a body of evidence greater than for any otherbiomarker supporting its utility as a measure of promising
treatment effect in phase II screening trials. Furthermore,
at both the phase II and phase III stage of drug development,clinical trials in advanced disease settings are increasinglyutilising time to progression (or progression free survival)as an endpoint upon which efﬁcacy conclusions are drawn,which is also based on anatomical measurement of tumoursize.
However, both of these tumour endpoints, objective re
sponse and time to disease progression, are useful only ifbased on widely accepted and readily applied standard criteria based on anatomical tumour burden. In 1981 the World
Health Organisation (WHO) ﬁrst published tumour response
criteria, mainly for use in trials where tumour response wasthe primary endpoint. The WHO criteria introduced the concept of an overall assessment of tumour burden by summingthe products of bidimensional lesion measurements anddetermined response to therapy by evaluation of change frombaseline while on treatment.
5However, in the decades that
followed their publication, cooperative groups and pharmaceutical companies that used the WHO criteria often ‘modiﬁed’ them to accommodate new technologies or to addressareas that were unclear in the original document. This ledto confusion in interpretation of trial results
6and in fact,
the application of varying response criteria was shown to leadto very different conclusions about the efﬁcacy of the sameregimen.
7In response to these problems, an International
Working Party was formed in the mid 1990s to standardiseand simplify response criteria. New criteria, known as RECIST
(Response Evaluation Criteria in Solid Tumours), were pub
lished in 2000.
8Key features of the original RECIST include
deﬁnitions of minimum size of measurable lesions, instructions on how many lesions to follow (up to 10; a maximumﬁve per organ site), and the use of unidimensional, ratherthan bidimensional, measures for overall evaluation of tumour burden. These criteria have subsequently been widelyadopted by academic institutions, cooperative groups, andindustry for trials where the primary endpoints are objectiveresponse or progression. In addition, regulatory authoritiesaccept RECIST as an appropriate guideline for these
assessments.
1.2. Why update RECIST?
Since RECIST was published in 2000, many investigators have
conﬁrmed in prospective analyses the validity of substituting
unidimensional for bidimensional (and even three dimensional) based criteria (reviewed in [9]). With rare exceptions
(e.g. mesothelioma), the use of unidimensional criteria seemsto perform well in solid tumour phase II studies.
However, a number of questions and issues have arisen
which merit answers and further clarity. Amongst theseare whether fewer than 10 lesions can be assessed withoutaffecting the overall assigned response for patients (or theconclusion about activity in trials); how to apply RECIST inrandomised phase III trials where progression, not response,is the primary endpoint particularly if not all patients havemeasurable disease; whether or how to utilise newer imaging technologies such as FDG PET and MRI; how to handleassessment of lymph nodes; whether response conﬁrmationis truly needed; and, not least, the applicability of RECIST intrials of targeted non cytotoxic drugs. This revision of the
RECIST guidelines includes updates that touch on all these
points.E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 229
1.3. Process of RECIST 1.1 development
The RECIST Working Group, consisting of clinicians with
expertise in early drug development from academic research
organisations, government and industry, together with imag
ing specialists and statisticians, has met regularly to set the
agenda for an update to RECIST, determine the evidenceneeded to justify the various changes made, and to reviewemerging evidence. A critical aspect of the revision processwas to create a database of prospectively documented solidtumour measurement data obtained from industry and academic group trials. This database, assembled at the EORTCData Centre under the leadership of Jan Bogaerts and PatrickTherasse (co authors of this guideline), consists of >6500 patients with >18,000 target lesions and was utilised to investigate the impact of a variety of questions (e.g. number of
target lesions required, the need for response conﬁrmation,
and lymph node measurement rules) on response and progression free survival outcomes. The results of this work,which after evaluation by the RECIST Working Group led tomost of the changes in this revised guideline, are reportedin detail in a separate paper in this special issue.
10Larry Sch
wartz and Robert Ford (also co authors of this guideline) alsoprovided key databases from which inferences have beenmade that inform these revisions.
11
The publication of this revised guideline is believed to be
timely since it incorporates changes to simplify, optimise
and standardise the assessment of tumour burden in clinical
trials. A summary of key changes is found in Appendix I. Because the fundamental approach to assessment remainsgrounded in the anatomical, rather than functional, assessment of disease, we have elected to name this version RECIST1.1, rather than 2.0.
1.4. What about volumetric or functional assessment?
This raises the question, frequently posed, about whether it is
‘time’ to move from anatomic unidimensional assessment of
tumour burden to either volumetric anatomical assessment
orto functional assessment (e.g. dynamic contrast enhanced
MRI or CT or (18)F ﬂuorodeoxyglucose positron emissiontomographic (FDG PET) techniques assessing tumour metabolism). As can be seen, the Working Group and particularlythose involved in imaging research, did not believe that thereis at present sufﬁcient standardisation and widespread availability to recommend adoption of these alternative assessment methods. The only exception to this is in the use ofFDG PET imaging as an adjunct to determination of progression, as described later in this guideline. As detailed in paper
in this special issue
12, we believe that the use of these prom
ising newer approaches (which could either add to orsubstitute
foranatomical assessment as described in RECIST) requires
appropriate and rigorous clinical validation studies. This pa
per by Sargent et al. illustrates the type of data that will beneeded to be able to deﬁne ‘endpoints’ for these modalitiesand how to determine where and when such criteria/modalities can be used to improve the reliability with which trulyactive new agents are identiﬁed and truly inactive new agentsare discarded in comparison to RECIST criteria in phase IIscreening trials. The RECIST Working Group looks forwardto such data emerging in the next few years to allow theappropriate changes to the next iteration of the RECISTcriteria.
2. Purpose of this guideline
This guideline describes a standard approach to solid tumour
measurement and deﬁnitions for objective assessment ofchange in tumour size for use in adult and paediatric cancerclinical trials. It is expected these criteria will be useful in alltrials where objective response is the primary study endpoint,as well as in trials where assessment of stable disease, tu
mour progression or time to progression analyses are under
taken, since all of these outcome measures are based on anassessment of anatomical tumour burden and its change onstudy. There are no assumptions in this paper about the proportion of patients meeting the criteria for any of these endpoints which will signal that an agent or treatment regimen isactive: those deﬁnitions are dependent on type of cancer inwhich a trial is being undertaken and the speciﬁc agent(s) under study. Protocols must include appropriate statistical sections which deﬁne the efﬁcacy parameters upon which thetrial sample size and decision criteria are based. In addition
to providing deﬁnitions and criteria for assessment of tumour
response, this guideline also makes recommendationsregarding standard reporting of the results of trials that utilisetumour response as an endpoint.
While these guidelines may be applied in malignant brain
tumour studies, there are also separate criteria published forresponse assessment in that setting.
13This guideline is notin
tended for use for studies of malignant lymphoma sinceinternational guidelines for response assessment in lymphoma are published separately.
14
Finally, many oncologists in their daily clinical practice fol
low their patients’ malignant disease by means of repeatedimaging studies and make decisions about continued therapyon the basis of both objective and symptomatic criteria. It isnot intended that these RECIST guidelines play a role in thatdecision making, except if determined appropriate by thetreating oncologist.
3. Measurability of tumour at baseline
3.1. Deﬁnitions
At baseline, tumour lesions/lymph nodes will be categorised
measurable or non measurable as follows:
3.1.1. Measurable
Tumour lesions : Must be accurately measured in at least one
dimension ( longest diameter in the plane of measurement is
to be recorded) with a minimum size of:
•10 mm by CT scan (CT scan slice thickness no greater than5 mm; see Appendix II on imaging guidance).
•10 mm caliper measurement by clinical exam (lesionswhich cannot be accurately measured with calipers should
be recorded as non measurable).
•20 mm by chest X ray.230 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
Malignant lymph nodes: To be considered pathologically en
larged and measurable, a lymph node must be P15 mm in
short axis when assessed by CT scan (CT scan slice thickness
recommended to be no greater than 5 mm). At baseline and infollow up, only the short axis will be measured and followed
(see Schwartz et al. in this Special Issue
15). See also notes be
low on ‘Baseline documentation of target and non target le
sions’ for information on lymph node measurement.
3.1.2. Non measurable
All other lesions, including small lesions (longest diameter
<10 mm or pathological lymph nodes with P10 to <15 mm
short axis) as well as truly non measurable lesions. Lesions
considered truly non measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, inﬂammatorybreast disease, lymphangitic involvement of skin or lung,abdominal masses/abdominal organomegaly identiﬁed byphysical exam that is not measurable by reproducible imaging
techniques.
3.1.3. Special considerations regarding lesion measurability
Bone lesions, cystic lesions, and lesions previously treated
with local therapy require particular comment:
Bone lesions:.
•Bone scan, PET scan or plain ﬁlms are not considered ade
quate imaging techniques to measure bone lesions. However, these techniques can be used to conﬁrm thepresence or disappearance of bone lesions.
•Lytic bone lesions or mixed lytic blastic lesions, with identi
ﬁable soft tissue components , that can be evaluated by cross
sectional imaging techniques such as CT or MRI can be considered as measurable lesions if the soft tissue component
meets the deﬁnition of measurability described above.
•Blastic bone lesions are non measurable.
Cystic lesions:.
•Lesions that meet the criteria for radiographically deﬁnedsimple cysts should not be considered as malignant lesions(neither measurable nor non measurable) since they are, bydeﬁnition, simple cysts.
•‘Cystic lesions’ thought to represent cystic metastases canbe considered as measurable lesions, if they meet the deﬁnition of measurability described above. However, if noncystic lesions are present in the same patient, these are preferred for selection as target lesions.
Lesions with prior local treatment:
•Tumour lesions situated in a previously irradiated area, orin an area subjected to other loco regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Study protocols shoulddetail the conditions under which such lesions would be
considered measurable.
3.2. Speciﬁcations by methods of measurements
3.2.1. Measurement of lesions
All measurements should be recorded in metric notation,
using calipers if clinically assessed. All baseline evaluationsshould be performed as close as possible to the treatment
start and never more than 4 weeks before the beginning ofthe treatment.
3.2.2. Method of assessment
The same method of assessment and the same technique
should be used to characterise each identiﬁed and reportedlesion at baseline and during follow up. Imaging based evaluation should always be done rather than clinical examinationunless the lesion(s) being followed cannot be imaged but areassessable by clinical exam.
Clinical lesions: Clinical lesions will only be considered mea
surable when they are superﬁcial and P10 mm diameter as
assessed using calipers (e.g. skin nodules). For the case of skinlesions, documentation by colour photography including a ruler to estimate the size of the lesion is suggested. As notedabove, when lesions can be evaluated by both clinical examand imaging, imaging evaluation should be undertaken sinceit is more objective and may also be reviewed at the end of thestudy.
Chest X ray: Chest CT is preferred over chest X ray, particu
larly when progression is an important endpoint, since CT ismore sensitive than X ray, particularly in identifying new le
sions. However, lesions on chest X ray may be considered
measurable if they are clearly deﬁned and surrounded by aerated lung. See Appendix II for more details.
CT, MRI: CT is the best currently available and reproducible
method to measure lesions selected for response assessment.This guideline has deﬁned measurability of lesions on CTscan based on the assumption that CT slice thickness is5 mm or less. As is described in Appendix II , when CT scans
have slice thickness greater than 5 mm, the minimum sizefor a measurable lesion should be twice the slice thickness.MRI is also acceptable in certain situations (e.g. for bodyscans). More details concerning the use of both CT and MRI
for assessment of objective tumour response evaluation are
provided in Appendix II .
Ultrasound: Ultrasound is not useful in assessment of lesion
size and should not be used as a method of measurement.Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, becausethey are operator dependent, it cannot be guaranteed thatthe same technique and measurements will be taken fromone assessment to the next (described in greater detail inAppendix II). If new lesions are identiﬁed by ultrasound inthe course of the study, conﬁrmation by CT or MRI is advised. If there is concern about radiation exposure at CT,
MRI may be used instead of CT in selected instances.
Endoscopy, laparoscopy: The utilisation of these techniques for
objective tumour evaluation is not advised. However, they
can be useful to conﬁrm complete pathological responsewhen biopsies are obtained or to determine relapse in trialswhere recurrence following complete response or surgicalresection is an endpoint.
Tumour markers: Tumour markers alone cannot be used to as
sess objective tumour response. If markers are initially aboveE U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 231
the upper normal limit, however, they must normalise for a
patient to be considered in complete response. Becausetumour markers are disease speciﬁc, instructions for theirmeasurement should be incorporated into protocols on adisease speciﬁc basis. Speciﬁc guidelines for both CA 125response (in recurrent ovarian cancer) and PSA response (inrecurrent prostate cancer), have been published.
16–18In addi
tion, the Gynecologic Cancer Intergroup has developed CA125progression criteria which are to be integrated with objectivetumour assessment for use in ﬁrst line trials in ovariancancer.
19
Cytology, histology: These techniques can be used to differenti
ate between PR and CR in rare cases if required by protocol(for example, residual lesions in tumour types such as germcell tumours, where known residual benign tumours can remain). When effusions are known to be a potential adverseeffect of treatment (e.g. with certain taxane compounds orangiogenesis inhibitors), the cytological conﬁrmation of the
neoplastic origin of any effusion that appears or worsens dur
ing treatment can be considered if the measurable tumourhas met criteria for response or stable disease in order to differentiate between response (or stable disease) and progressive disease.
4. Tumour response evaluation
4.1. Assessment of overall tumour burden and
measurable disease
To assess objective response or future progression, it is nec
essary to estimate the overall tumour burden at baseline and
use this as a comparator for subsequent measurements.
Only patients with measurable disease at baseline shouldbe included in protocols where objective tumour responseis the primary endpoint. Measurable disease is deﬁned bythe presence of at least one measurable lesion (as detailedabove in Section 3). In studies where the primary endpoint
is tumour progression (either time to progression or propor
tion with progression at a ﬁxed date), the protocol must
specify if entry is restricted to those with measurable diseaseor whether patients having non measurable disease only arealso eligible.
4.2. Baseline documentation of ‘target’ and ‘non-target’
lesions
When more than one measurable lesion is present at baseline
all lesions up to a maximum of ﬁve lesions total (and a max
imum of two lesions per organ) representative of all involved
organs should be identiﬁed as target lesions and will be re
corded and measured at baseline (this means in instances
where patients have only one or two organ sites involved amaximum of two and four lesions respectively will be re
corded). For evidence to support the selection of only ﬁve target lesions, see analyses on a large prospective database inthe article by Bogaerts et al.
10.
Target lesions should be selected on the basis of their size
(lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lendthemselves to reproducible repeated measurements .I tm a yb e
the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance thenext largest lesion which can be measured reproduciblyshould be selected. To illustrate this point see the examplein Fig. 3 of Appendix II .
Lymph nodes merit special mention since they are normal
anatomical structures which may be visible by imaging evenif not involved by tumour. As noted in Section 3, pathological
nodes which are deﬁned as measurable and may be identiﬁed as target lesions must meet the criterion of a short axisofP15 mm by CT scan. Only the short axis of these nodes
will contribute to the baseline sum. The short axis of thenode is the diameter normally used by radiologists to judgeif a node is involved by solid tumour. Nodal size is normallyreported as two dimensions in the plane in which the imageis obtained (for CT scan this is almost always the axial plane;
for MRI the plane of acquisition may be axial, saggital or
coronal). The smaller of these measures is the short axis.For example, an abdominal node which is reported as being20 mm ·30 mm has a short axis of 20 mm and qualiﬁes as a
malignant, measurable node. In this example, 20 mm shouldbe recorded as the node measurement (See also the examplein Fig. 4 in Appendix II ). All other pathological nodes (those
with short axis P10 mm but <15 mm) should be considered
non target lesions. Nodes that have a short axis <10 mmare considered non pathological and should not be recordedor followed.
Asum of the diameters (longest for non nodal lesions, short
axis for nodal lesions) for all target lesions will be calculatedand reported as the baseline sum diameters . If lymph nodes
are to be included in the sum, then as noted above, only theshort axis is added into the sum. The baseline sum diameters
will be used as reference to further characterise any objectivetumour regression in the measurable dimension of thedisease.
All other lesions (or sites of disease) including pathological
lymph nodes should be identiﬁed as non target lesions and
should also be recorded at baseline. Measurements are not re
quired and these lesions should be followed as ‘present’, ‘ab
sent’, or in rare cases ‘unequivocal progression’ (more detailsto follow). In addition, it is possible to record multiple nontarget lesions involving the same organ as a single item onthe case record form (e.g. ‘multiple enlarged pelvic lymphnodes’ or ‘multiple liver metastases’).
4.3. Response criteria
This section provides the deﬁnitions of the criteria used to
determine objective tumour response for target lesions.
4.3.1. Evaluation of target lesions
Complete Response (CR): Disappearance of all target lesions.
Any pathological lymph nodes (whether target ornon target) must have reduction in short axis to<10 mm.
Partial Response (PR): At least a 30% decrease in the sum of
diameters of target lesions, taking as reference thebaseline sum diameters.232 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
Progressive Disease (PD): At least a 20% increase in the sum
of diameters of target lesions, taking as reference
thesmallest sum on study (this includes the baseline
sum if that is the smallest on study). In addition tothe relative increase of 20%, the sum must also dem
onstrate an absolute increase of at least 5 mm. ( Note:
the appearance of one or more new lesions is also
considered progression).
Stable Disease (SD): Neither sufﬁcient shrinkage to qualify for
PR nor sufﬁcient increase to qualify for PD, taking asreference the smallest sum diameters while on study.
4.3.2. Special notes on the assessment of target lesions
Lymph nodes. Lymph nodes identiﬁed as target lesions should
always have the actual short axis measurement recorded (mea
sured in the same anatomical plane as the baseline examina
tion), even if the nodes regress to below 10 mm on study. Thismeans that when lymph nodes are included as target lesions,the ‘sum’ of lesions may not be zero even if complete responsecriteria are met, since a normal lymph node is deﬁned as havinga short axis of <10 mm. Case report forms or other data collection methods may therefore be designed to have target nodal lesions recorded in a separate section where, in order to qualifyfor CR, each node must achieve a short axis <10 mm. For PR,SD and PD, the actual short axis measurement of the nodes isto be included in the sum of target lesions.
Target lesions that become ‘too small to measure’. While on
study, all lesions (nodal and non nodal) recorded at baselineshould have their actual measurements recorded at each subsequent evaluation, even when very small (e.g. 2 mm). However, sometimes lesions or lymph nodes which are recordedas target lesions at baseline become so faint on CT scan thatthe radiologist may not feel comfortable assigning an exactmeasure and may report them as being ‘too small to measure’.When this occurs it is important that a value be recorded onthe case report form. If it is the opinion of the radiologist that
the lesion has likely disappeared, the measurement should be
recorded as 0 mm. If the lesion is believed to be present and isfaintly seen but too small to measure, a default value of 5 mmshould be assigned ( Note: It is less likely that this rule will be
used for lymph nodes since they usually have a deﬁnable sizewhen normal and are frequently surrounded by fat such as inthe retroperitoneum; however, if a lymph node is believed tobe present and is faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance aswell). This default value is derived from the 5 mm CT slicethickness (but should not be changed with varying CT slice
thickness). The measurement of these lesions is potentially
non reproducible, therefore providing this default value willprevent false responses or progressions based upon measurement error. To reiterate, however, if the radiologist isable to
provide an actual measure, that should be recorded, even ifit is below 5 mm.
Lesions that split or coalesce on treatment. As noted in Appen
dix II, when non nodal lesions ‘fragment’, the longest diameters of the fragmented portions should be added together tocalculate the target lesion sum. Similarly, as lesions coalesce,
a plane between them may be maintained that would aid inobtaining maximal diameter measurements of each individ
ual lesion. If the lesions have truly coalesced such that theyare no longer separable, the vector of the longest diameterin this instance should be the maximal longest diameter forthe ‘coalesced lesion’.
4.3.3. Evaluation of non target lesions
This section provides the deﬁnitions of the criteriausedto deter
mine the tumour response for the group of non target lesions.While some non target lesions may actually be measurable,they need not be measured and instead should be assessed onlyqualitatively at the time points speciﬁed in the protocol.
Complete Response (CR): Disappearance of all non target le
sions and normalisation of tumour marker level. Alllymph nodes must be non pathological in size(<10 mm short axis).
Non CR/Non PD: Persistence of one or more non target le
sion(s) and/or maintenance of tumour marker levelabove the normal limits.
Progressive Disease (PD): Unequivocal progression (see com
ments below) of existing non target lesions. ( Note:
the appearance of one or more new lesions is also
considered progression).
4.3.4. Special notes on assessment of progression of non
target disease
The concept of progression of non target disease requires
additional explanation as follows:
When the patient also has measurable disease. In this setting,
to achieve ‘unequivocal progression’ on the basis of the
non target disease, there must be an overall level of substantial worsening in non target disease such that, even in presence of SD or PR in target disease, the overall tumourburden has increased sufﬁciently to merit discontinuationof therapy (see examples in Appendix II and further details
below). A modest ‘increase’ in the size of one or more non target lesions is usually not sufﬁcient to quality for unequivocal
progression status. The designation of overall progression so
lelyon the basis of change in non target disease in the face of
SD or PR of target disease will therefore be extremely rare.
When the patient has only non measurable disease. This circum
stance arises in some phase III trials when it is not a criterion of
study entry to have measurable disease. The same general concepts apply here as noted above, however, in this instance thereis no measurable disease assessment to factor into the interpretation of an increase in non measurable disease burden.Because worsening in non target disease cannot be easilyquantiﬁed (by deﬁnition: if all lesions are truly non measur
able) a useful test that can be applied when assessing patients
for unequivocal progression is to consider if the increase inoverall disease burden based on the change in non measurabledisease is comparable in magnitude to the increase that wouldberequiredtodeclare PDfor measurabledisease: i.e. an increasein tumour burden representing an additional 73% increase in‘volume’ (which is equivalent to a 20% increase diameter in ameasurable lesion). Examples include an increase in a pleuraleffusion from ‘trace’ to ‘large’, an increase in lymphangiticE U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 233
disease from localised to widespread, or may be described in
protocols as ‘sufﬁcient to require a change in therapy’. Someillustrative examples are shown in Figs. 5 and 6 in Appendix II .
If ‘unequivocal progression’ is seen, the patient should be considered to have had overall PD at that point. While it would beideal to have objective criteria to apply to non measurable disease, the very nature of that disease makes it impossible to do
so, therefore the increase must be substantial.
4.3.5. New lesions
The appearance of new malignant lesions denotes disease
progression; therefore, some comments on detection of new
lesions are important. There are no speciﬁc criteria for theidentiﬁcation of new radiographic lesions; however, the ﬁnding of a new lesion should be unequivocal: i.e. not attributableto differences in scanning technique, change in imagingmodality or ﬁndings thought to represent something otherthan tumour (for example, some ‘new’ bone lesions may be
simply healing or ﬂare of pre existing lesions). This is partic
ularly important when the patient’s baseline lesions showpartial or complete response. For example, necrosis of a liverlesion may be reported on a CT scan report as a ‘new’ cysticlesion, which it is not.
A lesion identiﬁed on a follow up study in an anatomical
location that was notscanned at baseline is considered a new
lesion andwill indicate disease progression. An example of thisis the patient who has visceral disease at baseline and while onstudy has a CTor MRI brain ordered which reveals metastases.The patient’s brain metastases are considered to be evidence of
PD even if he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its
small size, continued therapy and follow up evaluation will
clarify if it represents truly new disease. If repeat scans conﬁrm there is deﬁnitely a new lesion, then progression shouldbe declared using the date of the initial scan.
While FDG PET response assessments need additional
study, it is sometimes reasonable to incorporate the use ofFDG PET scanning to complement CT scanning in assessmentof progression (particularly possible ‘new’ disease). New lesions on the basis of FDG PET imaging can be identiﬁed
according to the following algorithm:
a. Negative FDG PET at baseline, with a positive
lFDG PET
at follow up is a sign of PD based on a new lesion.
b. No FDG PET at baseline and a positive FDG PET at fol
low up:
If the positive FDG PET at follow up corresponds to anew site of disease conﬁrmed by CT, this is PD.If the positive FDG PET at follow up is not conﬁrmed asa new site of disease on CT, additional follow up CTscans are needed to determine if there is truly progression occurring at that site (if so, the date of PD will bethe date of the initial abnormal FDG PET scan).If the positive FDG PET at follow up corresponds to a
pre existing site of disease on CT that is not progress
ing on the basis of the anatomic images, this is not PD.4.4. Evaluation of best overall response
The best overall response is the best response recorded from
the start of the study treatment until the end of treatmenttaking into account any requirement for conﬁrmation. On oc
casion a response may not be documented until after the end
of therapy so protocols should be clear if post treatmentassessments are to be considered in determination of bestoverall response. Protocols must specify how any new therapyintroduced before progression will affect best response designation. The patient’s best overall response assignment willdepend on the ﬁndings of both target and non target diseaseand will also take into consideration the appearance of newlesions. Furthermore, depending on the nature of the studyand the protocol requirements, it may also require conﬁrmatory measurement (see Section 4.6). Speciﬁcally, in non ran
domised trials where response is the primary endpoint,conﬁrmation of PR or CR is needed to deem either one the‘best overall response’. This is described further below.
4.4.1. Time point response
It is assumed that at each protocol speciﬁed time point, a re
sponse assessment occurs. Table 1 on the next page provides
a summary of the overall response status calculation at eachtime point for patients who have measurable disease atbaseline.
When patients have non measurable (therefore non tar
get) disease only, Table 2 is to be used.
4.4.2. Missing assessments and inevaluable designation
When no imaging/measurement is done at all at a particular
time point, the patient is not evaluable (NE) at that time point.If only a subset of lesion measurements are made at anassessment, usually the case is also considered NE at thattime point, unless a convincing argument can be made thatthe contribution of the individual missing lesion(s) wouldnot change the assigned time point response. This would bemost likely to happen in the case of PD. For example, if a pa
tient had a baseline sum of 50 mm with three measured le
sions and at follow up only two lesions were assessed, butthose gave a sum of 80 mm, the patient will have achievedPD status, regardless of the contribution of the missing lesion.
4.4.3. Best overall response: all time points
The best overall response is determined once all the data for the
patient is known.
Best response determination in trials where conﬁrmation of com
plete or partial response IS NOT required : Best response in these
trials is deﬁned as the best response across all time points (for
example, a patient who has SD at ﬁrst assessment, PR at sec
ond assessment, and PD on last assessment has a best overallresponse of PR). When SD is believed to be best response, itmust also meet the protocol speciﬁed minimum time frombaseline. If the minimum time is not met when SD is otherwise the best time point response, the patient’s best responsedepends on the subsequent assessments. For example, a patient who has SD at ﬁrst assessment, PD at second and doesnot meet minimum duration for SD, will have a best responseof PD. The same patient lost to follow up after the ﬁrst SDassessment would be considered inevaluable.
lA ‘positive’ FDG PET scan lesion means one which is FDG avid
with an uptake greater than twice that of the surrounding tissue
on the attenuation corrected image.234 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
EUROPEAN JOURNAL OF CANCER 45 (2009) 228 247 235 
Table 1 -Time point response: patients with target(+/-
non-target) disease. 
Target lesions Non target lesions New Overall 
lesions response 
CR CR No CR 
CR Non CR/non PD No PR 
CR Not evaluated No PR 
PR Non PD or No PR 
not all evaluated 
SD Non PD or No SD 
not all evaluated 
Not all Non PD No NE 
evaluated 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
CR= complete response, PR= partial response, SD= stable disease, 
PD= progressive disease, and NE= inevaluable . 
Table 2 -Time point response: patients with non-target 
disease only. 
Non target lesions 
CR 
Non CR/non PD 
Not all evaluated 
Unequivocal PD 
Any New lesions 
No 
No 
No 
Yes or No 
Yes 
CR= complete ~esponse, PD = progressive 
NE= inevaluable. Overall response 
CR 
Non CR/non PD" 
NE 
PD 
PD 
disease, and 
a 'Non CR/non PD' is preferred over 'stable disease ' for non target 
disease since SD is increasingly used as endpoint for assessment 
of efficacy in some trials so to assign this category when no 
lesions can be measured is not advised . 
Best response determination in trials where confirmation of com 
plete or partial response IS required: Complete or partial re 
sponses may be claimed only if the criteria for each are met at a subsequent time point as specified in the protocol (gener 
ally 4 weeks later) . In this circumstance, the best overall re 
sponse can be interpreted as in '!'able 3. 
4.4.4. Special notes on response assessment 
When nodal disease is included in the sum of target lesions 
and the nodes decrease to 'normal' size (<10 mm), they may 
still have a measurement reported on scans. This measure 
ment should be recorded even though the nodes are normal 
in order not to overstate progression should it be based on 
increase in size of the nodes . As noted earlier, this means that 
patients with CR may not have a total sum of 'zero' on the 
case report form (CRF). 
In trials where confirmation of response is required, re 
peated 'NE' time point assessments may complicate best re 
sponse determination . The analysis plan for the trial must 
address how missing data/assessmen ts will be addressed in 
determination of response and progression. For example, in 
most trials it is reasonable to consider a patient with time 
point responses of PR NE PR as a confirmed response. 
Patients with a global deterioration of health status requir 
ing discontinuation of treatment without objective evidence 
of disease progression at that time should be reported as 
'symptomatic deterioration' . Every effort should be made to 
document objective progression even after discontinuation 
of treatment. Symptomatic deterioration is not a descriptor 
of an objective response: it is a reason for stopping study ther 
apy. The objective response status of such patients is to be 
determined by evaluation of target and non target disease 
as shown in Tables 1 3. 
Conditions that define 'early progression, early death and 
inevaluability' are study specific and should be clearly de 
scribed in each protocol (depending on treatment duration, 
treatment periodicity). 
In some circumstances it may be difficult to distinguish 
residual disease from normal tissue . When the evaluation of 
complete response depends upon this determination, it is 
recommended that the residual lesion be investigated (fine 
Table 3 -Best overall response when confirmation of CR and PR required. 
Overall response 
First time point 
CR 
CR 
CR 
CR 
CR 
PR 
PR 
PR 
PR 
PR 
NE Overall response 
Subsequent time point 
CR 
PR 
SD 
PD 
NE 
CR 
PR 
SD 
PD 
NE 
NE BEST overall response 
CR 
SD, PD or PR" 
SD provided minimum criteria for SD duration met, otherwise, PD 
SD provided minimum criteria for SD duration met, otherwise, PD 
SD provided minimum criteria for SD duration met, otherwise NE 
PR 
PR 
SD 
SD provided minimum criteria for SD duration met, otherwise, PD 
SD provided minimum criteria for SD duration met, otherwise NE 
NE 
CR= complete response, PR= partial response , SD= stable disease, PD= progressive disease, and NE= inevaluable. 
a lf a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to baseline , 
makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration 
for SD was met. However, sometimes 'CR' may be claimed when subsequent scans suggest small lesions were likely still present and in fact the 
patient had PR, not CR at the first time point . Under these circumstances, the original CR should be changed to PR and the best response is PR. 
needle aspirate/biopsy) before assigning a status of complete
response. FDG PET may be used to upgrade a response to a CRin a manner similar to a biopsy in cases where a residualradiographic abnormality is thought to represent ﬁbrosis orscarring. The use of FDG PET in this circumstance should beprospectively described in the protocol and supported by disease speciﬁc medical literature for the indication. However, it
must be acknowledged that both approaches may lead to
false positive CR due to limitations of FDG PET and biopsy resolution/sensitivity.
For equivocal ﬁndings of progression (e.g. very small and
uncertain new lesions; cystic changes or necrosis in existinglesions), treatment may continue until the next scheduledassessment. If at the next scheduled assessment, progressionis conﬁrmed, the date of progression should be the earlierdate when progression was suspected.
4.5. Frequency of tumour re-evaluation
Frequency of tumour re evaluation while on treatment
should be protocol speciﬁc and adapted to the type and schedule of treatment. However, in the context of phase II studieswhere the beneﬁcial effect of therapy is not known, follow upevery 6 8 weeks (timed to coincide with the end of a cycle) isreasonable. Smaller or greater time intervals than these couldbe justiﬁed in speciﬁc regimens or circumstances. The protocol should specify which organ sites are to be evaluated atbaseline (usually those most likely to be involved with metastatic disease for the tumour type under study) and how often
evaluations are repeated. Normally, all target and non target
sites are evaluated at each assessment. In selected circumstances certain non target organs may be evaluated less frequently. For example, bone scans may need to be repeatedonly when complete response is identiﬁed in target diseaseor when progression in bone is suspected.
After the end of the treatment, the need for repetitive tu
mour evaluations depends on whether the trial has as a goalthe response rate or the time to an event (progression/death).If ‘time to an event’ (e.g. time to progression, disease freesurvival, progression free survival) is the main endpoint of
the study, then routine scheduled re evaluation of protocol
speciﬁed sites of disease is warranted. In randomised comparative trials in particular, the scheduled assessmentsshould be performed as identiﬁed on a calendar schedule(for example: every 6 8 weeks on treatment or every 3 4months after treatment) and should not be affected by delaysin therapy, drug holidays or any other events that might leadto imbalance in a treatment arm in the timing of diseaseassessment.
4.6. Conﬁrmatory measurement/duration of response
4.6.1. Conﬁrmation
In non randomised trials where response is the primary end
point, conﬁrmation of PR and CR is required to ensure re
sponses identiﬁed are not the result of measurement error.This will also permit appropriate interpretation of results inthe context of historical data where response has traditionallyrequired conﬁrmation in such trials (see the paper by Bogaertset al. in this Special Issue
10). However, in all other circumstances, i.e. in randomised trials (phase II or III) or studieswhere stable disease or progression are the primary endpoints,conﬁrmation of response is not required since it will not add value to the interpretation of trial results. However, elimination ofthe requirement for response conﬁrmation may increase theimportance of central review to protect against bias, in particular in studies which are not blinded.
In the case of SD, measurements must have met the SD
criteria at least once after study entry at a minimum interval(in general not less than 6 8 weeks) that is deﬁned in thestudy protocol.
4.6.2. Duration of overall response
The duration of overall response is measured from the time
measurement criteria are ﬁrst met for CR/PR (whichever is ﬁrstrecorded) until the ﬁrst date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study).
The duration of overall complete response is measured
from the time measurement criteria are ﬁrst met for CR untilthe ﬁrst date that recurrent disease is objectively documented.
4.6.3. Duration of stable disease
Stable disease is measured from the start of the treatment (in
randomised trials, from date of randomisation) until the criteria for progression are met, taking as reference the smallest
sum on study (if the baseline sum is the smallest, this is the
reference for calculation of PD).
The clinical relevance of the duration of stable disease var
ies in different studies and diseases. If the proportion of patients achieving stable disease for a minimum period of timeis an endpoint of importance in a particular trial, the protocolshould specify the minimal time interval required betweentwo measurements for determination of stable disease.
Note: The duration of response and stable disease as well as
theprogression free survival are inﬂuenced by the frequencyoffollow up after baseline evaluation. It is not in the scope of thisguideline to deﬁne a standard follow up frequency. The frequency should take into account many parameters includingdisease types and stages, treatment periodicity and standard
practice. However, these limitations of the precision of the
measured endpoint should be taken into account if comparisons between trials are to be made.
4.7. Progression-free survival/proportion progression-free
4.7.1. Phase II trials
This guideline is focused primarily on the use of objective re
sponse endpoints for phase II trials. In some circumstances, ‘re
sponse rate’ may not be the optimal method to assess thepotential anticancer activity of new agents/regimens. In such
cases ‘progression free survival’ (PFS) or the ‘proportion pro
gression free’ at landmark time points, might be consideredappropriate alternatives to provide an initial signal of biologiceffect of new agents. It is clear, however, that in an uncontrolledtrial, these measures are subject to criticism since an apparently promising observation may be related to biological factorssuch as patient selection and not theimpact of theintervention.Thus, phase II screening trials utilising these endpoints are bestdesigned with a randomised control. Exceptions may exist236 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
where the behaviour patterns of certain cancers are so consis
tent (and usually consistently poor), that a non randomisedtrial is justiﬁable (see for example van Glabbeke et al.
20). How
ever, in these cases it will be essential to document with carethe basis for estimating the expected PFS or proportion progression free in the absence of a treatment effect.
4.7.2. Phase III trials
Phase III trials in advanced cancers are increasingly designed
to evaluate progression free survival or time to progression asthe primary outcome of interest. Assessment of progressionis relatively straightforward if the protocol requires all patients to have measurable disease. However, restricting entryto this subset of patients is subject to criticism: it may resultin a trial where the results are less likely to be generalisable if,in the disease under study, a substantial proportion of patients would be excluded. Moreover, the restriction to entrywill slow recruitment to the study. Increasingly, therefore, tri
als allow entry of both patients with measurable disease as
well as those with non measurable disease only. In this circumstance, care must be taken to explicitly describe the ﬁndings which would qualify for progressive disease for thosepatients without measurable lesions. Furthermore, in this set
ting, protocols must indicate if the maximum number of recorded target lesions for those patients with measurabledisease may be relaxed from ﬁve to three (based on the datafound in Bogaerts et al.
10and Moskowitz et al.11). As found in
the ‘special notes on assessment of progression’, these guidelines offer recommendations for assessment of progression
in this setting. Furthermore, if available, validated tumour mar
ker measures of progression (as has been proposed for ovariancancer) may be useful to integrate into the deﬁnition of progression. Centralised blinded review of imaging studies or ofsource imaging reports to verify ‘unequivocal progression’may be needed if important drug development or drug approval decisions are to be based on the study outcome. Finally,as noted earlier, because the date of progression is subject toascertainment bias, timing of investigations in study armsshould be the same. The article by Dancey et al. in this specialissue
21provides a more detailed discussion of the assessment
of progression in randomised trials.
4.8. Independent review of response and progression
For trials where objective response (CR + PR) is the primary end
point, and in particular where key drug development decisions are based on the observation of a minimum number ofresponders, it is recommended that all claimed responses bereviewed by an expert(s) independent of the study. If the studyis a randomised trial, ideally reviewers should be blinded totreatment assignment. Simultaneous review of the patients’
ﬁles and radiological images is the best approach.
Independent review of progression presents some more
complex issues: for example, there are statistical problems
with the use of central review based progression time inplace of investigator based progression time due to the potential introduction of informative censoring when the formerprecedes the latter. An overview of these factors and otherlessons learned from independent review is provided in anarticle by Ford et al. in this special issue.
224.9. Reporting best response results
4.9.1. Phase II trials
When response is the primary endpoint, and thus all patients
must have measurable disease to enter the trial, all patients
included in the study must be accounted for in the report of
the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assignedone of the following categories:
1. Complete response2. Partial response3. Stable disease4. Progression5. Inevaluable for response: specify reasons (for example: early
death, malignant disease; early death, toxicity; tumourassessments not repeated/incomplete; other (specify)).
Normally, all eligible patients should be included in the
denominator for the calculation of the response rate for phaseII trials (in some protocols it will be appropriate to include all
treated patients). It is generally preferred that 95% two sided
conﬁdence limits are given for the calculated response rate.Trial conclusions should be based on the response rate forall eligible (or all treated) patients and should notbe based
on a selected ‘evaluable’ subset.
4.9.2. Phase III trials
Response evaluation in phase III trials may be an indicator
of the relative anti tumour activity of the treatments evaluated and is almost always a secondary endpoint. Observed differences in response rate may not predict theclinically relevant therapeutic beneﬁt for the populationstudied. If objective response is selected as a primary endpoint for a phase III study (only in circumstances where adirect relationship between objective tumour response anda clinically relevant therapeutic beneﬁt can be unambigu
ously demonstrated for the population studied), the same
criteria as those applying to phase II trials should be usedand all patients entered should have at least one measurable lesion.
In those many cases where response is a secondary end
point and not all trial patients have measurable disease, themethod for reporting overall best response rates must bepre speciﬁed in the protocol. In practice, response rate maybe reported using either an ‘intent to treat’ analysis (all randomised patients in the denominator) or an analysis whereonly the subset of patients with measurable disease atbaseline are included. The protocol should clearly specify
how response results will be reported, including any subset
analyses that are planned.
The original version of RECIST suggested that in phase III
trials one could write protocols using a ‘relaxed’ interpretation of the RECIST guidelines (for example, reducing the number of lesions measured) but this should no longer be donesince these revised guidelines have been amended in such away that it is clear how these criteria should be applied forall trials in which anatomical assessment of tumour responseor progression are endpoints.E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 237
Appendix I. Summ ary of m ajor changes RECIST 1.0 to RECIST 1 .1 
Minimum size measurable 
lesions 
S~cial conside rations on 
lesion measurability 
Overall tumour burden 
Response criteria target 
disease 
Response criteria non target 
disease 
New lesions 
Overall response RECJST 1.0 
CT. 10 mµi spiral 
20 mm non spiral 
Clinical: 20 mm 
Lymph node: not mentioned 
10 lesions (5 per organ) 
CR lymph node not mentioned 
PD 20% increase over smallest sum on 
study or new 1esions RECIST 1.1 
CT 10 mm; delete reference to 
spiral scan 
Clinical: 10 mm (must be 
measurable with calipers) 
CT 
mm short a.xis, for target 
<15mm for non target 
<10 mm is non pathological 
Notes included on bone 
lesions, cystic lesions 
5 lesions (2 per organ) 
CR lymph nodes must be 
<10 mm short axis 
PD 20% increase over smallest 
sum on study (including 
baseline if that is smallest) and 
at least 5 mm increase or new 
lesions 
'unequivocal progression' considered as PD More detailed description of 
'un~uivocal progression' to 
indicate that it should not 
normally trump target disease 
status . It must be 
representative of overall 
disease status change. not a 
single lesion increase 
Table integrated target and non target 
lesions New section on New lesions 
1wo tables: one integrating 
tar~ t and non target and the 
other of non target only Rationale Reference in special issue 
(if applicable) 
Most scans used have 5 mm or less slice 
thickne ss Clearer to give instruction based on 
slice interval ii it is greater than s mm 
calipe r measurement will make this reliable 
Since nodes are norm al structure need to define 
pathological enlargement Short axis is most 
sensitive 
Clarify frequently asked questions 
Data warehouse analysis shows . no loss of 
information if lesio n number reduced from 10 to 
5. A maximum of 2 lesions per organ yii,lds 
sufficient representation per disease site 
In keeping with normal size of nodes 
Clarification that if baseline measurement is 
smaller than any on study measurement, it is 
reference against whic h PD is assessed 
5 mm absolute increase to guard against over 
calling PD when total sum is veiy small and 20% 
increas e is within measurement EITOr 
Confusion with RECIST 1.0 where some were 
consideringPDif'increase ' in any non target 
lesion, even when target disease is stable or 
responding 
To provide guidance on when a lesion is 
considered new (and thus PD) 
To account for the fact that RECJST criteria are 
now being used in trials where PFS is the 
endpoint and not all patients have measurable 
(target) disease at baseline Schwartz et al.15 
Bogaerts et al. 10 
Schwartz et al 15 "' c:: 
"' 0 .,, 
"' > z 
0 
C: ,., 
z > r-
e 
n > z n 
"' "' -4> 
V, 
..., 
0 
0 
'D 
..., 
..., 
00 
I ..., 
-4> ...... 
Confirmatory measure 
Progression free survival 
Reporting of response 
results 
Response in phase Ill 
trials 
Imaging appendix 
New appendices For CR and PR: criteria 
must be met again 4 
weeks after initial 
documentation 
General comments only 
9 categories suggested for 
reporting phase n results 
More relaxed guidelines 
possible if protocol specified 
Appendix I Special notes : 
How to assess and measure 
lymph nodes 
CR in face of residual tissue 
Discussion of 'equivocal' 
progression 
Retain this requirement ONLY 
for 
non randomised trials with 
primary endpoint of response 
More specific comments on 
use of PFS (or proportion 
progression free) as 
phase 11 endpoint 
Greater detail on PFS 
assessment in phase l1I trials 
Divided into phase n and phase 
Ill 
9 categories collapsed into 5 
In phase Ill, guidance given 
about reporting response 
This section removed and 
referenced in section 
above: no need to have 
different criteria for phase II 
andm 
Appendix Il: updated with 
detailed guidance on 
use of MRI; PET/CT 
Other practical guidance 
included 
Appendix I: comparison of 
RECIST 1.0 and 1.1 
Appendix Ill: frequently asked 
questions Frequently asked questions on these topics 
Data warehouse shows that response rates 
rise when confirmation is eliminated , but 
the only circumstance where this is 
important is in trials where there is no 
concurrent comparative control and where 
this measure is the primary endpoint 
Increasing use of PFS in phase Ill trials 
requires guidance on assessment of PD in 
patients with non measurable disease 
Simplifies reporting and clarifies !how to 
report phase n and Ill data consistently 
Simplification of response assessment by 
reducing number of lesions and eliminating 
need for confirmation in randomised 
studies where response is not the primary 
endpoint makes separate 'rules' 
unnecessary 
Evolving use of newer modalities addressed. 
Enhanced guidance in response to frequent 
questions and from radiology review 
experience Bogaerts et al. m 
Dancey et al. 21 
"' c:: ,., 
0 .., 
"' > z 
0 
c:: ,., 
z 
> .... 
0 .., 
r, 
> z r, 
"' "' -I' 
V1 
» 
0 
0 
\() 
Conﬂict of interest statement
None declared.
Acknowledgements
The RECIST Working Group would like to thank the following
organisations which made data bases available to us in orderto perform the analyses which informed decisions aboutchanges to this version of the criteria: Amgen; AstraZeneca;Breast Cancer International Research Group (BCIRG); BristolMyers Squibb; European Organisation for Research andTreatment of Cancer (EORTC) Breast Cancer Group and Gastrointestinal Group; Erasmus University Medical Center,Rotterdam, The Netherlands; Genentech; Pﬁzer; RadPharm;
Roche; Sanoﬁ Aventis.
We would also like to thank the following individuals from
academic, government, and pharmaceutical organisations for
providing helpful comments on an earlier draft of these revisedguidelines: Ohad Amit, Phil Murphy, Teri Crofts and Janet Begun, GlaxoSmithKline, USA; Laurence H. Baker, SouthwestOncology Group, USA; Karla Ballman, Mayo Clinic, USA;Charles Baum, Darrel Cohen, and Mary Ashford Collier, Pﬁzer,USA; Gary J. Becker, American Board of Radiology, Tucson,USA; Jean Yves Blay, University Claude Pertrand, Lyon France;Renzo Canetta, Bristol Myers Squibb, USA; David Chang, Am
gen Inc., USA; Sandra Chica, Perceptive Informations Inc. (PAR
EXEL), USA; Martin Edelman, University of MarylandGreenbaum Cancer Centre, USA; Gwendolyn Fyfe, Genentech,USA; Bruce Giantonio, Eastern Cooperative Oncology Group,USA; Gary Gordon, Abbott Pharmaceuticals, USA; Ronald Gottlieb, Roswell Park Cancer Institute, USA; Simon Kao, Universityof Iowa College of Medicine, USA; Wasaburo Koizumi, KitasatoUniversity, Japan; Alessandro Riva, Novartis Pharmaceuticals,USA; Wayne Rackhoff, Ortho Biotech Oncology Research andDevelopment, USA; Nagahiro Saijo, President Japanese Societyof Medical Oncology, Japan; Mitchell Schnall American College
of Radiology Imaging Network, USA; Yoshik Shimamura, PAR
EXEL International Inc., Japan; Rajeshwari Sridhara, Centrefor Drug Evaluation and Research, Food and Drug Administration, USA; Andrew Stone, Alan Barge, AstraZeneca, UnitedKingdom; Orhan Suleiman, Centre for Drug Evaluation and Research, Food and Drug Administration, USA; Daniel C. Sullivan,Duke University Medical Centre, USA; Masakazu Toi, KyotoUniversity, Japan; Cindy Welsh, Centre for Drug Evaluationand Research, Food and Drug Administration, USA.
Finally, the RECIST Working Group would like to thank indi
viduals who were not permanent members of the group (which
are all acknowledged as co authors) but who attended working
group meetings from time to time and made contributions tothe total process over the past 7 years: Richard Pazdur, Foodand Drug Administration, USA; Francesco Pignatti, EuropeanMedicines Agency, London, UK.
Appendix II. Speciﬁcations for standard
anatomical radiological imaging
These protocols for image acquisition of computed tomogra
phy (CT) and magnetic resonance imaging (MRI) are recommendations intended for patients on clinical trials where
RECIST assessment will be performed. Standardisation ofimaging requirements and image acquisition parameters isideal to allow for optimal comparability of subjects within astudy and results between studies. These recommendationsare designed to balance optimised image acquisition protocols with techniques that should be feasible to perform glob
ally at imaging facilities in all types of radiology practices.
These guidelines are not applicable to functional imagingtechniques or volumetric assessment of tumour size.
Scanner quality control is highly recommended and should
follow standard manufacturer and facility maintenanceschedules using commercial phantoms. It is likely that for RECIST unidimensional measurements this will be adequate toproduce reproducible measurements. Imaging quality controlfor CT includes an analysis of image noise and uniformity andCT number as well as spatial resolution. The frequency ofquality control analysis is also variable and should focus on
clinically relevant scanning parameters. Dose analysis is al
ways important and the use of imaging should follow theALARA principle, ‘As Low As Reasonably Achievable’, whichrefers to making every reasonable effort to maintain radiationexposures as far below the dose limits as possible.
Speciﬁc notes
Chest X ray measurement of lesions surrounded by pulmon
ary parenchyma is feasible, but not preferable as themeasurement represents a summation of densities. Further
more, there is poor identiﬁcation of new lesions within the
chest on X ray as compared with CT. Therefore, measurements of pulmonary parenchymal lesions as well as mediastinal disease are optimally performed with CT of the chest.MRI of the chest should only be performed in extenuating circumstances. Even if IV contrast cannot be administered (forexample, in the situation of allergy to contrast), a non contrast CT of the chest is still preferred over MRI or chest X ray.
CT scans: CT scans of the chest, abdomen, and pelvis should
be contiguous throughout all the anatomic region of interest.As a general rule, the minimum size of a measurable lesion at
baseline should be no less than double the slice thickness and
also have a minimum size of 10 mm (see below for minimumsize when scanners have a slice thickness more than 5 mm).While the precise physics of lesion size and partial volumeaveraging is complex, lesions smaller than 10 mm may be difﬁcult to accurately and reproducibly measure. While this ruleis applicable to baseline scans, as lesions potentially decreasein size at follow up CT studies, they should still be measured.Lesions which are reported as ‘too small to measure’ shouldbe assigned a default measurement of 5 mm if they are stillvisible.
The most critical CT image acquisition parameters for opti
mal tumour evaluation using RECIST are anatomic coverage,
contrast administration, slice thickness, and reconstruction interval.
a.Anatomic coverage: Optimal anatomic coverage for mostsolid tumours is the chest, abdomen and pelvis. Coverage should encompass all areas of known predilectionfor metastases in the disease under evaluation and240 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
EUROPEAN JOURNAL OF CANCER 45 (2009 ) 228 247 241 
should additionally investigate areas that may be 
involved based on signs and symptoms of individual 
patients. Because a lesion later identified in a body part 
not scanned at baseline would be considered as a new 
lesion representing disease progression, careful consid 
eration should be given to the extent of imaging coverage 
at baseline- and at subsequent follow up time poin ts. 
This will enable better consistency not only of tumour 
measurements but also identification of new disease. 
b. N contrast administration: Optimal visualisation and 
measurement of metastases in solid tumours requires 
consistent administration (dose and rate) of IV contrast 
as well as timing of scanning. 1ypically, most abdomi 
nal imaging is performed during the portal venous 
phase and (optimally) abou t the same time frame after 
injection on each examina tion (see Fig. 1 for impact of 
different phase of IV contrast on lesion measurement). 
Most solid tumours may be scanned with a single 
phase after administration of contrast. While triphasic 
CT scans are sometimes performed on other types of 
vascular tumours to improve lesion conspicuity, for 
consistency and uniformity, we would recommend tri 
phasic CT for hepatocellular and neuroendocrine 
tumo urs for which this scanning protocol is generally 
standard of care, and the improved temporal resolution 
of the triphasic scan will enhance the radiologists' abil 
ity to consistently and reproducibly measure these 
lesions. The precise dose and rate of N contrast is 
dependen t upon the CT scanning equipmen t. CT acqui 
sition protocol , the type of contrast used, the available 
venous access and the medica l condition of the 
patient. Therefore, the method of administration of 
intravenous contrast agents is variable . . Rather than 
try to institute rigid rules regarding methods for 
administering contrast agents and the volume injected, 
it is appropriate to suggest that an adequate volume of 
a suitable contrast agent should be given so that the 
metastases . are demonstrated to best effect and a con 
sistent method is used on subsequent examinations for 
any given patient (ideally, this would be specified in 
the protocol or for an institution). It is very important 
that the same technique be used at baseline and on fol low up examinations for a given patient. 1'his will 
greatly enhance the reproducibility of the tumour mea 
surements. If prior to enrolment it is known a patient is 
not able to undergo CT scans with N contrast due to 
allergy or renal insufficiency, the decis ion as to 
whether a non contrast CT or MRI (with or without N 
contrast) should be used to evaluate the subject at 
baseline and follow up should be guided by the tumour 
type under investigation and the anatomic location of 
the disease. For patients who develop contraindica 
tions to contrast after baseline contrast CT is done, 
the decision as to whether non contrast CT or MRI 
(enhanced or non enhanced) should be performed 
should also be based on the tumour type, anatomic 
location of the disease and should be optimised to 
allow for comparison to the prior studies if possible. 
Each case should be discussed with the radiologist to 
determine if substitution of these other approaches is 
possible and, if not, the patient should be considered 
not evaluable from that point forward. Care must be 
taken in measurement of target lesions on a different 
modality and interpretation of non target disease or 
new lesions, since the same lesion may appear to have 
a different size using a new modality (see Fig. 2 for a 
comparison of CT and MRI of the same lesion). Oral 
contrast is recommended to help visualise and differ 
entiate structures in the abdomen. 
c. Slice thickness and reconstruction interual: RECIST measure 
ments may be performed at most clinically obtained 
slice thicknesses. It is recommended that CT scans be 
performed at 5 mm contiguous slice thickness or less 
and indeed this guideline presumes a minimum 5 mm 
thickness in recommendations for measurable lesion 
definition. Indeed , variations in slice thickness can have 
an impact on lesion measurement and on detection of 
new lesions . However, consideration should also be 
given for minimising radiation exposure. With these 
patameters, a minimum 10 mm lesion is considered 
measurable at baseline . Occasionally, institutions may 
perform medically acceptable scans at slice thicknesses 
greater than s mm. If this occurs, the minimum size of 
measurable lesions at baseline should be twice the slice 
Fig. 1 -Difference in measurement/ visualisation with differen t phases of IV contrast administration. Hypervascu lar 
metastases imaged in the arteria l phase Qeft) and the portal veno us phase (righ t). Note that the number of lesions visib le 
differs greatly between the two phases of contrast administra tion as does any potential lesion measurement. Consisten t CT 
scan acquisition, including phase of contrast administration, is important for optima l and reproducib le tumour 
242 EUROPEAN JOURNAL OF CANCER 45 (2009} 228 247 
Fig. 2 -CT versus MRI of same lesions showing apparen t 'progression' due only to differing me1ho d of measuremen t. 
thickness of the baseline scans. Most contemporary CT 
scanners are multidetector which have many imaging 
options for these acquisition parameters .23 The equip 
ment vendo r and scanning manual should be reviewed 
if there are any specific system questions. 
d. Alternative contrast agents: There are a number of other, 
new contras.t agents, some organ specific.24 They may 
be used as part of patient care for instance, in liver 
lesion assessment, or lymph node characterisation25, 
but should not as yet be used in clinical trials. 
FOG PET has gained acceptance as a valuable tool for 
detecting, staging and restagi.ng several malignancies. Criteria 
for incorporating (or subst ituting) FDG PE T into anatomical 
assessment of tumour response in phase II trials are not :yet 
available, though much research is ongoing. Nevertheless, 
FOG PET is being used in many drug development trials both 
as a tool to assess therapeutic efficacy and also in assessment 
of progression. If FDG PET scans are included in a protocol, by 
consensus , an FOG uptake period of 60 min prior to imaging 
has been decided as the most appropria te for imaging of pa 
tients with malignancy .26 Whole body acquisition is impor 
tant since this allows for sampling of all areas of interest 
and can assess if new lesions have appeared thus determining 
the possibility of interval progression of disease. Images from 
the base of the skull to the level of the mid thigh shoul d be ob 
tained 60 min post injection . PET camera specifications are 
variable and manufacturer specific, so every attempt should 
be made to use the same scanner, or the same mode l scanner , 
for serial scans on the same patient Whole body acquisitions 
can be performed in eithe r 2 or 3 dimensional mode with 
attenuation correction, but the method chosen should be con 
sistent across all patients and serial scans in the clinical trial. 
PET/CT scan s: Combined modal ity scanning such as with 
PET CT is increas ingly used in clinical care, and is a modal 
ity/technology that is in rapid evolution; therefore , the recom 
mendations in this paper may change rather quickly with 
time. At present, low dose or attenuation correction CT por 
tions ofa combined PET CTare oflimited use in anatomically 
based efficacy assessments and it is therefore suggested that 
they should not be substituted for dedicate d diagnostic con 
trast enhanced CT scans for anatomically based RECISI' mea 
surernents . However, if a site can docum ent that the CT performed as part of a PET CT is of identical diagnostic qual 
ity to a diagnostic CT (with N and oral contrast) then the CT 
portion of the PET CT can be used for RECIST measuremen ts. 
Note , however, that the PET portion of the CT introduces addi 
tional data which may bias an investiga tor if it is not routinely 
or serially performed. 
Ultrasound examinations should not be used in clinical trials 
to measure tumour regression or progression of lesions be 
cause the examination is necessarily subjective and operator 
dependent. The reasons for this are several: Entire examina 
tions cannot be reproduced for independent review at a later 
date, and it mus t be assumed , whethe r or not it is the case, 
that the hard copy films availab le represent a true and accu 
rate reflection of even ts. Furthermore , if, for example , the 
only measurable lesion is in the para aortic region of the 
abdomen and if gas in the bowel overlies the lesion, the lesion 
will not be detected because the ultrasound beam cannot 
penetrate the gas. Accordingly, the disease staging (or restag 
ing for treatment evaluation} for this patien t will not be 
accurate. 
While evaluation of lesions by physical examination is also 
of limited reproducibility, it is permi tted when lesions are 
superficial, at least 10mm size, and can be assessed using 
calipers. In general, it is preferred if patients on clinical trials 
have at least one lesion that is measurable by CT. Other skin 
or palpable lesions may be measured on physical examina 
tion and be considered target lesions . 
Use of MRI remains a complex issue. MRI has excellent 
contrast, spatial and tempo ral resolution ; however, there 
are many image acquisition variables involved in MRI, which 
greatly impac t image quality, lesion conspicuity and mea 
surement . Furthermore , the availability of MRI is variable 
globally . As with CT, if an MRI is performed, the technical 
specifications of the scanning sequences used should be 
optimised for the evaluation of the type and site of disease. 
Furthermore , as with CT, the modality used at follow up 
should be the same as was used at baseline and the lesions 
should be measured/assessed on the same pulse sequence. 
Generally, axial imaging of the abdomen and pelvis with Tl 
and T2 weighted imaging along with gadolinium enhanced 
imaging should be performed. The field of view , matrix, 
number of excitations, phase encode steps , use of fat sup 
press ion and fast sequences should be optimised for the spe 
EUROPEAN JOURNAL OF CANCER 45 (2009 ) 228 247 243 
cific body part being imaged as well as the scanner utilised. It 
is beyond the scope of this document or appendix to pre 
scribe specific MRI pulse sequence parameters for all scan 
ners , body parts and diseases. Ideally, the same type of 
scanner should be used and the image acquisition protocol 
should be followed as closely as possible to prior scans. Body 
scans should be performed with breath hold scanning tech 
niques if poss ible. 
Selection of target lesions: In general, the largest lesions rep 
resentative of involved organs (up to a maximum of two per 
organ and five total) are selected to follow as target lesions. 
However, in some cases , the largest lesions may not be easily 
measured and are not suitable for follow up because of their 
configuration. In these cases, identification of the largest most 
reproduc ible lesions is advised. Fig. 3 provides an illustrative 
examp le where the largest lesion is not the most reproducible 
and another lesion is better to select and follow: 
Measurement of lesions 
The longest diameter of selected lesions should be measured 
in the plane in which the images were acquired. For body CT, 
this is the axial plane. In the event isotrop ic reconstructions 
are pertormed, measurements can be made on these recon 
structed images; however, it should be cautioned that not 
all radiology sites are capable of producing isotropic recon 
structions. This -could lead to the undesirable situation of 
measurements in the axial plane at one assessment point 
and in a different plane at a subsequent assessment There 
are some tumours, for instance paraspinal lesions, which 
are better measured in the coronal or sagittal plane. It would 
be acceptab le to measure these lesions in these planes if the reconstructions in those planes were isotropic or the images 
were acquired with MRI in those planes. Using the same plane 
of evaluation, the maximal diameter of each target lesion 
should always be measured at subsequent follow up time 
points even if this resul ts in measuring the lesion at a differ 
ent slice level orin a different orientation or vector compared 
with the baseline study. Software tools that calculate the 
maximal diameter for a perimeter of a tumour may be em 
ployed and may even reduce variability. 
The only exception to the longest diameter rule is lymph 
node measurement. Because malignant nodes are identifi.ed 
by the length of their short axis, this is the guide used to 
determine not only whether they are pathological but is also 
the dimension measured for adding into the sum of target le 
sions . Fig. 4 illustrates this point: the large arrow identifies a 
malignant node : the shorter perpendicular axis is ;;,,15 mm 
and will be recorded. Close by (small arrow) there is a normal 
node: note here the long axis is greater than 10 mm but the 
short axis is well below 10 mm. This node should be consid 
ered non pathological. 
If a lesion disappears and reappears at a subsequent time 
point it should continue to be measured. However, the pa 
tient's response at the point in time when the lesion reap 
pears will depend upon the status of his/her other lesions. 
For example, if the patient's tumour had reached a CR status 
and the lesion reappeared , then the patient would be consid 
ered PD at the time ofreappearance. In contrast, if the tumour 
status was a PR or SD and one lesion which had disappeared 
then reappears, its maximal diameter should be added to the 
sum of the remaining lesions for a calcu lated response: in 
other words, the reappearance of an apparently 'disappeared' 
single lesion amongst many which remain is not in itself en 
Fig. 3 -Largest lesion may not be most reproducib le: most reproducible should be selected as target. In this example, the 
primary gastric lesion (circled at baseline and at follow-up in the top two images) may be able to be measured with thin 
section volumetric CTwith the same degree of gastric distention at baseline and follow-up. However , this is potentia lly 
challenging to reproduce in a multicentre trial and if attempted should be done with careful imaging input and analysis. The 
most reproducib le lesion is a lymph node (circled at baseline and at follow -up in the bottom two images). 
244 EUROPEAN JOURNAL OF CANCER 45 (2009} 228 247 
Fig. 4 -Lymph node assessment: large arrow illustrates a 
pathological node with the short axis shown as a solid line 
which shou ld be measured and followed. Small arrow illus-
trates a non-pathological node which has a short axis 
<10mm. 
ough to qualify for: PD: that requires the sum of all lesions to 
meet the PD criteria. The rationale for such a categorisation is 
based upon the realisation that most lesions do not actually 
'disappear ' but are not visualised because they are beyond 
the resolving power of the imaging modality employed. 
The identification of the precise bounda:iy definition of a 
lesion may be difficult especially when the lesion is embed ded in an organ with a similar contrast such as the liver, pan 
creas , kidney, adrenal or spleen. Additionally, peritumoural 
oedema may surround a lesion and may be difficult to dis tin 
guish on certain modalities between this oedema and actual 
tumour . In fact, pathologically , the presence of tumour cells 
within the oedema region is variable. Therefore , it is most 
critical that the measurements be obtained in a reproducible 
manner from baseline and all subsequent follow up time 
points. This is also a strong reason to consistently utilise 
the same imaging modality. 
When lesions 'fragment', the individual lesion diameters 
should be added togethe r to calculate the target lesion 
sum. Similarly, as lesions coalesce, a plane between them 
may be maintained that would aid in obtaining maximal 
diameter measurements of each individual lesion. If the le 
sions have truly coalesced such that they are no longer sep 
arable, the vector of the longest diame ter in this instance 
should be the maximal longest diameter for the 'merged 
lesion'. 
Progression of non-target lesions 
To achieve 'unequivocal progr ession' there must be an overal! 
level of substantial worsening in non target disease that is of 
a magnitu de that, even in the presence of SD or PR in target 
disease, the treating phys ician would feel it important to 
change therapy . Examples of unequivocal progressio n are 
shown in Pigs. S and 6. 
Fig. 5 -Example of unequivocal progression in non-target lesions in live r. 
Fig. 6 -Example of unequivocal progression in non -target lesion (nodes~ 
Appendix III. Frequently asked questions
Question Answer
What should be done if several unique lesions at
baseline become conﬂuent at a follow up
evaluation?Measure the longest diameter of the conﬂuent mass and record to add into the sum of
the longest diameters
How large does a new lesion have to be to countas progression? Does any small subcentimetre
lesion qualify, or should the lesion be at least
measurable?New lesions do not need to meet ‘measurability criteria’ to be considered valid. If it isclear on previous images (with the same technique) that a lesion was absent then its
deﬁnitive appearance implies progression. If there is any doubt (because of the
techniques or conditions) then it is suggested that treatment continue until nextscheduled assessment when, generally, all should be clear. Either it gets bigger and the
date of progression is the date of the ﬁrst suspicion, or it disappears and one may then
consider it an artefact with the support of the radiologists
How should one lesion be measured if on
subsequent exams it is split into two?Measure the longest diameter of each lesion and add this into the sum
Does the deﬁnition of progression depend on
the status of all target lesions or only one?As per the RECIST 1.1 guideline, progression requires a 20% increase in the sum ofdiameters of all target lesions AND a minimum absolute increase of 5 mm in the sum
Are RECIST criteria accepted by regulatoryagencies?Many cooperative groups and members of pharma were involved in preparing RECIST1.0 and have adopted them. The FDA was consulted in their development and supportstheir use, though they don’t require it. The European and Canadian regulatory
authorities also participated and the RECIST criteria are now integrated in the European
note for guidance for the development of anticancer agents. Many pharmaceuticalcompanies are also using them. RECIST 1.1 was similarly widely distributed before
publication
What is the criterion for a measurable lesion if
the CT slice thickness is >5 mm?RECIST 1.1 recommends that CT scans have a maximum slice thickness of 5 mm and theminimum size for a measurable lesion is twice that: 10 mm (even if slice thickness is
<5 mm). If scanners with slice thickness >5 mm are used, the minimum lesion size must
have a longest diameter twice the actual slice thickness
What should we record when target lesions
become so small they are below the 10 mm
‘measurable’ size?Target lesion measurability is deﬁned at baseline. Thereafter, actual measurements,
even if <10 mm, should be recorded. If lesions become very small, some radiologists
indicate they are ‘too small to measure’. This guideline advises that when this occurs, ifthe lesion is actually still present, a default measurement of 5 mm should be applied. If
in fact the radiologist believes the lesion has gone, a default measurement of 0 mm
should be recorded
If a patient has several lesions which have
decreased in size to meet PR criteria and one
has actually disappeared, does that patient havePD if the ‘disappeared’ lesion reappears?Unless the sum meets the PD criteria, the reappearance of a lesion in the setting of PR (or
SD) is not PD. The lesion should simply be added into the sum.
If the patients had had a CR, clearly reappearance of an absent lesion would qualify forPD
When measuring the longest diameter of targetlesions in response to treatment, is the sameaxis that was used initially used subsequently,
even if there is a shape change to the lesion that
may have produced a new longest diameter?The longest diameter of the lesion should always be measured even if the actual axis isdifferent from the one used to measure the lesion initially (or at different time pointduring follow up)
The only exception to this is lymph nodes: as per RECIST 1.1 the short axis should
always be followed and as in the case of target lesions, the vector of the short axis maychange on follow up
Target lesions have been selected at baselineand followed but then one of these targetlesions then becomes non evaluable (i.e.different technique used)What may be done in such cases is one of the following:
What is the effect this has on the other targetlesions and the overall response?(a) If the patient is still being treated, call the centre to be sure that future evaluations aredone with the baseline technique so at least SOME courses are fully evaluable(b) If that is not possible, check if there IS a baseline exam by the same technique whichwas used to follow patients...in which case if you retrieve the baseline measures from
that technique you retrieve the lesion evaluability
(c) If neither (a) nor (b) is possible then it is a judgement call about whether you deletethe lesion from all forms or consider the impact of the lesion overall is so important that
its being non evaluable makes the overall response interpretation inevaluable without
it. Such a decision should be discussed in a review panelIt is NOT recommended that the lesion be included in baseline sums and then excludedfrom follow up sums since this biases in favour of a response
(continued on next page )E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 245
REFERENCES
1. Paesmans M, Sculier JP, Libert P, et al. Response to
chemotherapy has predictive value for further survival of
patients with advanced non small cell lung cancer: 10 years
experience of the European Lung Cancer Working Party. Eur J
Cancer 1997;33 :2326 32.
2. Buyse M, Thirion P, Carlson RW, et al. Relation between tumor
response to ﬁrst line chemotherapy and survival in advancedcolorectal cancer: a meta analysis. Meta analysis group inCancer. Lancet 2000;356 :373 8.
3. Gofﬁn J, Baral S, Tu D, et al. Objective responses in patients
with malignant melanoma or renal cell cancer in earlyclinical studies do not predict regulatory approval. Clin Cancer
Res2005;15 :5928 34.
4. El Maraghi RH, Eisenhauer EA. Review of phase II trial designs
used in studies of molecular targeted agents: outcomes andpredictors of success in phase III. J Clin Oncol 2008;10 :1346 54.
5. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting
results of cancer treatment. Cancer 1981; 47:207 14.6. Tonkin K, Tritchler D, Tannock I. Criteria of tumor response
used in clinical trials of chemotherapy. J Clin Oncol
1985;3 :870 5.
7. Baar J, Tannock I. Analyzing the same data in two ways: a
demonstration model to illustrate the reporting andmisreporting of clinical trials. J Clin Oncol 1989;7 :969 78.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines
to evaluate the response to treatment in solid tumors (RECISTGuidelines). J Natl Cancer Inst 2000;92 :205 16.
9. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a
review of validation studies on tumour assessment. Eur J
Cancer 2006;42 :1031 9.
10. Bogaerts J, Ford R, Sargent D, et al. Individual patient
data analysis to assess modiﬁcations to the RECIST criteria.
Eur J Cancer 2009; 45:248 60.
11. Moskowitz CS, Jia X, Schwartz LH, Gonen M. A simulation
study to evaluate the impact of the number of lesions
measured on response assessment. Eur J Cancer
2009;45 :300 10.
12. Sargent D, Rubinstein L, Schwartz L, et al. Validation of novel
imaging methodologies for use as cancer clinical trialsend points. Eur J Cancer 2009;45 :290 9.Appendix III continued
Question Answer
What if a single non target lesion cannot be reviewed, for
whatever reason; does this negate the overall assessment?Sometimes the major contribution of a single non target lesion may be inthe setting of CR having otherwise been achieved: failure to examine one
non target in that setting will leave you unable to claim CR. It is also
possible that the non target lesion has undergone such substantialprogression that it would override the target disease and render patientPD. However, this is very unlikely, especially if the rest of the measurable
disease is stable or responding
A patient has a 32% decrease in sum cycle 2, a 28% decrease cycle4 and a 33% decrease cycle 6. Does conﬁrmation of PR have to
take place in sequential scans or is a case like this conﬁrmed PR?It is not infrequent that tumour shrinkage hovers around the 30% mark.
In this case, most would consider PR to have been conﬁrmed looking at
this overall case. Had there been two or three non PR observationsbetween the two time point PR responses, the most conservativeapproach would be to consider this case SD
In the setting of a breast cancer neoadjuvant study, wouldmammography not be used to assess lesions? Is CT preferred inthis setting?Neither CT nor mammography are optimal in this setting. MRI is thepreferred modality to follow breast lesions in a neoadjuvant setting
A patient has a lesion measurable by clinical exam and by CTscan. Which should be followed?CT scan. Always follow by imaging if that option exists since it can bereviewed and veriﬁed
A lesion which was solid at baseline has become necrotic in thecentre. How should this be measured?The longest diameter of the entire lesion should be followed. Eventually,necrotic lesions which are responding to treatment decrease in size. Inreporting the results of trials, you may wish to report on this
phenomenon if it is seen frequently since some agents (e.g. angiogenesis
inhibitors) may produce this effect
If I am going to use MRI to follow disease, what is minimum size
for measurability?MRI may be substituted for contrast enhanced CT for some sites, but notlung. The minimum size for measurability is the same as for CT (10 mm)
as long as the scans are performed with slice thickness of 5 mm and nogap. In the event the MRI is performed with thicker slices, the size of ameasurable lesion at baseline should be two times the slice thickness. In
the event there are inter slice gaps, this also needs to be considered in
determining the size of measurable lesions at baseline
Can PET CT be used with RECIST? At present, the low dose or attenuation correction CT portion of a
combined PET CT is not always of optimal diagnostic CT quality for usewith RECIST measurements. However, if your site has documented thatthe CT performed as part of a PET CT is of the same diagnostic quality as
a diagnostic CT (with IV and oral contrast) then the PET CT can be used
for RECIST measurements. Note, however, that the PET portion of the CTintroduces additional data which may bias an investigator if it is notroutinely or serially performed246 E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247
13. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG.
Response criteria for phase II studies of supratentorial
malignant glioma. J Clin Oncol 1990; 8:1277 80.
14. Cheson BD, Pﬁstner B, Juweid ME, et al. Revised response
criteria for malignant lymphoma. J Clin Oncol 2007;10 :579 86.
15. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph
nodes with RECIST 1.1. Eur J Cancer 2009; 45:261 7.
16. Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to
evaluate the response to treatment in solid tumors (ovariancancer). J Natl Cancer Inst 2004;96 :487 8.
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response
guidelines for phase II clinical trials in androgen independentprostate cancer: recommendations from the Prostate SpeciﬁcAntigen Working Group. J Clin Oncol 1999; 17:3461 7.
18. Scher H, Halabi S, Tannock I, et al. Design and end points of
clinical trials for patients with progressive prostate cancerand castrate levels of testosterone: recommendations of theProstate Cancer Clinical Trials Working Group. J Clin Oncol
2008; 26:1148 59.
19. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines
to evaluate the response to treatment in solid tumors [ovarian
cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst
2000; 92:1534 5.20. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. EORTC Soft
Tissue and Bone Sarcoma Group: Progression free rate as the
principal end point for phase II trials in soft tissue sarcomas.
Eur J Cancer 2002;38 :543 9.
21. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the
assessment of progression in randomised cancer treatment
trials. Eur J Cancer 2009;45 :281 9.
22. Ford R, Schwartz L, Dancey J, et al. Lessons learned
from independent central review. Eur J Cancer 2009; 45:
268 74.
23. Catalano C, Francone M, Ascarelli A, Mangia M, Iacucci I,
Passariello R. Optimizing radiation dose and image quality.Eur Radiol 2007; 17(Suppl 6):F26 32.
24. Low RN. Abdominal MRI advances in the detection of liver
tumours and characterization. Lancet Oncol 2007;8 (6):525 35.
25. Barrett T, Choyke PL, Kobayashi H. Imaging of the lymphatic
system: new horizons. Contrast Media Mol Imaging
2006; 1(6):230 45.
26. Shankar LK, Hoffman JM, Bacharach S, et al. National
Cancer Institute. Consensus recommendations for the useof 18F FDG PET as an indicator of therapeutic response
in patients in National Cancer Institute Trials.
J Nucl Med 2006; 47(6):1059 66.E U R O P E A NJ O U R N A LO FC A N C E R 45 (2009) 228 247 247
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 90 20 June 2016Appendix 4. Criteria for Progression in Castration -Resistant Prostate Cancer
Variable Criteria
PSAIgnore early rises (prior to 12 weeks) in determining PSA response
For control/relieve/eliminate endpoints: Percent change from baseline at 12 weeks and maximal 
change at any time using a waterfall plot.
Progression:
Decline from baseline: record start of therapy to first PSA increase that is ≥25% and ≥ 2ng/mL 
above the nadir and confirmed by a second value 3 or more weeks later.
No decline from baseline: PSA progression ≥ 25% and ≥ 2 ng/ mL after 12 weeks
Soft tissueUse RECIST w ith caveats:
Only report changes in lymph nodes that were ≥ 2 cm  in diameter at baseline
Record changes in nodal and visceral soft tissue sites separately
Record complete elimination of disease at any site separat ely
Confirm favorable change with second scan
BoneThe appearance of ≥ 2 new  lesions, and, for the first reassessment only, a confirmatory scan 
performed 6 or more weeks later that shows a minimum of 
2 or more additional new lesions
The date of progressi on is the date of the first scan that shows the change
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 91 20 June 2016Appendix 5. Lymphoma Efficacy Assessments
Tumor Status Assessments
The determination of lymphoma response and progression will be based on standardized criteria 
{Cheson et al 2007 , Owen et al 2013 }as specifically  modified for this study  to reflect the 
biology  of the diseases under study .During the course of the stud y, investigators will 
periodicall y assess the status of each subject’s lymphoma . 
Method of As sessment
In addition to clinical examination, imaging
-based evaluation will be used in this study  in all 
subjects enrolled. CT scan is the preferred method for radiographic tumor assessment. MRI  
scanning may  be used at the investigator’s discretion in subj ects for whom this may  be a 
preferred alternative to CT scanning; however, if MRI  is performed, a non -contrast CT of the 
chest should also be performed. Contrast- enhanced scanning is preferred, but iodine -containing 
or gadolinium contrast material may  be o mitted in subjects for whom use of a contrast agent 
would be medicall y contraindicated. If available, positron emission tomography  (PET)scan data 
will be considered in response and progression assessment; however, PET scanning will not be a 
required component of assessment i n this study .  As appropriate, bone marrow aspirate/biops y 
information (eg, for confirmation of CR) will be also be consider ed. Clinical palpation, chest 
x-ray, ultrasound, endoscopy , laparoscop y, radionuclide scan, or tumor markers will not be 
considered for response assessment.
For radiographic assessments, the same method of assessment and the same technique 
(eg, scan type, scanner, subject position, dose of contrast, injection/scan interval) should be used 
to characterize each identified and reported lesion at baseline, while on study  drug treatment and 
during follow -up. Furthermore, the use of IV contrast should be consistent across time points. I n 
the event that the screening/baseline CT scan of the neck, chest, abdomen, and pelvis is 
performed without IV contrast, follow- up time points should also be performed without 
IVcontrast.
All relevant radiographic and clinical information required to make each tumor status assessment 
must be made available for source verification and for submission to the IRC.
Timing of Assessments
During screening, clinical and imaging
-based tumor assessments should be performed within the 
specified screening period. On- study  CT/MRI tumor assessments should be performed as 
indicated in Section 6.1.10. An end - of- study  CT/MRI  tumor assessment should be performed 
unless the subject already  has radiographic confirmation of disease progression 4weeks prior to 
study  discontinuation. If a subject permanentl y discontinues study drug prior to objective 
docum entation of ly mphoma progression, investigators should c ontinue further follow- up at 
~8-week intervals until ly mphoma progression is documented.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 92 20 June 2016Identification and Follow -up of Tumor Lesions and Organomegaly
Index Lesions
Up to 6 lesions (eg, ly mph nodes, liver or spleen nodules, and/or other circumscribed 
extra -nodal masses) should be selected as index lesions that will be used to quantitate the status 
of the disease during study. Ideall y, the index lesions should be located in disparate regions of 
the bod y and include mediastinal, abdominal, and retroperitoneal areas of disease whenever these 
sites are involved. 
Index lesions will be measured and recorded at baseline and at the stipulated intervals. The 
cross -sectional dimensions (the largest cross- sectio nal diameter, ie, the longest diameter 
[LD] ×the longest perpendicular diameter [ LPD ]) will be recorded (in cm) for each index lesion. 
Using the LD and LPD, the product of the perpendicular diameters (PPD) for each index lesion 
will be calculated. The sum of the products (SPDs) for all index lesions will be calculated and 
recorded. The baseline SPDs will be used as references b y which objective tumor response will 
be characterized during treatment. The nadir LDs of individual lesions and the nadir SPDs wil l 
be used as references b y which objective tumor progression will be characterized during stud y. 
All PPD and SPD measurements will be reported in centimeters squared.
Nodal Index Lesions
A nodal mass may  be selected as a nodal index lesion if it is both abnormal and measurable at 
baseline. A l ymph node lesion is considered abnormal if it has a single diameter that is  1.0cm 
and is considered measurable if it has 2 perpendicular diameters that can be accuratel y measured 
in cross se ction with the LD being 1.0cm and the L PD also being 1.0cm.
Abnormal, measurable nodal lesions will be subcategorized as either large or small.
Large nodal lesions have an LD that is >1.5 cm and an L PD that is 1.0cm.
Small nodal lesions have an LD that is >1.0 cm and 1.5cm and an LPD that is >1.0 cm.
Index lesions measuring >1.5 cm in the LD, regardless of the measurement of the L PD, will be 
prioritized during baseline index lesion selection .
At follow -up time points, the SPD of all nodal index lesions will be considered. Because nodal 
index lesions that have one or both diameters >0 cm and 1.0 cm cannot be reliably  measured, a 
default value of 1.0 cm will be assigned for each diameter that meets these criteria and the 
resulting PPD will be used in SPD calculations. Based on this convention, a CR may  be achieved 
even if an SPD value is >0 cm2(ie, if all ly mph nodes measure <1.0 cm2).
New or enlarging nodal lesions that are still  1.0cm by  1.0 cm will not be considered to 
represent recurrent disease or PD. A new node that measures >1.5 cm in an y diameter or a new 
node that measures >1.0 cm to 1.5cm in the L D and measures >1.0 cm in the L PD will be 
considered PD.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 93 20 June 2016In cases in which a large ly mph node mass has split into multiple components, only  those 
elements that are >1.0 cm in at least 1 diameter will be considered abnormal and used in 
calculating the SPD. Components that are ≤1.0 cm in the L D are assumed to be normal lymph 
node structures. PD will not be based on the growth of a lesion sub -component until it meets the 
criteria for abnormal. Lesion sub -components that are abnormal (>1.0 cm in 1diameter) will 
have the true PPDs calculated with the result used only  for calculating an accura te nadir. Lesion 
sub-components that are normal ( 1.0cm in the LD) will have the de fault PPD of 1.0 cm2
(1.0cmx 1.0 cm) stored only  for the purposes of calculat ing the nadir value. 
If lesions merge, a boundary  between the lesions will be established so the L D of each individual 
lesion can continue to be measured. If the lesions have m erged in a way  that they  can no longer 
be separated b y this boundary, the newl y merged lesion will be measured bi -dimensionally .
Extra- Nodal Index Lesions
An extra -nodal mass may  be selected as an index lesion if it is both abnormal and measurable at 
basel ine. An extra -nodal mass of any  size is considered abnormal. It is considered measurable at 
baseline if it has 2 perpendicular diameters that can be accuratel y measured in cross section with 
the L D being 1.0cm and the L PD also being 1.0cm.
At follow -uptime points, the PPD of each single extra -nodal index lesion and the SPD of all 
extra -nodal index lesions will be considered. Because extra -nodal index lesions that have one or 
both diameters >0 cm and < 1.0 cm cannot be reliably  measured, a default value of 1.0 cm will 
be assigned for each diameter that meets these criteria and the resulting PPD will be used in SPD 
calculations. If an extra- nodal lesion is no longer clearl y visible, it will be considered resolved 
and its PPD will be defined as 0 cm2. 
If an extra -nodal lesion that had resolved (ie, had a PPD of 0cm2) subsequently  reappears 
unequivocall y, the subject will be considered to have PD. A new unequivocal extra -nodal l esion 
of an y size that appears at a site that was not previously  involved wi th lymphoma and is 
discernible to the radiologist b y CT scan will be considered PD.
Non-Index Lesions
Any other measurable and abnormal nodal or extra -nodal lesions not selected for quantitation as 
index lesions may  be considered non -index lesions. I n addition, non- measurable evidence of 
lymphoma such as abnormal, non- measurable nodal lesions, extra -nodal lesions with both 
diameters <1.0 cm, bone lesions, leptomeningeal disease, ascites, pleural or pericardial effusions, 
lymphangitis of the skin or lung, abdominal masses that are not confirmed and followed b y 
imaging techniques, cystic lesions, previously  irradiated lesions, or lesions with artifacts may  be 
considered as non -index disease. 
If present at baseline, up to 6 non- index lesions should be recorded. Measurements are not 
required. 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 94 20 June 2016Non-index disease will be used as a general reference to further cha racterize regression or 
progression of l ymphoma during assessments of the objective tumor response during treatment. 
These lesions should be followed as “present” or “absent”.
Spleen and Liver
Qualitative assessments of the sizes of the spleen and liver will be performed. In addition, the 
presence or absence of splenic and/or hepatic nodules will be recorded. 
Bone Marrow
Bone marrow assessments will be based on morphologic evaluation of bone marrow biopsies. 
Immunohistochemistry  may  be used to assess respo nseif the sample is indeterminate b y 
morphology .
In a subject who has a baseline bone marrow biopsy  showing bone marrow involvement with 
lymphoma or does not have a baseline bone 
marrow examination, declaration of an on -study  CR 
requires bone marrow biops y documentation of the absence of bone marrow lymphoma. In a 
subject who has a baseline bone marrow biops y showing no evidence of lymphoma, declaration 
of an on- study  CR does not require bone marrow examination as long as other criteria for CR are 
met.
Definitions of Tumor Response and Progression
Responses will be categorized as complete response (CR), partial response (PR), stable disease 
(SD), or progressive disease (PD). In addition, a response category  of not evaluable (NE) is 
provided for situations i n which there is inadequate information to otherwise categorize response 
status. 
The best overall response will be determined. The best overall response is the best response 
recorded from the start of study  drug until PD/ recurrence (taking as reference for PD the smallest 
measurements recorded since study  drug started). Subjects with a best overall response of NE 
will be included in the denominators in calculations of tumor response rate.
Response Categories
Complete Response
To satisfy  criteria for CR, al l of the following criteria must be met:
No evidence of new disease
Regression of all index nodal lesions to normal size ( ≤1.5 cm in the LD for nodes that were 
considered large at baseline and < 1.0 cm in the LD and ≤1.0 cm in the L PD for nodes that 
were c onsidered small at baseline) (see Nodal Index Lesions section for definitions of 
large and small nodes)
Regression to normal of all nodal non-index disease 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 95 20 June 2016Disappearance of all detectable extra -nodal index and non- index disease
Normal spleen and liver siz e by imaging studies, no hepatic or splenic l ymphoma nodules, 
and no new liver or spleen enlargement
Morphologically  negative bone marrow based on an adequate unilateral core biopsy  if the 
sample is indeterminate by  morphology , it should be negative b y imm unohistochemistry  
If PET performed (not required), no evidence of residual disease
Partial Response
To satisfy  criteria for PR, all of the following criteria must be met as noted below:
No evidence of new disease
A 50% decrease from baseline in the SPD of the index lesions
No increase in the size of non -index disease
No increase in the size of the liver or spleen and no new liver or spleen enlargement
Persistence of bone marrow involvement in a subject who meets other criteria for CR based 
on the 
disappearance of all nodal and extra -nodal masses
If PET performed (not required): 
Typically  FDG -avid l ymphoma: if no baseline PET scan or if the PET scan was positive 
before initiating study  drug(s), the on -treatment PET is positive in 1previously  invo lved 
site. I f baseline PET was performed and was negative, there is no new PET evidence of 
disease
Variabl y FDG -avid ly mphoma/FDG -avidity  unknown: if no pretreatment PET scan or if 
the pretreatment PET scan was negative for l ymphoma, CT criteria should be used in 
assessing the tumor during stud y. If the PET scan was positive before initiating study 
drug(s), the on- treatment PET is positive in 1 previously  involved site.
Stable Disease
To satisfy  criteria for SD, all of the following criteria must be met:
No evidence of new disease
Neither sufficient tumor shrinkage from baseline to qualify for PR nor sufficient evidence of 
tumor growth to qualify  for PD
Progressive Disease
The occurrence of an y of the following events indicates progressive disease (PD):
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 96 20 June 2016Evidence of an y new disease that was not present at baseline:
A new node that measures >1.5 cm in LD and > 1.0 cm in the L PD.
A new node that measures >1.0 cm to <1.5 cm in the LD and >1.0 cm in the L PD
Unequivocal reappearance of  an extra -nodal lesion that had resolved (ie, had previousl y 
been assigned a PPD of 0 cm2)
A new unequivocal extra- nodal lesion of an y size
New non -index disease (eg, effusions, ascites, or other organ abnormalities) of any  size 
unequivocall y attributable to lymphoma (usually require s PET, biopsy , cytology , or other 
non-radiologic confirmation to confirm disease attributable to ly mphoma). 
Note: Isolated new effusions, ascites, or bone lesions are not sufficient evidence alone of 
PD unless histologically confirmed. In subjects with no prior history of pulmonary 
lymphoma, new lung nodules identified by CT are usually benign. Thus, a declaration of 
PD should not be made if this is the only manifestation of an apparently new lesion.
New or recurrent bone marrow involvement with lymphoma i f the last prior bone marrow 
biopsy  performed as part of the study
 (baseline or on -study ) was negative for ly mphoma
Evidence of worsening of nodal or extra- nodal index lesions:
Increase from the nadir by  50% in the SPD of index lesions
Increase from the nadir by  50% in the LD of an individual node or extra -nodal mass that 
now has an LD of >1.5 cm and an L PD of > 1.0 cm
Unequivocal increase in the size of non- index disease
If PET performed (not required):
The appearance of an y new lesion compatible with ly mphoma with confirmation by  other 
radiographic or histological modalities
The reappearance of an y activity  in a pre -existent lesion that meets size criteria for a new 
lesion on CT
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 97 20 June 2016Note: If there is uncertainty regarding whether there is definitive lymphoma progression, the 
subject should continue study drug and remain under close observation (eg, evaluated at 
scheduled intervals. In particular, worsening of constitutional symptoms in the absence of 
objective evidence of worsening lymphoma will not be considered definitive disease progression; 
in such subjects, both lymphoma -relate d and non -lymphoma -related causes for the 
constitutional symptoms should be considered. Transient worsening of disease during temporary 
interruption of study dr ug(s) (eg, for intercurrent illness) may also not indicate definitive disease 
progression. In these instances, CT/MRI should be attempted in order to document whether 
definitive disease progression has occurred. If subsequent evaluations suggest that the s ubject 
has experienced persistent definitive disease progression, then the date of progression will be the 
time point at which progression was first objectively documented.
Non-Evaluable
In a subject who does not have evidence of PD, the occurrence of an y of the following conditions 
indicates a response status of NE:
There are no images or inadequate or missing images.
Note: A time-point will be considered to have a response of NE if any index lesion is missing. PD 
may be assigned at any time point regardle ss of the extent of missing index or non -index lesions. 
Missing non-index lesions will not impact the ability to assess for response or disease 
progression. 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 98 20 June 2016Appendix 6. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
CTCAE v 4.03 can be accessed from the below link: 
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20 -%20DMCC.pdf
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 99 20 June 2016Appendix 7. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contracept ive 
Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
perm anentl y sterile or with medically documented ovarian failure.  
Except in Group 2, subjects with breast cancer who are also receiving hormonal therapies, 
women are considered to be in a postmenopausal state when they  are > 60 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
In addition, Group 2 subjects (breast cancer) who are pre/perimenopausal women are considered 
in a postmenopausal state due to treatment with the LHRH agonist goserelin. Patients must have 
commenced treatment with goserelin or an alternative L HRH agonist a t least 4 weeks prior to 
firstdose of study  drug, leading to a reduction in luteinizing hormone production and consequent 
reduction of sex steroid hormones to castration levels by  the time of exposure to study  drugs.
b.Definition of Male Fertility
For the p urposes of this study , a male born subject is considered to be fertile after the initiation 
of pubert y unless permanently  sterile b y bilateral orchidectom y or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregn ancy and Hormonal Contraception
GS-5829 is contraindicated in pregnancy  as an y potential for human teratogenicity/fetotoxicity  in 
early pregnancy is currently unknown. GS -5829 has insufficient data to exclude the possibility  of 
a clinically  relevant intera ction with hormonal contraception that results in reduced contraception 
efficacy .  Therefore, contraceptive steroids are not recommended as a contraceptive method 
either solel y or as a part of a contraceptive regimen. Please refer to the latest version of the 
investigator’s brochure for additional information.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 100 20 June 2016b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  They  must also not rely  on hormone -containing contraceptives as a 
form of birth control during the stud y.  They must have a negative serum pregnancy test at 
Screening and a negative pregnancy  test on the Baseline/Day  1 visit prior to initial 
randomization.  Preg nancy  tests will be performed at protocol -specified dates thereafter.  Female 
subjects must agree to one of the following from Screening until 30 day s following the end of 
relevant s ystemic exposure.
Complete abstinence from intercourse of reproductive pot ential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) wit h a failure rate of <1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
3) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treat ment and until 90 days after the 
end of relevant s ystemic exposure.  Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90days 
after the end of relevant systemic exposure.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 101 20 June 2016only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30 day s of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.6.2.1.
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 102 20 June 2016Appendix 8. Performance Status Scoring System (ECOG)
Grade ECOG
0 Fully active, able to carry on all pre -disease performance without restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house w ork, office work
2Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of w aking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of w aking hours
4 Com pletely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 103 20 June 2016Appendix 9. Exemestane (Aromasin®) Prescribing Information
http://www.pfizer.com/products/product -detail/aromasin
GS-5829
Protocol GS –US-350-1599 Final
Gilead Sciences, Inc. Amendment 6
CONFIDENTIAL Page 104 20 June 2016Appendix 10. Fulvestrant (Faslodex®) Prescribing Information
http://www.faslodexhcp.com/home.html